Irak4 degradation agent and preparation method and application thereof
Patent Information
- Application Number
- TW111131761
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-08-17
- Filing Date
- 2022-08-23
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-08-22
AI Technical Summary
Current small molecule inhibitors for IRAK4 are prone to drug resistance and may not adequately suppress IRAK4-mediated signaling pathways due to IRAK4's dual functions as a scaffold protein and kinase, limiting their therapeutic efficacy in treating IRAK4-related diseases.
Employing Proteolysis Targeting Chimeras (PROTACs) to degrade IRAK4 protein through a bifunctional molecule that recognizes IRAK4 and an E3 ubiquitin ligase, forming a ternary complex for ubiquitination and proteasomal degradation, bypassing the need for direct inhibition of the kinase activity.
PROTACs effectively degrade IRAK4, potentially overcoming drug resistance and providing a more robust therapeutic approach for IRAK4-related diseases by directly removing the protein, thereby inhibiting its signaling pathways.
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceuticals, specifically to compounds that target the degradation of IRAK4 protein, pharmaceutical compositions thereof, methods for their preparation, and their use in the preparation of medicaments for the treatment and / or prevention of IRAK4-mediated diseases or conditions, such as cancer, immune diseases, and inflammatory diseases. Prior Technology
[0002] Interleukin-1 receptor kinase 4 (IRAK4) is a serine / threonine-specific protein kinase with biologically important kinase activity, playing a crucial role in activating the immune system. Studies have shown that IRAK4 is a key downstream factor in the signaling pathways of interleukin (IL)-1β family receptors (including IL-1R, IL-18R, IL-33R, and IL-36R) and Toll-like receptors (TLRs). Both IRAK4-deficient mice and IRAK4-deficient patients do not respond to stimulation by TLRs (except TLR3) and the IL-1β family.
[0003] Based on the presence or absence of MyD88, TLR / IL-1β-mediated signaling pathways can be divided into MyD88-dependent and MyD88-independent pathways. Among them, the signal transduction pathways mediated by IL-1R and TLR2, TLR4, TLR7 / 8, and TLR9 all depend on MyD88 as a regulator to activate downstream inflammatory signaling pathways. After TLR / IL-1β binds to its ligand, it recruits MyD88 molecules. MyD88 further recruits IRAK4 into the TLR / IL-1β complex through its N-terminal death domain, and interacts with and activates IRAK1 or IRAK2, thereby transmitting signals downstream to E3 ubiquitin ligase TNF receptor-associated factor (TRAF6), activating serine / threonine kinase TAK1, and subsequently activating NF-κB and MAPK signaling pathways, leading to the release of various inflammatory cytokines and anti-apoptotic molecules. The IRAK4-dependent TLR / IL-1β signaling pathway has been shown to be associated with a variety of diseases, such as multiple sclerosis, atherosclerosis, myocardial infarction, myocarditis, Vogt-Koyanagi-Harada syndrome, systemic lupus erythematosus (SLE), obesity, type 1 diabetes, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus, psoriasis, vitiligo, giant cell arteritis, chronic inflammatory bowel disease, and viral diseases such as HIV (human immunodeficiency virus) and hepatitis viruses; skin diseases such as psoriasis, atopic dermatitis, Kindler's syndrome, bullous pemphigoid, allergic contact dermatitis, alopecia areata, acne paradox, and acne vulgaris; and other inflammatory diseases such as allergies, Becton's disease, gout, and adult-onset Still's syndrome. Diseases such as pericarditis and chronic inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, transplant rejection and graft-versus-host disease; gynecological diseases such as adenomyosis, dysmenorrhea, dyspareunia, and endometriosis, especially pain associated with endometriosis and other symptoms associated with endometriosis such as dysmenorrhea, dyspareunia, dysuria, and dysdefecation; ocular diseases such as retinal ischemia, keratitis, allergic conjunctivitis, keratoconjunctivitis sicca, macular degeneration, and uveitis; fibrotic diseases such as liver fibrosis, myocarditis, primary biliary cirrhosis, and cystic fibrosis; chronic liver diseases such as fatty liver hepatitis, especially non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH);Cardiovascular diseases and neurological disorders, such as myocardial reperfusion injury, myocardial infarction, hypertension, as well as Alzheimer's disease, stroke, traumatic brain injury, amyotrophic lateral sclerosis (ALS), and Parkinson's disease; itching and pain (including acute, chronic, inflammatory, and neuropathic pain) such as hyperalgesia, atypical pain, premenstrual pain, pain associated with endometriosis, postoperative pain, interstitial cystitis, CRPS (complex regional pain syndrome), trigeminal neuralgia, prostatitis, pain caused by spinal cord injury, pain caused by inflammation, lower back pain, cancer pain, chemotherapy-related pain, HIV treatment-induced neuropathy, burn-related pain, and chronic pain; oncological diseases such as certain lymphomas: ABC-DLBCL (activated B-cell diffuse large cell B-cell lymphoma), mantle cell lymphoma, and Woldanström disease, as well as chronic lymphocytic leukemia, melanoma, pancreatic tumors and hepatocellular carcinoma, ras-dependent tumors, breast cancer, ovarian cancer, colorectal cancer, head and neck cancer, lung cancer, and prostate cancer. ;
[0004] The regulation of IRAK4-mediated signaling pathways is primarily related to its kinase function. However, some reports indicate that in certain cell types, IRAK4's regulation of downstream signaling processes is related to its non-kinase function. Cushing et al. stated that although IRAK4 phosphorylation levels were reduced in IL-1β-stimulated human skin fibroblasts, pharmacological inhibition of IRAK4 did not lead to inhibition of IL-6 and TNF-α. Supporting these results is that in IRAK4-deficient fibroblasts, compared to wild-type cells, the scaffold function of IRAK4 is important for IL-1 signaling, but its kinase function is redundant. Meanwhile, Chiang and colleagues also stated that IRAK4 kinase activity is not essential in human B and T cells, dendritic cells, and monocytes, and siRNA gene excision also showed that IRAK4 plays a scaffold function in these cells. Several potent and selective inhibitors targeting IRAK4 have been reported, such as CA-4948, BAY-1834845, BMS-986126, and PF-06650833. These inhibitors selectively inhibit the kinase activity of IRAK4 and are mainly used for the prevention and treatment of autoimmune diseases, inflammatory diseases, and neoplastic diseases. However, because IRAK4 acts as both a scaffold protein and an active kinase, and because traditional small-molecule inhibitors are prone to drug resistance, simply inhibiting IRAK4 kinase activity may not be sufficient to produce a therapeutic effect.
[0005] Proteolysis Targeting Chimeria (PROTAC) is a technology different from traditional small molecule inhibitors. Traditional small molecule inhibitors usually need to act on the active site of the target protein to inhibit its activity, while PROTAC is a heterogeneous bifunctional molecule. One end is a small molecule inhibitor that recognizes the target protein through a linker chain, and the other end is an E3 ubiquitin ligase ligand that recognizes E3 ubiquitin ligase. This bifunctional molecule recognizes the target protein and E3 ubiquitin ligase in vivo, bringing the target protein and E3 ubiquitin ligase closer to form a ternary complex. After ubiquitination of the target protein, it is degraded in vivo through the ubiquitin-proteasome pathway. Compared to traditional small molecule inhibitors, PROTACs offer several advantages. First, they only require the target protein to be brought closer to the E3 ubiquitin ligase, leading to substrate degradation. This mode of action allows the technology to be applied to some undrugable targets. Second, after the target protein is degraded, the PROTAC molecule can be released to participate in the degradation of the next protein. This catalytic degradation effect allows for efficient degradation with a smaller dose of PROTAC. Third, traditional small molecule inhibitors often develop resistance due to point mutations, causing them to lose their inhibitory effect on the target. PROTACs, however, can directly degrade the target protein, thus avoiding resistance caused by point mutations to some extent. Therefore, compared to traditional small molecule inhibitors, using PROTAC technology for the development of new small molecule drugs has significant advantages and feasibility, and is expected to become a promising next-generation drug. PROTAC technology has also been applied to the modification of various target drugs, such as androgen receptors, estrogen protein receptors, and BTK. Several classes of IRAK4 degraders are disclosed in US2019 / 0151295, US2019 / 0192688, WO2019 / 160915 and WO2020 / 113233, and more IRAK4 degraders are yet to be developed. Summary of the Invention
[0006] This application claims priority to Chinese patent application 202110966608X, filed August 23, 2021; Chinese patent application 2022105581585, filed May 19, 2022; and Chinese patent application 2022109894485, filed August 17, 2022. The full text of the aforementioned Chinese patent applications is incorporated herein by reference.
[0007] This invention provides compounds of Formula I, including stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, prodrugs, or pharmaceutically acceptable salts thereof; PTM-L-ULM Ⅰ in: The PTM has the following structure PTM-1 In the PTM-1 mentioned above: m can be 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, or 4; Ring A'' is a 6-10 membered aryl group or contains one, two, or three 5-11 membered monocyclic or bicyclic heteroaryl groups selected from N, O, or S heteroatoms; Ring A is a 6-10 membered aryl group or contains one, two, or three 5-11 membered monocyclic or bicyclic heteroaryl groups selected from N, O, or S heteroatoms; Each R1 is independently selected from: C1-C4 alkyl, -O(C1-C4 alkyl), -N(C1-C4 alkyl) 1-2, C3-C8 cycloalkyl, -O(C3-C8 cycloalkyl), -NH(C3-C8 cycloalkyl), 3-8-membered heterocyclic alkyl, -O(3-8-membered heterocyclic alkyl), -NH(3-8-membered heterocyclic alkyl), 6-10-membered aryl, -O(6-10-membered aryl), -NH(6-10-membered aryl), 5-6-membered heteroaryl, -O(5-6-membered heteroaryl), -NH(5-6-membered heteroaryl), CN, halogen, -OH, -NH 2, -NHC(O)(C1-C4 alkyl), -NHS(O)(C1-C4 alkyl), -NHS(O) 2(C1-C4 alkyl), -COOH, -C(O)NH 2. -S(O)₂H, -S(O)₂NH₂, -C(O) (C₁-C₄ alkyl), -C(O)NH (C₁-C₄ alkyl), -C(O)N (C₁-C₄ alkyl), -C(O)O (C₁-C₄ alkyl), -S(O) (C₁-C₄ alkyl), -S(O)₂ (C₁-C₄ alkyl), -S(O)₂NH (C₁-C₄ alkyl), -S(O)₂N (C₁-C₄ alkyl)₂ or -S(O)NH (C₁-C₄ alkyl), wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl are optionally selected from halogens, cyano, -OH, C₁-C₄ alkyl, -O (C₁-C₄ alkyl), methylpiperidine, -S(O)₂H, -S(O)₂ (C₁-C₄ alkyl), C₁-C₄ alkyl, -C ... Substitution of groups with 1-C 4 alkyl), -C(O)N (C 1-C 4 alkyl) 1-2 and C(O)O (C 1-C 4 alkyl); Alternatively, R1 together with the atoms it is attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; Each R4 is independently hydrogen, C1-C4 alkyl, -O (C1-C4 alkyl), C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, 5-6-membered heteroaryl, CN, halogen, -OH, -NHC(O) (C1-C4 alkyl), -NHS(O) (C1-C4 alkyl), -NHS(O)2 (C1-C4 alkyl), -COOH, -C(O)NH2, -S(O)2H, -S(O)2NH2, -C(O) (C1-C4 alkyl), -C(O)NH (C1-C4 alkyl), -C(O)N (C1-C4 alkyl)2, -C(O)O (C1-C4 alkyl), -S(O) (C1-C4 alkyl), -S(O)2 (C The alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted with groups selected from halogens, cyano, -OH, C1-C4 alkyl, -O (C1-C4 alkyl), methylpiperidine, -S(O)2H, -S(O)2 (C1-C4 alkyl), -C(O)N (C1-C4 alkyl) 1-2, and -C(O)O (C1-C4 alkyl); X is O, S, CH₂, or N; R2 and R3 are independently selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, or 5-6-membered heteroaryl, wherein each alkyl, cycloalkyl, heterocyclic alkyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from halogen, OH, oxo, N(Rb)2, oxopyrrolyl, and mofolinyl, or R2 and R3 together with the atoms to which they are attached form a C3-C8 cycloalkyl or a 3-8-membered heterocyclic alkyl, wherein the cycloalkyl and heterocyclic alkyl are optionally substituted by one or more substituents selected from Ra; Ra is independently selected from oxogroups, C1-C4 alkyl groups, C3-C6 cycloalkyl groups, CF3, CHF2, OH, halogens, or NH2, wherein the alkyl group is optionally substituted with a C3-C6 cycloalkyl group or CF3; and Rb is independently selected from H or C1-C4 alkyl groups; L is the connecting chain, which covalently connects PTM and ULM; The ULM has the following structure ULM-1 In the case of ULM-1: X'' is C or N; Y'' can be C, N, O, or S; Q1, Q2, Q3, Q4, and Q5 are each independently CR 3'' or N; R 3'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocycloalkyl, 6-10-membered aryl, 5-10-membered heteroaryl, -O (C1-C6 alkyl), -O- (C3-C8 cycloalkyl), -O- (3-8-membered heterocycloalkyl), N (C1-C6 alkyl) 1-2, NH (C3-C8 cycloalkyl), NH (3-8-membered heterocycloalkyl), -O- (6-10-membered aryl), or -O- (5-10-membered heteroaryl); the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted by 1-3 groups independently selected from hydroxyl, halogen, cyano, and amino; or R 3'' together with the atoms it is attached to form a cycloalkyl, heterocycloalkyl, heteroaryl, or aryl group; m'' is 1, 2, or 3; R 1'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocycloalkyl, 6-10-membered aryl, 5-10-membered heteroaryl, or -O (C1-C6 alkyl), wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted by 1-3 groups independently selected from hydroxyl, halogen, cyano, and amino; R 2'' is hydrogen, deuterium, C1-C6 alkyl or C3-C6 cycloalkyl, wherein the C1-C6 alkyl and C3-C6 cycloalkyl are optionally substituted by 1 to 3 groups independently selected from hydroxyl, halogen, cyano, amino and -OC(O)(C1-C6 alkyl).
[0008] Preferably, in some embodiments of the present invention, each of R 3'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, -O (C1-C6 alkyl), -O- (C3-C8 cycloalkyl), -O- (3-8-membered heterocyclic alkyl), N (C1-C6 alkyl) 1-2, NH (C3-C8 cycloalkyl), NH (3-8-membered heterocyclic alkyl), -O- (6-10-membered aryl), or -O- (5-10-membered heteroaryl); the alkyl, cycloalkyl, heterocyclic alkyl, aryl, and heteroaryl groups are optionally substituted by 1-3 groups independently selected from hydroxyl, halogen, cyano, and amino; or R 3'' together with the atoms to which it is attached forms a cycloalkyl or heterocyclic alkyl group.
[0009] Preferably, in some embodiments of the present invention, R 3'' and the atoms it is attached to form a heteroaryl group, which is not... , , , or .
[0010] Preferably, in some embodiments of the present invention, In the PTM-1 mentioned above: m is 0 or 1; n is 0, 1, or 2; Ring A'' is a 6-10 membered aryl group or contains one, two, or three 5-11 membered monocyclic or bicyclic heteroaryl groups selected from N, O, or S heteroatoms; Ring A is a 6-10 aryl group or a 5-6 heteroaryl group; R1 is independently selected from: C1-C4 alkyl, -O(C1-C4 alkyl), -N(C1-C4 alkyl) 1-2, C3-C8 cycloalkyl, -O(C3-C8 cycloalkyl), -NH(C3-C8 cycloalkyl), 3-8-membered heterocyclic alkyl, -O(3-8-membered heterocyclic alkyl), -NH(3-8-membered heterocyclic alkyl), 6-10-membered aryl, -O(6-10-membered aryl), -NH(6-10-membered aryl), 5-6-membered heteroaryl, -O(5-6-membered heteroaryl), -NH(5-6-membered heteroaryl), CN, halogen, -OH, -NH 2, -NHC(O)(C1-C4 alkyl), -NHS(O)(C1-C4 alkyl), -NHS(O) 2(C1-C4 alkyl), -COOH, -C(O)NH 2. -S(O)₂H, -S(O)₂NH, -C(O) (C₁-C₄ alkyl), -C(O)NH (C₁-C₄ alkyl), -C(O)N (C₁-C₄ alkyl), -C(O)O (C₁-C₄ alkyl), -S(O) (C₁-C₄ alkyl), -S(O)₂ (C₁-C₄ alkyl), -S(O)₂NH (C₁-C₄ alkyl), -S(O)₂N (C₁-C₄ alkyl), -S(O)NH (C₁-C₄ alkyl), wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally selected from halogens, cyano, -OH, C₁-C₄ alkyl, -O (C₁-C₄ alkyl), methylpiperidine, -S(O)₂H, -S(O)₂ (C₁-C₄ alkyl), ... Substitution with groups of 1-C 4 alkyl), -C(O)N (C 1-C 4 alkyl) 1-2, or -C(O)O (C 1-C 4 alkyl); Alternatively, R1 together with the atoms it is attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; R4 represents hydrogen, C1-C4 alkyl, -O (C1-C4 alkyl), C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, 5-6-membered heteroaryl, CN, halogen, -OH, -NHC(O) (C1-C4 alkyl), -NHS(O) (C1-C4 alkyl), -NHS(O)2 (C1-C4 alkyl), -COOH, -C(O)NH2, -S(O)2H, -S(O)2NH2, -C(O) (C1-C4 alkyl), -C(O)NH (C1-C4 alkyl), -C(O)N (C1-C4 alkyl)2, -C(O)O (C1-C4 alkyl), -S(O) (C1-C4 alkyl), -S(O)2 (C1-C4 alkyl), -S(O)2 (C1-C4 alkyl). -4 alkyl), -S(O)2NH (C1-C4 alkyl), -S(O)2N (C1-C4 alkyl)2, -S(O)NH (C1-C4 alkyl) or -X(R2)(R3), wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl are optionally substituted with a group selected from halogen, cyano, -OH, C1-C4 alkyl, -O (C1-C4 alkyl), methylpiperidine, -S(O)2H, -S(O)2 (C1-C4 alkyl), -C(O)N (C1-C4 alkyl)1-2, or -C(O)O (C1-C4 alkyl); or X is O, S, CH₂, or N; R2 and R3 are independently selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10 aryl, or 5-6-membered heteroaryl, wherein each alkyl, cycloalkyl, heterocyclic alkyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from halogen, OH, oxo, N(Rb)2, oxopyrrolyl, or mofolinyl, or R2 and R3 together with the atoms to which they are attached form a C3-C8 cycloalkyl or a 3-8-membered heterocyclic alkyl, wherein the cycloalkyl or heterocyclic alkyl is optionally substituted by one or more substituents selected from Ra; Ra is independently selected from oxogroups, C1-C4 alkyl groups, C3-C6 cycloalkyl groups, CF3, CHF2, OH, halogens, or NH2, wherein the alkyl group is optionally substituted with a C3-C6 cycloalkyl group or CF3; and Rb is independently selected from H or C1-C4 alkyl groups; L is the connecting chain, which covalently connects PTM and ULM; The ULM has the following structure ULM-1 In the case of ULM-1: X'' is C or N; Y'' can be C, N, O, or S; Q1, Q2, Q3, Q4, and Q5 are each independently CR 3'' or N; R 3'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, -O (C1-C6 alkyl), -O- (C3-C8 cycloalkyl), -O- (3-8-membered heterocyclic alkyl), N (C1-C6 alkyl) 1-2, NH (C3-C8 cycloalkyl), NH (3-8-membered heterocyclic alkyl), -O- (6-10 aryl), -O- (5-10-membered heteroaryl); the alkyl, cycloalkyl, heterocyclic alkyl, aryl, and heteroaryl groups are optionally substituted by 1-3 groups independently selected from hydroxyl, halogen, cyano, and amino; or R 3'' together with the atoms it is attached to form a cycloalkyl, heterocyclic alkyl, heteroaryl, or aryl group; m'' is 1, 2, or 3; R 1'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, -O (C1-C6 alkyl), wherein the alkyl, cycloalkyl, heterocyclic alkyl, aryl, or heteroaryl group is optionally substituted by 1-3 groups independently selected from hydroxyl, halogen, cyano, or amino. R 2'' is hydrogen, deuterium, C1-C6 alkyl or C3-C6 cycloalkyl, wherein the C1-C6 alkyl and C3-C6 cycloalkyl are optionally substituted by 1 to 3 groups independently selected from hydroxyl, halogen, cyano, amino or -OC(O) (C1-C6 alkyl).
[0011] Preferably, in some embodiments of the present invention, In the PTM-1 mentioned above: m can be 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, or 4; Ring A'' is a 6-10 membered aryl group or contains one, two, or three 5-11 membered monocyclic or bicyclic heteroaryl groups selected from N, O, or S heteroatoms; Ring A is a 6-10 membered aryl group or contains one, two, or three 5-11 membered monocyclic or bicyclic heteroaryl groups selected from N, O, or S heteroatoms; R1 is independently selected from: C1-C4 alkyl, -O(C1-C4 alkyl), -N(C1-C4 alkyl) 1-2, C3-C8 cycloalkyl, -O(C3-C8 cycloalkyl), -NH(C3-C8 cycloalkyl), 3-8-membered heterocyclic alkyl, -O(3-8-membered heterocyclic alkyl), -NH(3-8-membered heterocyclic alkyl), 6-10-membered aryl, -O(6-10-membered aryl), -NH(6-10-membered aryl), 5-6-membered heteroaryl, -O(5-6-membered heteroaryl), -NH(5-6-membered heteroaryl), CN, halogen, -OH, -NH 2, -NHC(O)(C1-C4 alkyl), -NHS(O)(C1-C4 alkyl), -NHS(O) 2(C1-C4 alkyl), -COOH, -C(O)NH 2. -S(O)₂H, -S(O)₂NH, -C(O) (C₁-C₄ alkyl), -C(O)NH (C₁-C₄ alkyl), -C(O)N (C₁-C₄ alkyl), -C(O)O (C₁-C₄ alkyl), -S(O) (C₁-C₄ alkyl), -S(O)₂ (C₁-C₄ alkyl), -S(O)₂NH (C₁-C₄ alkyl), -S(O)₂N (C₁-C₄ alkyl), -S(O)NH (C₁-C₄ alkyl), wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally selected from halogens, cyano, -OH, C₁-C₄ alkyl, -O (C₁-C₄ alkyl), methylpiperidine, -S(O)₂H, -S(O)₂ (C₁-C₄ alkyl), ... Substitution with groups of 1-C 4 alkyl), -C(O)N (C 1-C 4 alkyl) 1-2, or -C(O)O (C 1-C 4 alkyl); Alternatively, R1 together with the atoms it is attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; R4 represents hydrogen, C1-C4 alkyl, -O (C1-C4 alkyl), C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, 5-6-membered heteroaryl, CN, halogen, -OH, -NHC(O) (C1-C4 alkyl), -NHS(O) (C1-C4 alkyl), -NHS(O)2 (C1-C4 alkyl), -COOH, -C(O)NH2, -S(O)2H, -S(O)2NH2, -C(O) (C1-C4 alkyl), -C(O)NH (C1-C4 alkyl), -C(O)N (C1-C4 alkyl)2, -C(O)O (C1-C4 alkyl), -S(O) (C1-C4 alkyl), -S(O)2 (C1-C4 alkyl), -S(O)2 (C1-C4 alkyl). -4 alkyl), -S(O)2NH (C1-C4 alkyl), -S(O)2N (C1-C4 alkyl)2, -S(O)NH (C1-C4 alkyl) or -X(R2)(R3), wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl are optionally substituted with a group selected from halogen, cyano, -OH, C1-C4 alkyl, -O (C1-C4 alkyl), methylpiperidine, -S(O)2H, -S(O)2 (C1-C4 alkyl), -C(O)N (C1-C4 alkyl)1-2, or -C(O)O (C1-C4 alkyl); X is O, S, CH₂, or N; R2 and R3 are independently selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, or 5-6-membered heteroaryl, wherein each alkyl, cycloalkyl, heterocyclic alkyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from halogen, OH, oxo, N(Rb)2, oxopyrrolyl, or mofolinyl, or R2 and R3 together with the atoms to which they are attached form a C3-C8 cycloalkyl or a 3-8-membered heterocyclic alkyl, wherein the cycloalkyl or heterocyclic alkyl is optionally substituted by one or more substituents selected from Ra; Ra is independently selected from oxogroups, C1-C4 alkyl groups, C3-C6 cycloalkyl groups, CF3, CHF2, OH, halogens, or NH2, wherein the alkyl group is optionally substituted with a C3-C6 cycloalkyl group or CF3; and Rb is independently selected from H or C1-C4 alkyl groups; L is the connecting chain, which covalently connects PTM and ULM; The ULM has the following structure ULM-1 In the case of ULM-1: X'' is C or N; Y'' can be C, N, O, or S; Q1, Q2, Q3, Q4, and Q5 are each independently CR 3'' or N; R 3'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, -O (C1-C6 alkyl), -O- (C3-C8 cycloalkyl), -O- (3-8-membered heterocyclic alkyl), N (C1-C6 alkyl) 1-2, NH (C3-C8 cycloalkyl), NH (3-8-membered heterocyclic alkyl), -O- (6-10 aryl), -O- (5-10-membered heteroaryl); the alkyl, cycloalkyl, heterocyclic alkyl, aryl, and heteroaryl groups are optionally substituted by 1-3 groups independently selected from hydroxyl, halogen, cyano, and amino; or R 3'' together with the atoms it is attached to form a cycloalkyl, heterocyclic alkyl, heteroaryl, or aryl group; m'' is 1, 2, or 3; R 1'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3-8 heterocyclic alkyl, 6-10 aryl, 5-10 heteroaryl, -O (C1-C6 alkyl), wherein the alkyl, cycloalkyl, heterocyclic alkyl, aryl, or heteroaryl group is optionally substituted by 1-3 groups independently selected from hydroxyl, halogen, cyano, or amino. R 2'' is hydrogen, deuterium, C1-C6 alkyl or C3-C6 cycloalkyl, wherein the C1-C6 alkyl and C3-C6 cycloalkyl are optionally substituted by 1 to 3 groups independently selected from hydroxyl, halogen, cyano, amino or -OC(O)(C1-C6 alkyl).
[0012] Preferably, in some embodiments of the present invention, in PTM-1, ring A'' is a 9-10 membered bicyclic heteroaryl group containing one, two, or three heteroatoms selected from N, O, or S; preferably, ring A'' is... , , , , , , , or .
[0013] Preferably, in some embodiments of the present invention, the PTM is PTM-2 In the PTM-2 mentioned above: B is CH, N, O, or S; M can be CH, N, O, or S; D is either CH or N; E is either CH or N; F is either CH or N; G is either CH or N; J is either CH or N; When B or M is S or O, D is CH, E is N, F is CH, G is N and J is CH; and B and M cannot be both S and / or O at the same time. The rings A, R1, n, R4, and m are as described in PTM-1.
[0014] Preferably, in some embodiments of the present invention, the PTM-2 in for , , , or .
[0015] Preferably, in some embodiments of the present invention, the PTM is In the PTM-2′ and PTM-2′′ mentioned above: B is CH, N, O, or S; M can be CH, N, O, or S; D is either CH or N; E is either CH or N; F is either CH or N; G is either CH or N; J is either CH or N; When B or M is S or O, D is CH, E is N, F is CH, G is N and J is CH; and B and M cannot be both S and / or O at the same time. The rings A, A'', R1, n, R4, and m are as described in PTM-1.
[0016] Preferably, in some embodiments of the present invention, the PTM-2′ in for , , , , or .
[0017] Preferably, in some embodiments of the present invention, the PTM is: The rings A, A'', R1, R2, R3, R4, m, and n are defined and described as in PTM-1.
[0018] Preferably, in some embodiments of the present invention, among PTM-1, PTM-2, PTM-2′, and PTM-3: Ring A is phenyl or contains one, two or three 5-6 membered heteroaryl groups selected from N or O heteroatoms; preferably, ring A is phenyl, pyridinyl, pyrroloyl, pyrazolyl, imidazolyl, pyrimidinyl, triazolyl, tetrazolyl, thienyl, thiazolyl, furanyl, succinyl, isozolyl or isothiazolyl; more preferably, ring A is pyrazolyl or thienyl.
[0019] Preferably, in some embodiments of the present invention, n is 1 or 2 in PTM-1, PTM-2, PTM-2′ and PTM-3; preferably n is 2.
[0020] Preferably, in some embodiments of the present invention, R1 in PTM-1, PTM-2, PTM-2′ and PTM-3 is independently selected from: C1-C4 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclic alkyl, CN or halogen, wherein the alkyl, cycloalkyl and heterocyclic alkyl are optionally substituted with halogen, OH, CH3 or OCH3; preferably, R1 is independently selected from: C1-C4 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclic alkyl containing one or two N heteroatoms, CN or halogen, wherein the alkyl, cycloalkyl and heterocyclic alkyl are optionally substituted with halogen, OH, CH3 or OCH3; more preferably, R1 is CHF2, CF3, cyclohexyl, piperidinyl, methyl, cyano or piperidine.
[0021] Preferably, in some embodiments of the present invention, R1 in PTM-1, PTM-2, and PTM-3 is independently selected from: C1-C4 alkyl, C3-C6 cycloalkyl, 3-6-membered heterocyclic alkyl, CN, or halogen, wherein the alkyl, cycloalkyl, and heterocyclic alkyl are optionally substituted with halogen, OH, CH3, or OCH3; preferably, R1 is independently selected from: C1-C4 alkyl, C3-C6 cycloalkyl, 3-6-membered heterocyclic alkyl containing one or two N-heteroatoms, CN, or halogen, wherein the alkyl, cycloalkyl, and heterocyclic alkyl are optionally substituted with halogen, OH, CH3, or OCH3; further preferably, R1 is CHF2, CF3, cyclohexyl, piperidinyl, or piperidine.
[0022] In some embodiments of the present invention, R1 is independently selected from: C1-C4 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclic alkyl containing one or two N heteroatoms, CN or halogen, wherein the alkyl, cycloalkyl and heterocyclic alkyl are optionally substituted with halogen, OH, C1-C4 alkyl or C1-C4 alkoxy.
[0023] Preferably, in certain embodiments of the present invention, R2 and R3 in PTM-1, PTM-2, and PTM-3 are each independently selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, or 3-8-membered heterocyclic alkyl, each optionally substituted by one or more halogens, OH, N(Rb)2, or morpholinyl, or R2 and R3 together with the nitrogen atom to which they are attached form a 3-8-membered heterocyclic alkyl, the heterocyclic alkyl being optionally substituted by one or more substituents selected from Ra; Ra is independently selected from C1-C4 alkyl, C3-C6 cycloalkyl, CF3, CHF2, OH, halogen, or NH2, the alkyl being optionally substituted by C1-C4 alkyl, C3-C6 cycloalkyl, or CF3; and Rb is independently selected from H or C1-C4 alkyl; more preferably, R2 and R 3, together with the nitrogen atom to which they are attached, form a 3-8 member heterocyclic alkyl group containing one heterocyclic alkyl group selected from N or O in addition to the attached N atom. The heterocyclic alkyl group is optionally substituted by one or more substituents selected from Ra. Ra is independently selected from C1-C4 alkyl, CF3, CHF2, OH, halogen, or NH2. More preferably, R2 and R3, together with the nitrogen atom to which they are attached, form... More preferably, R2 and R3 together with the nitrogen atoms they are bonded to form .
[0024] Preferably, in some embodiments of the present invention, R2 and R3 together with the nitrogen atom to which they are attached form a 3-8 member heterocyclic alkyl group containing one heterooxygen atom selected from N, S, or O in addition to the attached N atom. The heterocyclic alkyl group is optionally substituted by one or more substituents selected from Ra. Ra is independently selected from C1-C4 alkyl groups, C1-C4 alkyl groups substituted with one, two, or three halogens (preferably C1-C4 alkyl groups substituted with one, two, or three fluorines, more preferably methyl groups substituted with one, two, or three fluorines), OH, halogens, or NH2. Preferably, R2 and R3 together with the nitrogen atom to which they are attached form... , , , , or .
[0025] Preferably, in certain embodiments of the present invention, R2 and R3 in PTM-1, PTM-2′ and PTM-3 are each independently selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl or 3-8 membered heterocyclic alkyl, each optionally substituted by one or more halogens, OH, N(Rb)2 or morphofolinyl, or R2 and R3 together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclic alkyl, the heterocyclic alkyl being optionally substituted by one or more substituents selected from Ra; Ra is independently selected from C1-C4 alkyl, C3-C6 cycloalkyl, CF3, CHF2, OH, halogen or NH2, the alkyl being optionally substituted by C3-C6 cycloalkyl or CF3; and Rb is independently selected from H or C1-C4 alkyl; preferably, R2 and R 3, together with the nitrogen atom to which they are attached, form a 3-8 member heterocyclic alkyl group containing one N or O heterooxy atom in addition to the attached N atom. The heterocyclic alkyl group is optionally substituted by one or more substituents selected from Ra; wherein Ra is independently selected from C1-C4 alkyl, CF3, CHF2, OH, halogen, or NH2; preferably, R2 and R3 together with the nitrogen atom to which they are attached form , , , , , , or .
[0026] Preferably, in certain embodiments of the present invention, R2 and R3 in PTM-1, PTM-2′ and PTM-3 are each independently selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl and 3-8 membered heterocyclic alkyl, each optionally substituted by one or more halogens, OH, N(Rb)2 and morphofolinyl, or R2 and R3 together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclic alkyl, the heterocyclic alkyl being optionally substituted by one or more substituents selected from Ra; Ra is independently selected from C1-C4 alkyl, C3-C6 cycloalkyl, CF3, CHF2, OH, halogen or NH2, the alkyl being optionally substituted by C1-C4 alkyl, C3-C6 cycloalkyl and CF3; and Rb is independently selected from H and C1-C4 alkyl; preferably, R2 and R 3, together with the nitrogen atom to which they are attached, form a 3-8 member heterocyclic alkyl group containing one N or O heterooxy atom in addition to the attached N atom. The heterocyclic alkyl group is optionally substituted by one or more substituents selected from Ra; wherein Ra is independently selected from C1-C4 alkyl, CF3, CHF2, OH, halogens, and NH2; preferably, R2 and R3 together with the nitrogen atom to which they are attached form , , , or .
[0027] Preferably, in some embodiments of the present invention, the PTM has the following structure: in, n′ is 0, 1, 2, or 3; R1, R2, R3, R4, m and n are described and defined as in PTM-1, PTM-2, PTM-2′ and PTM-3.
[0028] Preferably, in some embodiments of the present invention, the PTM has the following structure: The R1, R2, R3, R4, m and n mentioned therein are described and defined as in PTM-1, PTM-2, PTM-2′ and PTM-3.
[0029] Preferably, in some embodiments of the present invention, the PTM has the following structure: in, n′ is 0, 1, 2, or 3; R is each independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl or -O (C1-C6 alkyl), wherein the alkyl group is optionally substituted by 1 to 3 groups independently selected from hydroxyl, halogen, cyano and amino; p is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; R1, R2, R3, R4, m and n are described and defined as in PTM-1, PTM-2′ and PTM-3.
[0030] Preferably, in some embodiments of the present invention, the PTM has the following structure: The R1, R2 and R3 mentioned therein are described and defined as in PTM-1, PTM-2′ and PTM-3.
[0031] Preferably, in some embodiments of the present invention, the PTM has the following structure: , , . The R′ and p mentioned therein are defined and described as in PTM-3b′, PTM-3c′, and PTM-3d′.
[0032] Preferably, in some embodiments of the present invention, the PTM has the following structure: , , , , , , , , , , or .
[0033] In some embodiments of the present invention, one or two of Q1, Q2, Q3, Q4, and Q5 in the ULM-1 are N, and the rest are each independently CR 3''.
[0034] In some embodiments of the present invention, Q1, Q2, Q3, Q4, and Q5 in the ULM-1 are each independently CR 3''.
[0035] In some embodiments of the present invention, X'' in ULM-1 is N.
[0036] In some embodiments of the present invention, X'' in ULM-1 is C.
[0037] In some embodiments of the present invention, Y'' in ULM-1 is N.
[0038] In some embodiments of the present invention, each of R 1'' in the ULM-1 is independently hydrogen, deuterium, -F, -Cl, or C1-C6 alkyl, wherein the alkyl group is optionally substituted with 1-3 halogens; preferably R 1'' is hydrogen.
[0039] In some embodiments of the present invention, R 2'' in ULM-1 is hydrogen or C1-C6 alkyl, wherein the alkyl group is optionally substituted with 1-3 halogens; preferably R 2'' is hydrogen.
[0040] In some embodiments of the present invention, each of the R 3'' in the ULM-1 is independently hydrogen, deuterium, halogen, -O (C1-C6 alkyl), or C1-C6 alkyl, wherein the alkyl group is optionally substituted with 1-3 halogens; preferably, each of the R 3'' is independently hydrogen, deuterium, F, Cl, methyl, methoxy, ethoxy, trifluoromethoxy, 2-hydroxypropyl-2-yl or trifluoromethyl.
[0041] In some embodiments of the present invention, each of R 3'' is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl or -O (C1-C6 alkyl); the alkyl group is optionally substituted by 1 to 3 groups independently selected from hydroxyl and halogen groups.
[0042] In some embodiments of the present invention, the ULM has the following structure. ULM-1a The Q1, Q2, Q3, Q4, Q5, R1'', R2'' and m'' mentioned above are as defined in ULM-1.
[0043] In some embodiments of the present invention, the ULM has the following structure. ULM-1b The R1'', R2'', R3'' and m'' mentioned therein are as defined in ULM-1 above.
[0044] In some embodiments of the present invention, the ULM has the following structure. ULM-1c The R1'', R2'' and R3'' mentioned therein are as defined in ULM-1 above.
[0045] In some embodiments of the present invention, the ULM has the following structure. ULM-1d The R 3'' mentioned therein is as defined in ULM-1 above.
[0046] In some embodiments of the present invention, the ULM has the following structure. ULM-1e The Q1, Q2, Q3, Q5, R1'', R2'', and m'' mentioned above are as defined in ULM-1.
[0047] In some embodiments of the present invention, the ULM has the following structure. ULM-1f The R1'', R2'', R3'', and m'' mentioned therein are as defined in ULM-1 above.
[0048] In some embodiments of the present invention, the ULM has the following structure. ULM-1g The R1'', R2'', and R3'' mentioned therein are as defined in ULM-1 above. ULM-1h The R 3'' mentioned therein is as defined in ULM-1 above.
[0049] In some embodiments of the present invention, the ULM has the following structure. ;R 3'' is a halogen, C1-C6 alkyl, or -O (C1-C6 alkyl).
[0050] In some embodiments of the present invention, the ULM is selected from... or .
[0051] In some embodiments of the present invention, the ULM is selected from... or Preferred , , , or .
[0052] In some embodiments of the present invention, the ULM has the following structure. ULM-1aa The terms Q1, Q2, Q3, Q4, Q5, R1'', R2'', and m'' are as defined in ULM-1 above.
[0053] In some embodiments of the present invention, the ULM has the following structure. ULM-1bb The R1'', R2'', R3'', and m'' mentioned therein are as defined in ULM-1 above.
[0054] In some embodiments of the present invention, the ULM has the following structure. ULM-1cc The R1'', R2'', and R3'' mentioned therein are as defined in ULM-1 above.
[0055] In some embodiments of the present invention, the ULM has the following structure. ULM-1dd The R 3'' mentioned therein is as defined in ULM-1 above.
[0056] In some embodiments of the present invention, the ULM has the following structure. ULM-1ee The Q1, Q2, Q3, Q5, R1'', R2'', and m'' mentioned above are as defined in ULM-1.
[0057] In some embodiments of the present invention, the ULM has the following structure. ULM-1ff The R1'', R2'', R3'', and m'' mentioned therein are as defined in ULM-1 above.
[0058] In some embodiments of the present invention, the ULM has the following structure. ULM-1gg The R1'', R2'', and R3'' mentioned therein are as defined in ULM-1 above. ULM-1hh The R 3'' mentioned therein is as defined in ULM-1 above.
[0059] In some embodiments of the present invention, the ULM is selected from... or .
[0060] In some embodiments of the present invention, the ULM is selected from... or .
[0061] In some embodiments of the present invention, L is a key.
[0062] In some embodiments of the present invention, L is -(CH 2) j-, and one or more methylene groups in -(CH 2) j- are optionally selected from -NR 3'-, -O-, -S-, -S(O)-, -S(O)NR 3'-, -NR 3'S(O)-, -S(O) 2-, -S(O) 2NR 3'-, -NR 3'S(O) 2-, -NR 4'S(O) 2NR 3'-, -CR 1'R 2'-, -C(O)-, -C(O)O-, -OC(O)-, -NR 3'C(O)O-, -OC(O)NR 3'-, -C(O)NR 3'-, -NR 3'C(O)-, -NR 4'C(O)NR 3'-, -P(O)-, -P(O)O-, -OP(O)-, -OP(O)O-, vinylene, ethynylene, C3-C12 cycloalkylene, 3-12-membered heterocyclic alkylene, 6-10-membered arylene, or 5-10-membered heteroaryl groups containing one or more heteroatoms selected from N, O, or S, wherein the vinylene, cycloalkylene, heterocyclic alkylene, arylene, and heteroaryl groups are each optionally and independently replaced by one or more groups selected from halogen, -OR 3', -NR 3'R 4', oxo, nitro, cyano, C1-C6 alkyl, -S(C1-C6 alkyl), C3-C10 cycloalkyl, 3-10-membered heterocyclic alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, -C(O)R 1', -C(O)OR 3', -OC(O)R 1', -C(O)NR 3', -NR 3'C(O)R 1', -S(O)R 1', -S(O)NR 3', -S(O) 2R 1', -S(O) 2NR 3', -NR 3'S(O) 2R 1', -NR 4'S(O) 2NR 3', -OC(O)NR 3' and NR 4'C(O)NR 3', wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are each independently and optionally substituted by one or more substituents selected from halogens, -OH, -NR 3'R 4', oxo, nitro, cyano, C1-C6 alkyl, C3-C10 cycloalkyl, 3-10-membered heterocycloalkyl, 6-10-membered aryl and 5-10-membered heteroaryl groups;R1' and R2' are each independently a halogen, -OH, -NR3'R4', C1-C6 alkyl, chloroC1-C6 alkyl, hydroxyC1-C6 alkyl, -O (C1-C6 alkyl), -NH (C1-C6 alkyl), -NH (C1-C6 alkyl), C3-C10 cycloalkyl, -O (C3-C10 cycloalkyl), -NH (C3-C10 cycloalkyl), 3-10 heterocyclic alkyl, -O (3-10 heterocyclic alkyl), -NH (3-10 heterocyclic alkyl), 6-10 aryl, -O (6-10 aryl), -NH (6-10 aryl), 5-10 heteroaryl, -O (5-10 heteroaryl) or -NH (5-10 heteroaryl), R3' and R 4' is independently hydrogen, deuterium, C1-C6 alkyl, C3-C10 cycloalkyl, 3-10 heterocyclic alkyl, 6-10 aryl, or 5-10 heteroaryl; j is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
[0063] In some embodiments of the present invention, L is -(CH 2) j-, and one or more methylene groups in -(CH 2) j- are optionally selected from -NR 3'-, -O-, -S-, -S(O)-, -S(O)NR 3'-, -NR 3'S(O)-, -S(O) 2-, -S(O) 2NR 3'-, -NR 3'S(O) 2-, -NR 4'S(O) 2NR 3'-, -CR 1'R 2'-, -C(O)-, -C(O)O-, -OC(O)-, -NR 3'C(O)O-, -OC(O)NR 3'-, -C(O)NR 3'-, -NR 3'C(O)-, -NR 4'C(O)NR 3'-, -P(O)-, -P(O)O-, -OP(O)-, -OP(O)O-, vinylene, ethynylene, C3-C12 cycloalkylene, 3-12-membered heterocyclic alkylene, 6-10-membered arylene, or 5-10-membered heteroaryl groups containing one or more heteroatoms selected from N, O, or S, wherein the vinylene, cycloalkylene, heterocyclic alkylene, arylene, and heteroaryl groups are each optionally and independently replaced by one or more groups selected from halogen, -OR 3', -NR 3'R 4', oxo, nitro, cyano, C1-C6 alkyl, -S(C1-C6 alkyl), C3-C10 cycloalkyl, 3-10-membered heterocyclic alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, -C(O)R 1', -C(O)OR 3', -OC(O)R 1', -C(O)NR 3', -NR 3'C(O)R 1', -S(O)R 1', -S(O)NR 3', -S(O) 2R 1', -S(O) 2NR 3', -NR 3'S(O) 2R 1', -NR 4'S(O) 2NR 3', -OC(O)NR 3' and NR 4'C(O)NR 3', wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are each independently and optionally substituted by one or more substituents selected from halogens, -OH, -NR 3'R 4', oxo, nitro, cyano, C1-C6 alkyl, C3-C10 cycloalkyl, 3-10-membered heterocycloalkyl, 6-10-membered aryl and 5-10-membered heteroaryl groups;R1' and R2' are each independently a halogen, -OH, -NR3'R4', C1-C6 alkyl, chloroC1-C6 alkyl, hydroxyC1-C6 alkyl, -O (C1-C6 alkyl), -NH (C1-C6 alkyl), -NH (C1-C6 alkyl), C3-C10 cycloalkyl, -O (C3-C10 cycloalkyl), -NH (C3-C10 cycloalkyl), 3-10 heterocyclic alkyl, -O (3-10 heterocyclic alkyl), -NH (3-10 heterocyclic alkyl), 6-10 aryl, -O (6-10 aryl), -NH (6-10 aryl), 5-10 heteroaryl, -O (5-10 heteroaryl) or -NH (5-10 heteroaryl), R3' and R 4' is independently hydrogen, deuterium, C1-C6 alkyl, C3-C10 cycloalkyl, 3-10 heterocyclic alkyl, 6-10 aryl, or 5-10 heteroaryl; j is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
[0064] Preferably, in some embodiments of the present invention, L is -(CH 2) j-, and one or more methylene groups in -(CH 2) j- are optionally selected from -NR 3'-, -O-, -CR 1'R 2'-, -C(O)-, -S(O)-, -S(O) 2-, -C(O)O-, -OC(O)-, -C(O)NR 3'-, -NR 3'C(O)-, -S(O) 2NR 3'-, -NR 3'S(O) 2-, vinylidene, ethynylidene, phenyl, 8-10-membered bicyclic arylide, 3-7-membered saturated / or partially unsaturated cycloalkylene, 4-11-membered saturated / or partially unsaturated spirocycloalkylene, 4-11-membered saturated / or partially unsaturated cycloalkylene, 8-10 Bicyclic saturated / partially unsaturated cycloalkylene groups; 4-7 saturated / partially unsaturated heterocyclic alkylene groups having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms; 4-11 saturated / partially unsaturated spirocyclic alkylene groups having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms; 4-11 saturated / partially unsaturated fused heterocyclic alkylene groups having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms; 8- The 10-membered bicyclic saturated / partially unsaturated heterocyclic alkylene group, a 5-6-membered heteroaryl group having 1-4 independently selected nitrogen, oxygen, or sulfur heteroatoms, or an 8-10-membered bicyclic heteroaryl group having 1-5 independently selected nitrogen, oxygen, or sulfur heteroatoms, wherein the vinylene, ethynylene, cycloalkylene, heterocyclic alkylene, phenyl, spirocycloalkylene, fused heterocyclic alkylene, spirocycloalkylene, fused heterocyclic alkylene, and heteroaryl group are each optionally and independently replaced by one or more groups selected from halogen, oxo, -NR. 3'R 4', -OR 3', nitro, -CN, C1-C6 alkyl, C3-C10 cycloalkyl, and 3-10 heterocyclic alkyl groups are substituted, wherein the alkyl, cycloalkyl, and heterocyclic alkyl groups are optionally substituted by one or more substituents selected from halogens, -OH, -NH 2, -CN, C1-C4 alkyl, and C3-C6 cycloalkyl, and R 1' and R 2' are each independently substituted by halogens, -OH, -NH 2, C1-C4 alkyl, C1-C4 chloroalkyl, C1-C4 hydroxyalkyl, -O (C1-C4 alkyl), -NH (C1-C4 alkyl), -NH (C1-C4 alkyl), C3-C6 cycloalkyl, -O (C3-C6 cycloalkyl), -NH (C3-C4 cycloalkyl), C3-C6 cycloalkyl, -O (C3-C6 cycloalkyl), -NH (C3-C4 cycloalkyl), -6-membered cycloalkyl), 3-6-membered heterocycloalkyl, -O (3-6-membered heterocycloalkyl) or -NH (C3-C6 cycloalkyl); R3' and R4' are each independently hydrogen, deuterium, C1-C4 alkyl, C3-C6 cycloalkyl or 3-6-membered heterocycloalkyl, and j is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.
[0065] Preferably, in some embodiments of the present invention, L is -(CH 2) j-, and one or more methylene groups in -(CH 2) j- are optionally selected from -NR 3'-, -O-, -CR 1'R 2'-, -C(O)-, -S(O)-, -S(O) 2-, -C(O)O-, -OC(O)-, -C(O)NR 3'-, -NR 3'C(O)-, -S(O) 2NR 3'-, -NR 3'S(O) 2-, vinylidene, ethynylidene, phenyl, 8-10 member bicyclic arylide, 3-7 member saturated / partially unsaturated monocyclic cycloalkylene, 4-11 member saturated / partially unsaturated spirocycloalkylene, 4-11 member saturated / partially unsaturated cycloalkylene, 8-10 member bicyclic arylide, 3-7 member saturated / partially unsaturated monocyclic cycloalkylene, 4-11 member saturated / partially unsaturated cycloalkylene, 8-10 member bicyclic arylide, 4-10 member bicyclic arylide, 4-11 member bicyclic arylide, 8-10 member bicyclic arylide, 4-10 member bicyclic arylide, 4-11 member bicyclic arylide, 8-10 member bicyclic arylide, 4-11 member bicyclic arylide, 4 ... Bicyclic saturated / or partially unsaturated cycloalkylene groups; 4-7 saturated / or partially unsaturated heterocyclic alkylene groups having 1-2 independently selected nitrogen or oxygen heteroatoms; 4-11 saturated / or partially unsaturated spirocyclic alkylene groups having 1-2 independently selected nitrogen or oxygen heteroatoms; 4-11 saturated / or partially unsaturated fused heterocyclic alkylene groups having 1-2 independently selected nitrogen or oxygen heteroatoms; 8-10 saturated heterocyclic alkylene groups having 1-2 independently selected nitrogen or oxygen heteroatoms. The bicyclic saturated / partially unsaturated heterocyclic alkylene groups, 5-6-membered heterocyclic aryl groups having 1-4 independently selected nitrogen or oxygen heteroatoms, or 8-10-membered bicyclic heterocyclic aryl groups having 1-5 independently selected nitrogen or oxygen heteroatoms, wherein the vinylene, ethynylene, cycloalkylene, heterocyclic alkylene, phenyl, spirocycloalkylene, fused heterocyclic alkylene, fused heterocyclic alkylene, spirocycloalkylene, and heterocyclic aryl groups are each optionally and independently replaced by one or more groups selected from halogen, oxo, -NR. 3'R 4', -OR 3', nitro, -CN, C1-C6 alkyl, C3-C6 cycloalkyl, and 3-6 membered heterocyclic alkyl groups are substituted, wherein the alkyl, cycloalkyl, and heterocyclic alkyl groups are optionally substituted by one or more substituents selected from halogens, -OH, -NH 2, -CN, C1-C4 alkyl, and C3-C6 cycloalkyl groups, and R 1' and R 2' are each independently substituted by halogens, -OH, -NH 2, C1-C4 alkyl, C1-C4 chloroalkyl, C1-C4 hydroxyalkyl, -O (C1-C4 alkyl), -NH (C1-C4 alkyl), -NH (C1-C4 alkyl), C3-C6 cycloalkyl, -O (C3-C6 cycloalkyl), -NH (C3-C6 cycloalkyl), and -NH (C3-C6 cycloalkyl). -6-membered cycloalkyl), 3-6-membered heterocycloalkyl, -O (3-6-membered heterocycloalkyl) or -NH (C3-C6 cycloalkyl); R3' and R4' are each independently hydrogen, deuterium, C1-C4 alkyl, C3-C6 cycloalkyl or 3-6-membered heterocycloalkyl, and j is 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0066] Preferably, in some embodiments of the present invention, L is -(CH 2) j-, and one, two, three, or four methylene groups in -(CH 2) j- are optionally selected from -NH-, -NCH 3-, -NCH 2CH 3-, -O-, -C(CH 3) 2-, -CHF-, -CHCF 3-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -C(O)NCH 3-, -NHC(O)-, -NCH 3C(O)-, vinylidene, ethynylidene, cyclopropylidene, cyclobutylidene, cyclopentylidene, cyclohexylidene, oxadicyclopropylidene, oxadicyclobutylidene, oxadicyclopentylidene, oxadicyclohexylidene, azapyridineidene, azapyridineidene, azapyridineidene, morphofolinyl, morphofolinyl, phenylene, pyrrolidineidene, thiopheneylidene, furanylidene, imidazolyl, pyrazolidineidene, triazolidineidene, tetrazolidineidene, azolidineidene, isozolidineidene, thiazolyl, isothiazolidineidene, pyridinidineidene, pyridinidineidene, pyridinidineidene , , , , , , , , , , , and The substituent group is replaced by one or more substituents selected from halogens, oxo-, -NR 3'R 4', -OR 3', C1-C4 alkyl groups, wherein the alkyl group is optionally replaced by one or more substituents selected from halogens, -OH and -NH 2, wherein R 3' and R 4' are each independently hydrogen, deuterium or C1-C4 alkyl, and j is 2, 3, 4, 5, 6, 7 or 8.
[0067] Preferably, in some embodiments of the present invention, L is -(CH 2) j-, and one, two, or three methylene groups in -(CH 2) j- are optionally selected from -NH-, -NCH 3-, -NCH 2CH 3-, -O-, -C(CH 3) 2-, -CHF-, -CHCF 3-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -C(O)NCH 3-, -NHC(O)-, -NCH 3C(O)-, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, oxadicyclopropylene, oxadicyclobutylene, oxadicyclopentylene, oxadicyclohexylene, azapyridine, azapyridine, azapyridine, morphophoryl, morphophoryl, morphophoryl , , , , , , , , , , , and The substituent group is replaced by one or more substituents selected from F, Cl, oxo, -NR 3'R 4', -OR 3' and C1-C4 alkyl, the alkyl group is optionally replaced by one or more substituents selected from halogen, -OH and -NH 2, R 3' and R 4' are each independently hydrogen, deuterium, methyl, ethyl and propyl, and j is 2, 3, 4, 5, 6, 7 or 8.
[0068] Preferably, in some embodiments of the present invention, L is -(CH 2) j-, and one, two, or three methylene groups in -(CH 2) j- are optionally selected from -O-, -NH-, -NCH 3-, -NCH 2CH 3-, -C(O)-, -C(O)NH-, -NHC(O)-, -NCH 3C(O)-, -C(O)NCH 3-, , , , , , or The group substitution, j is 2, 3, 4, 5, 6, 7 or 8.
[0069] Preferably, in some embodiments of the present invention, L is selected from -(CH 2) j-1-C(O)-, wherein the methylene group in -(CH 2) j-1-C(O)- is as defined in L above, and is optionally replaced by one or more groups, wherein j is as defined in L above.
[0070] Preferably, in some embodiments of the present invention, L is selected from... or .
[0071] Preferably, in some embodiments of the present invention, L is LA. LA In the LA mentioned above: Ring D is absent or is a C3-C12 cycloalkyl group or contains 1-2 3-12 membered heteroalkyl groups selected from N, O, or S heteroatoms, wherein the cycloalkyl groups and heteroalkyl groups are optionally substituted with substituents selected from deuterium, halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl). Ring B is absent or is a C3-C12 heterocyclic alkyl group or contains 1-2 3-12 membered heterocyclic alkyl groups selected from N, O, or S heteroatoms, wherein the heterocyclic alkyl group and heterocyclic alkyl group are optionally substituted with a substituent selected from deuterium, halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl) substituents; The ring C is absent, a C3-C12 cycloalkyl group, or a 3-12 membered heteroalkyl group containing 1-2 heteroatoms selected from N, O, or S. The cycloalkyl group and heteroalkyl group may optionally be substituted with a substituent selected from deuterium, halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl). X'''' represents a bond, -NH-, -NCH 3-, -O-, -C(CH 3) 2-, -S-, -C=C-, -C≡C-, -CHF-, -CHCF 3-, -C(O)-, -S(O)-, -S(O) 2-, -C(O)O-, -OC(O)-, -C(O)NH-, -C(O)NCH 3-, -NHC(O)-, or -NCH 3C(O)-; L3 is -(CH2)k-, wherein one or both methylene groups in L3 are optionally replaced by a group selected from deuterium, -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -N(C1-C6 hydroxyalkyl)- or -N(C3-C8 cycloalkyl)-, and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0072] Preferably, in some embodiments of the present invention, L is LA. LA In the LA mentioned above: Ring D is absent or is a C3-C12 heterocyclic alkyl group or contains 1-2 3-12 membered heterocyclic alkyl groups selected from N, O or S heteroatoms, wherein the heterocyclic alkyl groups and heterocyclic alkyl groups are optionally substituted with substituents selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl or -O-(C1-C6 alkyl) substituents; Ring B is absent or is a C3-C12 heterocyclic alkyl group or contains 1-2 3-12 membered heterocyclic alkyl groups selected from N, O, or S heteroatoms, wherein the heterocyclic alkyl group and heterocyclic alkyl group are optionally substituted with a substituent selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl) substituents; The ring C is absent, a C3-C12 heterocyclic alkyl group, or a 3-12 membered heterocyclic alkyl group containing 1-2 heteroatoms selected from N, O, or S. The heterocyclic alkyl group and heterocyclic alkyl group may optionally be substituted with a substituent selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl). X'''' represents a bond, -NH-, -NCH 3-, -O-, -C(CH 3) 2-, -S-, -C=C-, -C≡C-, -CHF-, -CHCF 3-, -C(O)-, -S(O)-, -S(O) 2-, -C(O)O-, -OC(O)-, -C(O)NH-, -C(O)NCH 3-, -NHC(O)-, or -NCH 3C(O)-; L3 is -(CH2)k-, wherein one or both methylene groups in L3 are optionally replaced by a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -N(C1-C6 hydroxyalkyl)- or -N(C3-C8 cycloalkyl)-, and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0073] Preferably, in some embodiments of the present invention, L is LA. LA In the LA mentioned above: The ring D is absent; it is a 6-10 aryl group, a 5-10 heteroaryl group, or a C3-C12 cycloalkylene group or a 3-12 heteroalkylene group containing 1-2 heteroatoms selected from N, O, or S; the cycloalkylene group and heteroalkylene group may optionally be substituted with a substituent selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl); Ring B is absent or is a C3-C12 heterocyclic alkyl group or contains 1-2 3-12 membered heterocyclic alkyl groups selected from N, O, or S heteroatoms, wherein the heterocyclic alkyl group and heterocyclic alkyl group are optionally substituted with a substituent selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl) substituents; The ring C is absent, a C3-C12 heterocyclic alkyl group, or a 3-12 membered heterocyclic alkyl group containing 1-2 heteroatoms selected from N, O, or S. The heterocyclic alkyl group and heterocyclic alkyl group may optionally be substituted with a substituent selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl). X'''' is a bond, -NH-, -NCH 3-, -O-, -C(CH 3) 2-, -S-, -C=C-, -C≡C-, -CHF-, -CHCF 3-, -C(O)-, -S(O)-, -S(O) 2-, -C(O)O-, -OC(O)-, -C(O)NH-, -C(O)NCH 3-, -NHC(O)-, -(CH 2) t- or -NCH 3C(O)-; one or more methylene groups in -(CH 2) t- are optionally replaced by a group selected from -O-, -NH-, -C≡C-, -N(C 1-C 6 alkyl)-, -C(O)-, and t is 0, 1, 2, 3, 4, 5, 6 or 7.
[0074] L3 is -(CH2)k-, wherein one or both methylene groups in L3 are optionally replaced by a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -N(C1-C6 hydroxyalkyl)-, -C≡C-, -C(O)- or -N(C3-C8 cycloalkyl)-, and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Preferably, in some embodiments of the present invention, when ring A'' is a 5-11 membered bicyclic heteroaryl containing one, two, or three heteroatoms selected from N, O, or S, and ring D is a 6-10 membered aryl, 5-10 membered heteroaryl, C3-C12 cycloalkylene, or a 3-12 membered heteroalkylene containing one or two heteroatoms selected from N, O, or S, the cycloalkylene and heteroalkylene are substituted with substituents selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, and -O-(C1-C6 alkyl).
[0075] Preferably, in some embodiments of the present invention, when ring A'' is In this case, ring D is a C3-C12 cycloalkylene group or contains 1-2 3-12 heteroalkylene groups selected from N, O or S heteroatoms, wherein the cycloalkylene group and heteroalkylene group are independently substituted by 1, 2 or 3 hydroxyl groups or by 1, 2 or 3 -O- (C1-C6 alkyl) groups.
[0076] In some embodiments of the present invention, L is LA. LA The LA mentioned therein is Scheme 1, Scheme 2, Scheme 3 or Scheme 4. Option 1 Ring D is a C3-C12 cyclohexane or a 3-12 membered heterocyclic alkyl group containing 1-2 N heteroatoms, wherein the cyclohexane and heterocyclic alkyl group are optionally selected from halogens, -O-(C1-C6 alkyl) or hydroxyl groups; Ring B is a C3-C12 cyclohexane or a 3-12 membered heterocyclic alkyl group containing 1-2 heteroatoms selected from N, O, or S. The cyclohexane and heterocyclic alkyl groups may optionally be substituted with a substituent selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl). Ring C does not exist; X'''' is -C(O)-; L3 is -(CH2)k-, wherein one or both methylene groups in L3 are optionally replaced by a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -C(O)-, -N(C1-C6 hydroxyalkyl)- or -N(C3-C8 cycloalkyl)-, and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Option 2 Ring D is a C3-C12 cycloalkylene group or a 3-12 membered heteroalkylene group containing 1-2 N heteroatoms, wherein the cycloalkylene group and heteroalkylene group are optionally selected from halogens, methoxy groups, or hydroxyl groups; Ring B is a 7-11 membered spirocyclic or fused heterocyclic alkyl group containing one or two nitrogen atoms; Ring C does not exist; X'''' is -C(O)-; L3 is -(CH2)k-, where k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; Option 3 Ring D is a C3-C12 cycloalkylene group or a 3-12 membered heteroalkylene group containing 1-2 N heteroatoms, wherein the cycloalkylene group and heteroalkylene group are optionally selected from halogens, hydroxyl groups, or methoxy groups; Ring B is a 3-12 membered heterocyclic alkyl group containing 1-2 heteroatoms selected from N, O, or S. Ring C does not exist; X'''' is -C(O)-; L3 is -(CH2)k-, where k is 1, 2, 3 or 4. Option 4 Ring D is a cyclohexene group or a 6-membered heterocyclic alkyl group containing 1-2 N heteroatoms, wherein the cyclohexene group and the 6-membered heterocyclic alkyl group are optionally selected from halogens, hydroxyl groups, or methoxy groups; Ring B is , or (For example , ); Ring C does not exist; X'''' is -C(O)-; L3 is -(CH2)k-, and one or both methylene groups in L3 are replaced by a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -C(O)-, -N(C1-C6 hydroxyalkyl)- or -N(C3-C8 cycloalkyl)-, and k is 1, 2, 3 or 4.
[0077] Preferably, in some embodiments of the present invention, ring D is absent in LA.
[0078] Preferably, in some embodiments of the present invention, in the LA, ring D is a 4-7 member saturated monocyclic heterocyclic alkyl group containing one or two nitrogen atoms, a 7-11 member spirocyclic alkyl group containing one or two nitrogen atoms, or a fused heterocyclic alkyl group.
[0079] Preferably, in some embodiments of the present invention, in the LA, ring D is a 6-10 aryl group, a 4-7 saturated monocyclic heterocyclic alkyl group containing 1 or 2 nitrogen atoms, a 7-11 spirocyclic alkyl group containing 1 or 2 nitrogen atoms, or a fused heterocyclic alkyl group.
[0080] Preferably, in some embodiments of the present invention, in the LA, ring D is a 4-7 member saturated monocyclic heterocyclic alkyl group containing one or two nitrogen atoms, a 7-11 member spirocyclic alkyl group containing one or two nitrogen atoms, or a fused heterocyclic alkyl group.
[0081] Preferably, in some embodiments of the present invention, in the LA, ring D is a 7-11 member spirocycloalkyl group containing one or one nitrogen atom.
[0082] Preferably, in some embodiments of the present invention, in the LA, ring D is a 7-11 member spirocycloalkyl group containing one or two nitrogen atoms.
[0083] Preferably, in some embodiments of the present invention, in the LA, ring D is , , , , or .
[0084] Preferably, in some embodiments of the present invention, ring B is absent in LA.
[0085] Preferably, in some embodiments of the present invention, in the LA, ring B is a 4-7 member saturated monocyclic heterocyclic alkyl group containing one or two nitrogen atoms, a 7-11 member spirocyclic alkyl group containing one or two nitrogen atoms, or a fused heterocyclic alkyl group.
[0086] Preferably, in some embodiments of the present invention, in the LA, ring B is a 4-7 member saturated monocyclic heterocyclic alkyl group containing one or two nitrogen atoms.
[0087] Preferably, in some embodiments of the present invention, in the LA, ring B is piperidinyl, piperidinyl, or... , , , , , , or .
[0088] Preferably, in certain embodiments of the present invention, the cyclic C is a 4-11 member saturated or partially unsaturated spirocycloalkyl, a 4-11 member saturated or partially unsaturated fused cycloalkyl, an 8-10 member bicyclic saturated or partially unsaturated cycloalkyl, a 4-7 member saturated or partially unsaturated heterocycloalkyl having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms, a 4-11 member saturated or partially unsaturated spirocycloalkyl, a 4-11 member saturated / or partially unsaturated fused heterocycloalkyl having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms, or an 8-10 member bicyclic saturated / or partially unsaturated heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are optionally selected from deuterium, halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6... Substitution with 6-hydroxyalkyl and -O-(C1-C6alkyl) substituents.
[0089] Preferably, in certain embodiments of the present invention, in the LA, the ring C is a 3-7 member saturated or partially unsaturated cycloalkylene group, a 4-11 member saturated or partially unsaturated spirocycloalkylene group, a 4-11 member saturated or partially unsaturated fused cycloalkylene group, an 8-10 member bicyclic saturated or partially unsaturated cycloalkylene group, a 4-7 member saturated or partially unsaturated heteroalkylene group having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms, a 4-11 member saturated or partially unsaturated spirocycloalkylene group having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms, a 4-11 member saturated / or partially unsaturated fused heteroalkylene group having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms, or an 8-10 member bicyclic saturated / or partially unsaturated heteroalkylene group having 1-2 independently selected nitrogen, oxygen, or sulfur heteroatoms.
[0090] Preferably, in some embodiments of the present invention, in the LA, the ring C is a 4-7 member saturated monocyclic heterocyclic alkyl group containing one or two nitrogen atoms, a 7-11 member spirocyclic alkyl group containing one or two nitrogen atoms, or a fused heterocyclic alkyl group.
[0091] Preferably, in some embodiments of the present invention, in the LA, the ring C is a 7-11 member spirocycloalkyl or fused heterocycloalkyl containing one or two nitrogen atoms.
[0092] Preferably, in some embodiments of the present invention, in the LA, ring C is , , , , , , or .
[0093] Preferably, in some embodiments of the present invention, in the LA, ring C is , , , or .
[0094] Preferably, in some embodiments of the present invention, in LA, X'''' is a bond, -CH 2- or -C(O)-.
[0095] Preferably, in some embodiments of the present invention, in the LA, X'''' is a bond or -C(O)-.
[0096] Preferably, in some embodiments of the present invention, X'''' in LA is -C(O)-.
[0097] Preferably, in some embodiments of the present invention, in LA, L3 is -(CH2)k-, and one methylene group in L3 is optionally replaced by a group selected from -O-, -NH-, -NCH3- or -NCH2CH3-; k is 1, 2, 3 or 4.
[0098] Preferably, in some embodiments of the present invention, in LA, L3 is -(CH2)k-, and one or two methylene groups in L3 are optionally replaced by a group selected from deuterium-C(O)-, -O-, -NH-, -NCH3- or -NCH2CH3-; k is 1, 2, 3 or 4.
[0099] Preferably, in some embodiments of the present invention, ring D and ring B are absent in LA, ring C is a 7-11 member spirocycloalkyl group containing one or two nitrogen atoms; X'''' is -C(O)-; L3 is -(CH2)k-; k is 1, 2, 3, 4 or 5.
[0100] Preferably, in some embodiments of the present invention, formula L is selected from... .
[0101] Preferably, in some embodiments of the present invention, ring D and ring B are absent in LA, ring C is a 4-7 membered heterocyclic alkyl group containing one or two nitrogen atoms; X'''' is -C(O)-, bond or -CH 2-; L 3 is -(CH 2) k-; k is 1, 2, 3, 4 or 5.
[0102] Preferably, in some embodiments of the present invention, formula L is selected from... or .
[0103] Preferably, in some embodiments of the present invention, in LA, ring D is a C4-C7 membered cycloalkyl or a 4-7 membered heterocycloalkyl; ring B and ring C are 5-11 membered heterocyclic alkylenes that are absent or contain one or two nitrogen atoms; X'''' is -C(O)- or -(CH2)t-, where t is 0, 1, 2, 3, 4 or 5; L3 is -(CH2)k-, where k is 1, 2, 3, 4 or 5.
[0104] Preferably, in some embodiments of the present invention, formula L is selected from... Preferred .
[0105] In some embodiments of the present invention, the pharmaceutically acceptable salt may be a formate.
[0106] Preferably, in certain embodiments of the present invention, the compound of formula I, its stereoisomers, enantiomers, diastereomers, deuterated derivatives, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts are: , ,
[0107] Preferably, in certain embodiments of the present invention, the compound of Formula I, and / or its stereoisomers, enantiomers, diastereomers, deuterates, metabolites, hydrates, solvents, prodrugs, and / or pharmaceutically acceptable salts thereof are... or .
[0108] The present invention also discloses a compound of formula VII or VIII, the stereoisomer, enantiomer, diastereomer, deuteride or salt thereof: Z is , , , , , , 、 , , , , , , or ; Z' is , , or ; Wherein, m, n, A, A', R1, R2, R3 and R4 are as described above.
[0109] In some embodiments of the present invention, the compound of formula VII is the compound shown in formula VII-1. .
[0110] In some embodiments of the present invention, The compound of formula VII is any one of the following compounds: , , , , , , , , , , , , , , , , , , , , , , 、 , , , ; And / or, the compound of formula VIII is any of the following compounds: , , or .
[0111] Preferably, in certain embodiments of the present invention, the compound of formula I, and / or its stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof are compounds of formula II, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof. II The R1, n, R4, B, D, E, F, G, J and ring A are defined and described as in PTM-2'; the Q1, Q2, Q3, Q4, Q5, X'', Y'', m'', R1'', R2'' are defined and described as in ULM-1; and the L3, ring D, ring B, ring C and X'''' are defined and described as in LA.
[0112] Preferably, in certain embodiments of the present invention, the compound of formula I, and / or its stereoisomers, enantiomers, diastereomers, deuterates, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof are compounds of formula III, and / or their stereoisomers, enantiomers, diastereomers, deuterates, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof. III Wherein R1, n, R2, R3, and ring A are defined and described as in PTM-3; Q1, Q2, Q3, Q4, Q5, X'', Y'', m'', R1'', and R2'' are defined and described as in ULM-1; and L3, ring D, ring B, ring C, and X'''' are defined and described as in LA.
[0113] Preferably, in certain embodiments of the present invention, the compound of formula I, and / or its stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof are compounds of formula IV, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof. IV Wherein R1, n, R2, R3, and ring A are defined and described as in PTM-3; X'', m'', and R3'' are defined and described as in ULM-1 of this document; L3 is defined and described as in LA of this document; o, p, q, and r are each independently 1 or 2; w1 and w2 are each independently CH or N, and at least one of them is N.
[0114] Preferably, in certain embodiments of the present invention, the compound of formula I, and / or its stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof, are compounds of formula V, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof. V Wherein R1, n, R4, B, D, E, F, G, J and ring A″ are defined and described as in PTM-2′; Q1, Q2, Q3, Q4, Q5, X'', Y'', m'', R1'', R2'' are defined and described as in ULM-1 of this document; and L3, ring D, ring B, ring C and X'''' are defined and described as in LA of this document.
[0115] Preferably, in certain embodiments of the present invention, the compound of formula I, and / or its stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof are compounds of formula VI, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, metabolites, hydrates, solvates, prodrugs, and / or pharmaceutically acceptable salts thereof. VI Wherein R1, n, R2, R3, and ring A″ are defined and described as in PTM-3; Q1, Q2, Q3, Q4, Q5, X'', Y'', m'', R1'', and R2'' are defined and described as in ULM-1; and L3, ring D, ring B, ring C, and X'''' are defined and described as in LA.
[0116] This invention provides methods for preparing compounds of formula I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or their pharmaceutically acceptable salts.
[0117] The present invention provides pharmaceutical compositions comprising therapeutically effective amounts of compounds of formula I, II, III, IV, V, VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, as well as pharmaceutically acceptable carriers, diluents, or excipients.
[0118] The present invention provides pharmaceutical compositions comprising therapeutically effective amounts of compounds of formula I, II, III, IV, V, VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or their pharmaceutically acceptable salts, as well as pharmaceutically acceptable carriers.
[0119] The present invention provides a method for degrading IRAK4 protein, comprising contacting a compound of formula I, II, III, IV, V, VI, and / or its stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, with IRAK4 protein.
[0120] This invention provides the use of substance A in the preparation of an IRAK4 protein degrader, wherein substance A comprises compounds of formulas I, II, III, IV, V, and VI as described above, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
[0121] The compounds of formulas I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, are used as medicines for the treatment or prevention of IRAK4-mediated diseases or conditions.
[0122] The compounds of formulas I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, are used as medicines for the treatment or prevention of diseases or conditions mediated by TLR (other than TLR3R) or the IL-1β receptor family (including IL-1R, IL-18R, IL-33R, and IL-36R).
[0123] The compounds of formulas I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, are used as pharmaceuticals for the treatment or prevention of IRAK4-mediated diseases or conditions, wherein the IRAK4-mediated diseases or conditions are MyD88-driven diseases or conditions.
[0124] This invention provides the use of compounds of formula I, II, III, IV, V, VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment or prevention of IRAK4-mediated diseases or conditions.
[0125] In this invention, the IRAK4-mediated disease or condition is a disease or condition driven by MyD88.
[0126] This invention provides the use of compounds of formula I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment or prevention of diseases or conditions mediated by TLR (other than TLR3R) or the IL-1β receptor family (including IL-1R, IL-18R, IL-33R, and IL-36R).
[0127] This invention provides the use of compounds of formula I, II, III, IV, V, VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment or prevention of IRAK4-mediated diseases or conditions, wherein the IRAK4-mediated diseases or conditions are MyD88-driven diseases or conditions.
[0128] This invention provides the use of compounds of formula I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment or prevention of cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, conditions related to cell death, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.
[0129] This invention provides compounds of formulas I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, for use in the preparation of medicaments for the treatment or prevention of cancer or proliferative diseases, wherein the cancer or proliferative disease is brain cancer, kidney cancer, liver cancer, adrenal cancer, bladder cancer, breast cancer, stomach cancer, ovarian cancer, colon cancer, rectal cancer, prostate cancer, pancreatic cancer, lung cancer, etc. Cancer, vaginal cancer, cervical cancer, testicular cancer, urogenital tract cancer, esophageal cancer, laryngeal cancer, skin cancer, bone cancer, thyroid cancer, sarcoma, glioblastoma, neuroblastoma, multiple myeloma, gastrointestinal cancer, neck or head tumors, epidermal hyperplasia, psoriasis, benign prostatic hyperplasia, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer, lymphoma, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, follicular carcinoma, undifferentiated tumor, papilloma, seminoma, melanoma, ABC DLBCL, Hodgkin's lymphoma, primary cutaneous T-cell lymphoma, chronic lymphocytic leukemia, smoldering indolent multiple myeloma, leukemia, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary exudative lymphoma, Burkitt's lymphoma / leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, multiple myeloma, or plasmacytoma or intravascular large B-cell lymphoma.
[0130] This invention provides the use of compounds of formula I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment or prevention of neurodegenerative diseases, said neurodegenerative diseases being Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, ischemic or traumatic cerebral injury, glutamate neurotoxicity, hypoxia, epilepsy, diabetes treatment, metabolic syndrome, obesity, and neurodegenerative diseases caused by organ transplantation or graft-versus-host disease.
[0131] This invention provides the use of compounds of formulas I, II, III, IV, V, and VI, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for the treatment or prevention of inflammatory diseases, said inflammatory diseases being eye diseases such as eye allergies, conjunctivitis, dry eye syndrome, or vernal conjunctivitis; diseases affecting the nose, including allergic rhinitis; and autoimmune blood disorders such as hemolysis. Anemia, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, dermatomyositis, chronic active hepatitis, myasthenia gravis, Stephen Johnson syndrome, idiopathic stomatitis, autoimmune inflammatory bowel disease, irritable bowel syndrome, celiac disease, periostitis of the dental root, hyaline membrane disease, nephropathy, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine ophthalmopathy, Graves' disease. Diseases, sarcomas, dry eye, vernal conjunctivitis and keratitis, interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, nephritis, vasculitis, interstitial cystitis, diverticulitis, glomerulonephritis, chronic granulomatous diseases, endometriosis, leptospirosis nephropathy, glaucoma, retinal diseases, aging, headache, pain, complex regional pain syndrome, cardiomegaly, muscular atrophy, catabolism, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ectodermal dysplasia, Behçet's disease, incontinence of pigmentation, Paget's disease Diseases, pancreatitis, hereditary periodic febrile syndrome, asthma, acute lung injury, acute respiratory distress syndrome, eosinophilia, allergic reactions, systemic allergic reactions, sinusitis, eye allergies, silica-induced diseases, COPD, lung disease, cystic fibrosis, liver fibrosis, kidney fibrosis, alcoholic fatty liver, non-alcoholic fatty liver, cardiac fibrosis, psoriasis, Crohn's disease, inflammatory bowel disease, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation associated with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease Disease), lichen planus, type 1 diabetes, type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergy, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, allergic purpura (Henoch-Schonlein)Purpura), hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, localized pneumonia, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis Colitis, uveitis, vaginitis, vasculitis, vulvitis, alopecia areata, erythema multiforme, herpetic dermatitis, sclerosis, leukoplakia, hypersensitivity vasculitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, acquired bullous epidermolysis bullosa, acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, cryptothermal protein-associated peritoneal syndrome, or osteoarthritis.
[0132] This invention provides a method for treating or preventing IRAK4-mediated diseases or conditions, comprising administering to a patient in need a therapeutically effective amount of a compound of formula I, II, III or IV, and / or its stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
[0133] This invention provides a method for treating or preventing IRAK4-mediated diseases or conditions, comprising administering to a patient in need a therapeutically effective amount of a compound of formula I, II, III or IV, and / or its stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs and / or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein the IRAK4-mediated disease or condition is a MyD88-driven disease or condition.
[0134] This invention provides a method for treating or preventing diseases or conditions mediated by TLRs (other than TLR3R) or the IL-1 receptor family (including IL-1R, IL-18R, IL-33R, IL-36R), comprising administering to a patient in need a therapeutically effective amount of a compound of formula I, II, III or IV, and / or its stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs and / or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.
[0135] This invention provides methods for preparing compounds of Formula I, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof. The above The NH group is the portion connecting the chain L; the NH group can be a primary or secondary amine; the NH group is linked to the chain L by... The ester group in the compound undergoes a substitution reaction under alkaline conditions to prepare compound I, wherein R 100' is pentafluorophenyl or p-nitrophenyl; and PTM is... Wherein ring A, ring A'', n, R1, R4, and m are as defined and described in PTM-1; the ULM is The Q1, Q2, Q3, Q4, Q5, X'', Y'', m'', R1'', and R2'' mentioned herein are as defined in ULM-1; the base in the substitution reaction includes, but is not limited to, triethylamine, N,N-diisopropylethylamine, potassium carbonate, sodium carbonate, and sodium bicarbonate.
[0136] This invention provides methods for preparing compounds of formula II, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof.
[0137] This invention provides methods for preparing compounds of formula IV, and / or their stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates, solvates, metabolites, prodrugs, and / or pharmaceutically acceptable salts thereof. IVa IVb IV Wherein rings A, n, R1, R2, and R3 are as defined and described in PTM-3; L3 is as defined and described in LA; W2 is NH; W1 is CH or N; o, p, q, and r are each independently 1 or 2; X'' is CH or N; R3'' and m'' are as defined and described in ULM-1; R100' is pentafluorophenyl or p-nitrophenyl; the substitution reaction of formula IVa with formula IVb yields compound IV; the base in the substitution reaction includes, but is not limited to, triethylamine, N,N-diisopropylethylamine, potassium carbonate, sodium carbonate, and sodium bicarbonate.
[0138] Detailed explanation: Unless otherwise stated, the following terms used in the specification and claims have the following meanings.
[0139] "Alkyl" refers to a saturated aliphatic hydrocarbon group, including straight-chain or branched alkyl groups; C1-C8 alkyl refers to alkyl groups containing 1-8 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, etc. 2-Methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-Ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, or various branched isomers thereof; preferably C1-C6 alkyl; more preferably C1-C4 alkyl. The alkyl group may be substituted or unsubstituted.
[0140] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent; "C3-C12 cycloalkyl" refers to a cycloalkyl group containing 3 to 12 carbon atoms; "C3-C8 membered cycloalkyl" refers to a cycloalkyl group containing 3 to 8 carbon atoms; "C5-C10 membered cycloalkyl" refers to a cycloalkyl group containing 5 to 10 carbon atoms.
[0141] Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptanetrienyl, cyclooctyl, etc., preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; preferably C3-C8 membered cycloalkyl; more preferably C3-C6 cycloalkyl.
[0142] Polycyclic cycloalkyl groups include spirocyclic, fused-ring, and bridged-ring cycloalkyl groups. "Spirocycloalkyl" refers to a polycyclic group in which a single carbon atom (called a spiro atom) is shared between the rings. They may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Based on the number of shared spiro atoms between the rings, spirocycloalkyl groups are classified as monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl, with bispirocycloalkyl being preferred. Non-limiting examples of spirocycloalkyl groups include: .
[0143] "Fused cycloalkyl" refers to a polycyclic aromatic hydrocarbon group in which each ring shares a pair of adjacent carbon atoms with the other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a fully conjugated π-electron system. Based on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused cycloalkyl, with bicyclic fused cycloalkyl being preferred. Non-limiting examples of fused cycloalkyl groups include: .
[0144] "Bridged cycloalkyl" refers to a polycyclic aromatic hydrocarbon group in which any two rings share two non-directly bonded carbon atoms. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Based on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl. Non-limiting examples of bridged cycloalkyl groups include:
[0145] The cycloalkyl ring may be fused to an aryl, heteroaryl, or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl ring. Non-limiting examples include indenyl, tetrahydronaphthyl, benzocycloheptyl, etc. The cycloalkyl ring may be optionally substituted or unsubstituted.
[0146] "Heterocyclic alkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein one or more ring atoms are selected from nitrogen, oxygen, or S(O)r (where r is an integer 0, 1, or 2), but does not contain a ring portion of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. "3-12-membered heterocyclic alkyl" refers to a cyclic group containing 3 to 12 ring atoms, "5-10-membered heterocyclic alkyl" refers to a cyclic group containing 5 to 10 ring atoms, and "3-8-membered heterocyclic alkyl" refers to a cyclic group containing 3 to 8 ring atoms. Preferably, "3-12-membered heterocyclic alkyl" contains 1 to 3 heteroatoms selected from N, O, or S, and more preferably, 3-12-membered heterocyclic alkyl contains 1 or 2 N atoms.
[0147] Non-limiting examples of monocyclic heterocyclic alkyl groups include pyrrolidinyl, piperidinyl, piperidine, mofolinyl, thiomofolinyl, homopiperidine, etc., with piperidinyl and piperidine being preferred.
[0148] Polycyclic heterocyclic alkyl groups include spirocyclic, fused-ring, and bridged-ring heterocyclic alkyl groups. "Spirocycloalkyl" refers to a polycyclic heterocyclic alkyl group in which one or more ring atoms share a single atom (called a spiro atom), wherein one or more ring atoms are selected from nitrogen, oxygen, or S(O)r (where r is an integer 0, 1, or 2), and the remaining ring atoms are carbon. They may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Spirocycloalkyl groups are classified into monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl groups based on the number of shared spiro atoms between rings, preferably saturated "3-12 membered bispirocycloalkyl" containing 1-3 heteroatoms selected from N, O, or S; more preferably saturated "3-12 membered bispirocycloalkyl" containing 1 or 2 N atoms. Non-limiting examples of spirocycloalkyl groups include: .
[0149] "Fused heterocyclic alkyl" refers to a polycyclic heterocyclic alkyl group in which each ring shares an adjacent pair of atoms with other rings in the system. One or more rings may contain one or more double bonds, but no ring has a fully conjugated π-electron system. One or more ring atoms are selected from nitrogen, oxygen, or S(O)r (where r is an integer 0, 1, or 2), and the remaining ring atoms are carbon. Based on the number of constituent rings, they can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic alkyl. Preferably, they contain 1-3 "3-12 membered bicyclic fused heterocyclic alkyl" selected from N, O, or S heteroatoms; more preferably, they are saturated "3-12 membered bicyclic fused heterocyclic alkyl" containing 1 or 2 N atoms. Non-limiting examples of fused heterocyclic alkyl groups include: .
[0150] "Bridged heterocyclic alkyl" refers to a polycyclic heterocyclic alkyl group in which any two rings share two non-directly bonded atoms. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. One or more ring atoms are selected from nitrogen, oxygen, or S(O)r (where r is an integer 0, 1, or 2), and the remaining ring atoms are carbon. Based on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged alkyl. Non-limiting examples of bridged heterocyclic alkyl include: .
[0151] The heterocyclic alkyl ring may be fused to an aryl, heteroaryl, or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic alkyl ring. Non-limiting embodiments include: The heterocyclic alkyl group may be optionally substituted or unsubstituted.
[0152] "Aryl" refers to a polycyclic group consisting of an all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) and having a conjugated π-electron system. "6-10-membered aryl" refers to an all-carbon aryl group containing 6-10 carbons, such as phenyl and naphthyl; preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclic alkyl, or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring. Non-limiting embodiments include: The aryl group may be optionally substituted or unsubstituted.
[0153] "Heteroaryl" refers to a heteroaryl system containing 1 to 4 heteroatoms, wherein the heteroatoms include nitrogen, oxygen, or S(O)r (where r is an integer 0, 1, or 2). A 5-6 member heteroaryl refers to a heteroaryl system containing 5-6 ring atoms, and a 5-10 member heteroaryl refers to a heteroaryl system containing 5-10 ring atoms, preferably a 5-6 member heteroaryl; more preferably a 5-6 member heteroaryl containing 1 or 2 N atoms; non-limiting embodiments include furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyridine, pyrazole, imidazoleyl, triazolyl, tetrazolyl, etc.; preferably pyridinyl. The heteroaryl ring can be fused to an aryl, heterocyclic alkyl, or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. Non-limiting embodiments include: The heteroaryl group may be optionally substituted or unsubstituted.
[0154] "Alkenyl" refers to an alkyl group as defined above, consisting of at least two carbon atoms and at least one carbon-carbon double bond. "C2-8 alkenyl" refers to a straight-chain or branched alkenyl group containing 2-8 carbons, including but not limited to vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, preferably "C2-6 alkenyl", and more preferably "C2-4 alkenyl". The alkenyl group may be substituted or unsubstituted.
[0155] "Alynyl" refers to an alkyl group as defined above, consisting of at least two carbon atoms and at least one carbon-carbon triple bond. "C2-8 alkynyl" refers to a straight-chain or branched alkynyl group containing 2-8 carbon atoms, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl, preferably "C2-6 alkynyl", and more preferably "C2-4 alkynyl". The alkynyl group may be substituted or unsubstituted.
[0156] "Subunit" refers to a divalent group, such as alkylene (divalent alkyl), alkenylene (divalent alkenyl), ynylene (divalent ynyl), cycloalkylene (divalent cycloalkyl), heteroalkylene (divalent heterocyclic alkyl), arylene (divalent aryl), and heteroarylene (divalent heteroaryl). The alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic alkyl, aryl, and heteroaryl groups are as defined above, and the subunits may be optionally substituted or unsubstituted.
[0157] "Alkoxy" refers to -O-(alkyl), wherein the alkyl group is as defined above. "C1-C8 alkoxy" refers to an alkyloxy group containing 1-8 carbons, and non-limiting examples include methoxy, ethoxy, propoxy, butoxy, etc. The alkoxy group may be optionally substituted or unsubstituted.
[0158] "Cycloalkoxy" refers to -O- (unsubstituted cycloalkyl), wherein the cycloalkyl group is as defined above. C3-C8 cycloalkoxy refers to a cycloalkyloxy group containing 3-8 carbons, and non-limiting examples include cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexyloxy, etc. The cycloalkoxy group may be optionally substituted or unsubstituted.
[0159] "Halogenated alkyl" refers to an alkyl group substituted with one or more fluorine, chlorine, bromine or iodine atoms, wherein the alkyl group is as defined above, and non-limiting examples include difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, etc.
[0160] "Haloalkoxy" refers to a group in which a hydrogen atom on an alkyl group is replaced by one or more fluorine, chlorine, bromine, or iodine atoms, wherein the alkoxy group is as defined above. Examples include difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, and tribromomethoxy.
[0161] "Hydroxyalkyl" refers to an alkyl group optionally substituted with one or more -OH groups, wherein the alkyl group is as defined above, and non-limiting examples include hydroxymethyl, hydroxyethyl, hydroxypropyl, and hydroxyisopropyl.
[0162] "Aminoalkyl" means an alkyl group that is optionally substituted with one or more -NH 2, wherein the alkyl group is as defined above, and non-limiting embodiments include aminomethyl, aminoethyl, aminopropyl, and aminoisopropyl.
[0163] "Ammonia" and "amine" are recognized in this field and refer to substituted or unsubstituted ammonia.
[0164] "Oxygenation" refers to the O group.
[0165] "Halogen" refers to fluorine, chlorine, bromine, or iodine.
[0166] “Cyano” refers to -CN.
[0167] "Hydrogen group" refers to -OH.
[0168] "Raney-Ni" refers to Raney nickel (a hydrogen-active catalytic reducer).
[0169] “HATU” refers to 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate.
[0170] "DIEA" refers to diisopropylethylamine.
[0171] “MeOH” refers to methanol.
[0172] "NaBH 3CN" refers to sodium cyanoboronhydride.
[0173] "LiAlH4" refers to lithium hydrogen aluminum.
[0174] "THF" refers to tetrahydrofuran.
[0175] "DMF" refers to dimethylformamide.
[0176] “Py-BOP” refers to benzotriazol-1-yl-oxytripyrrolidinyl phosphate hexafluorophosphate.
[0177] “HATU” refers to 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate.
[0178] "TFA" refers to triethylamine.
[0179] “EA” refers to ethyl acetate.
[0180] “CbzCl” refers to benzyl chloroformate.
[0181] “Cs 2CO 3” refers to cesium carbonate.
[0182] "NaHCO3" refers to sodium hydrogen carbonate.
[0183] “IBX” refers to 2-iodobenzoic acid.
[0184] “STAB” refers to sodium triacetylated boron hydrogenide.
[0185] "DMSO" refers to dimethyl monoxide.
[0186] "K2CO3" refers to potassium carbonate.
[0187] "DCM" refers to dichloromethane.
[0188] “KI” refers to potassium iodide.
[0189] "NH 4Cl" refers to ammonium chloride.
[0190] "Na 2SO 4" refers to sodium sulfate.
[0191] "LiBH 4" refers to lithium borohydride.
[0192] “NMP” refers to N-methylpyrrolidone.
[0193] "i-PrOH" refers to isopropanol.
[0194] “EtOH” refers to ethanol.
[0195] “Pd(OH)2 / C” refers to palladium hydroxide / carbon.
[0196] “DCE” refers to 1,2-dichloroethane.
[0197] "PE" refers to petroleum ether.
[0198] “sat.” refers to a saturated solution.
[0199] "PCC" refers to pyridinium chlorochromate.
[0200] “CuI” refers to copper iodide.
[0201] “TsCl” refers to 4-toluenesulfonyl chloride.
[0202] “HNO 3” refers to nitric acid.
[0203] "NaBH(OAc)3" refers to sodium borohydride acetate.
[0204] “Dess-Martin” refers to (1,1,1-triethoxy)-1,1-dihydro-1,2-benzyliodo-3(1H)-one.
[0205] "DMP" refers to dimethyl phthalate.
[0206] "TEA" refers to triethylamine.
[0207] “DAST” refers to diethylaminosulfur trifluoride.
[0208] “NBS” refers to N-bromobutyldiimide.
[0209] “(Ph)2NH” refers to diphenylamine.
[0210] “Pd 2(dba) 3” refers to tris(dibenzylacetone)dipapa.
[0211] "Xantphos" refers to 4,5-bis(diphenylphosphine)-9,9-dimethyloxanethium.
[0212] “NaOt-Bu” refers to sodium tert-butanol.
[0213] "DPBS" refers to Duchenne phosphate buffer.
[0214] "PBS" refers to phosphate buffered saline solution.
[0215] "SDS-PAGE" refers to sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
[0216] "PVDF" refers to polyvinylidene fluoride.
[0217] "Multiple" refers independently to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0218] "Optional" means that the event or environment described below may but does not have to occur, and this description includes situations in which the event or environment may or may not occur. For example, "optionally alkyl-substituted heterocyclic alkyl groups" means that alkyl groups may but do not have to be present, and this description includes cases where heterocyclic alkyl groups are substituted with alkyl groups and cases where heterocyclic alkyl groups are not substituted with alkyl groups.
[0219] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to five, and more preferably one to three hydrogen atoms, being independently substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art to which this invention pertains can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group having free hydrogen may be unstable when bonded to a carbon atom having an unsaturated bond (such as an alkene).
[0220] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, to promote the absorption of the active ingredient, and thus to exert its biological activity.
[0221] This invention also provides pharmaceutically acceptable salts of compounds of formulas I, II, III, and IV. The term "pharmaceutically acceptable salt" refers to an acid addition salt or base addition salt of a relatively non-toxic compound of this invention. The acid addition salt is a salt formed by a compound of formula (I) of this invention with a suitable inorganic or organic acid. These salts can be prepared during the final separation and purification process of the compound, or can be prepared by reacting a purified compound of formula (I) in its free base form with a suitable organic or inorganic acid. Representative acid addition salts include hydrobromide, hydrochloride, sulfate, hydrogen sulfate, sulfite, acetate, oxalate, valerate, oleate, palmitate, stearate, silicate, borate, benzoate, lactate, phosphate, hydrogen phosphate, carbonate, bicarbonate, toluene, citrate, maleate, fumarate, succinate, tartrate, benzoate, methanesulfonate, p-toluenesulfonate, gluconate, lactobionate, and lauryl sulfonate, etc. The base addition salt is a salt formed by a compound of formula (I) and a suitable inorganic or organic base, including, for example, salts formed with alkali metals, alkaline earth metals, or quaternary ammonium cations, such as sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, tetramethyl quaternary ammonium salts, tetraethyl quaternary ammonium salts, etc.; amine salts include salts formed with ammonia (NH3), primary amines, secondary amines, or tertiary amines, such as methylamine salts, dimethylamine salts, trimethylamine salts, triethylamine salts, ethylamine salts, etc.
[0222] The compounds of the present invention or pharmaceutically acceptable salts thereof may be administered to mammals, including humans, orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), topically (in powder, ointment or drops), or intratumorally.
[0223] The dosage of the compound of the present invention can be approximately 0.05-300 mg / kg body weight / day, preferably 10-300 mg / kg body weight / day, and more preferably 10-150 mg / kg body weight / day.
[0224] The compounds of the present invention or their pharmaceutically acceptable salts can be formulated into solid dosage forms for oral administration, including but not limited to capsules, tablets, pills, powders and granules. In these solid dosage forms, the compound of formula (I) of the present invention is mixed as an active ingredient with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following components: (1) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol and silica; (2) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (3) humectants, such as glycerin; (4) disintegrants, such as agar, calcium carbonate, potato starch or cassava starch, alginic acid, certain complex silicates and sodium carbonate; (5) slowing agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glyceryl monostearate; (8) adsorbents, such as kaolin; and (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. Buffers may also be included in capsules, tablets, and pills.
[0225] The solid dosage forms, such as tablets, sugar pills, capsules, pellets, and granules, can be coated or microencapsulated using coating and shell materials such as enteric coatings and other materials known in the art. They may contain opaque agents, and the release of the active ingredient from such compositions can be delayed in a portion of the digestive tract. Examples of encapsulating components that can be used are polymeric substances and waxes. If necessary, the active ingredient may also be formed into microcapsules with one or more of the excipients described above.
[0226] The compounds of this invention, or pharmaceutically acceptable salts thereof, can be formulated into liquid dosage forms for oral administration, including but not limited to pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and tinctures. In addition to the active ingredient, the compound of formula (I), or a pharmaceutically acceptable salt thereof, the liquid dosage form may contain inert diluents conventionally used in the art, such as water and other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures thereof. Besides these inert diluents, the liquid dosage forms of this invention may also contain conventional adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and fragrances.
[0227] The suspending agent includes, for example, ethoxylated isooctadecyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitol, microcrystalline cellulose, aluminum methoxide and agar, or mixtures thereof.
[0228] The compounds of this invention or pharmaceutically acceptable salts thereof can be formulated into dosage forms for parenteral injection, including but not limited to physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions, or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.
[0229] The compounds of this invention or pharmaceutically acceptable salts thereof can also be formulated into dosage forms for topical administration, including ointments, powders, suppositories, drops, sprays, and inhalers. The compound of formula (I) of this invention or a pharmaceutically acceptable salt thereof, as the active ingredient, is mixed under sterile conditions with a physiologically acceptable carrier and optionally a preservative, buffer, or, if necessary, a propellant.
[0230] The present invention also provides pharmaceutical compositions comprising a compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier, excipient, or diluent. In preparing the pharmaceutical compositions, the compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof is typically mixed with a pharmaceutically acceptable carrier, excipient, or diluent.
[0231] The compositions of the present invention can be formulated into conventional pharmaceutical preparations using conventional preparation methods. Examples include tablets, pills, capsules, powders, granules, emulsions, flocculants, dispersions, solutions, syrups, elixirs, ointments, drops, suppositories, inhalers, and sprays.
[0232] The compounds described in this invention, or their pharmaceutically acceptable salts, can be administered alone or (if desired) in combination with other pharmaceutically acceptable therapeutic agents, such as other antitumor drugs, anti-inflammatory drugs, or autoimmune drugs. The components to be combined can be administered simultaneously or sequentially, in a single formulation or in different formulations. The combinations may include not only combinations of the compounds of this invention and one other active agent, but also combinations of the compounds of this invention and two or more other active agents.
[0233] This invention demonstrates through IRAK4 kinase activity assays that the compounds of this invention can effectively bind to or inhibit the IRAK4 target protein; through Western blotting, it demonstrates that the compounds of this invention can effectively and specifically degrade IRAK4 protein in THP-1 cells; through LPS-induced assays of cytokine concentrations secreted by normal human whole blood PBMCs, it demonstrates that the compounds of this invention can effectively inhibit the production of IL-6 by immune cells; and through Western blotting, it demonstrates that the compounds of this invention have significant degradation effects on both the long chain (IRAK4-L) and short chain (IRAK4-S) of IRAK4 in human PBMCs. The compounds of formulas I, II, III, and IV of this invention, and / or their stereoisomers, enantiomers, diastereomers, deuterates, hydrates, solvates, metabolites, prodrugs, and / or their pharmaceutically acceptable salts, can effectively degrade IRAK4 protein, thereby achieving the effect of preventing or treating IRAK4-related diseases or conditions.
[0234] To make the above and other objects, features and advantages of the present invention more apparent and understandable, specific embodiments are described below in conjunction with the accompanying drawings for detailed explanation. Simple Explanation of the Diagram
[0235] none Implementation
[0236] The present invention will be further described in detail and completely below with reference to embodiments, but this is by no means a limitation of the present invention, nor is the present invention limited to the content of the embodiments. The starting materials in the embodiments of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art. Unless otherwise specified, experimental methods in the embodiments of the present invention that do not specify specific conditions are generally performed under conventional conditions or according to the conditions recommended by the raw material or product manufacturer.
[0237] I. Compound Preparation Examples Intermediate 1: 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid Step 1: Preparation of 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid 3-Amino-4-methoxybenzoic acid (5.0 g, 2.93 mmol) was suspended in acrylic acid (8.05 mL, 117 mmol) and stirred at 100 °C for 3 h. The reaction mixture was then cooled to room temperature. Acetic acid (33 mL) was added, and the stirred suspension was heated at 100 °C for 10 min. Urea (11.00 g, 183 mmol) was added, and the reaction mixture was stirred at 120 °C overnight. The reaction mixture was added to a mixture of ice water and concentrated hydrochloric acid (37%), stirred, and the resulting suspension was stored at 5 °C overnight. The mixture was then filtered, and the solid was washed with water and dried to obtain a solid. The solid was ground in hydrochloric acid solution (0.05 M), filtered, washed with methyl tert-butyl ether, and dried under reduced pressure at 40 °C to obtain the target product 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid. 1H NMR (400 MHz, DMSO- d 6) δ 12.70 (s, 1H), 10.34 (s, 1H), 7.92 (dd, J= 8.6, 2.2 Hz, 1H), 7.83 (d, J= 2.2 Hz, 1H), 7.21 (d, J= 8.8 Hz, 1H), 3.94 - 3.82 (m, 3H), 3.60 (t, J= 6.7 Hz, 2H), 2.69 (s, 2H). The following intermediates are prepared using the same method as intermediate 1: intermediate structure name LC-MS Intermediate 2 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-ethoxybenzoic acid (ESI, m / z): [M+H] +=279.1 Intermediate 3 4-Chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoic acid (ESI, m / z): [M+H] +=269.0 Intermediate 4 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethoxy)benzoic acid (ESI, m / z): [M+H] +=319.1 Intermediate 5 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-fluorobenzoic acid (ESI, m / z): [M+H] +=253.0 Intermediate 6 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethyl)benzoic acid (ESI, m / z): [M+H] +=303.0 Intermediate 7 4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoic acid (ESI, m / z): [M+H] +=235.1 Intermediate 35 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methylbenzoic acid (ESI, m / z): [M+H] +=249.1
[0238] Intermediate 8: 3-(2,6-dioxopiperidin-3-yl)-4-fluorobenzoic acid Step 1: Preparation of 2,6-bis(benzyloxy)pyridine At 0 °C, benzyl alcohol (109.6 g, 1.01 mol) was added to a solution of sodium hydride (60% mineral oil mixture, 54.0 g, 1.35 mol) in N,N-dimethylformamide (600 mL). After stirring for 30 minutes, 2,6-dichloropyridine (50.0 g, 0.338 mol) was added. The reaction mixture was heated to 80 °C and stirred overnight. After cooling to room temperature, the reaction mixture was quenched with ice water (1000 mL). The solid was filtered and dried to give the target product, 2,6-bis(benzyloxy)pyridine. 1H NMR (DMSO- d 6, 400 MHz): δ7.68 (t, J= 8.4 Hz, 1H), 7.48-7.36 (m, 10H), 6.45 (d, J= 8.4 Hz, 2H), 5.38 (s, 4H). LC-MS: (ESI, m / z): [M+H] +=292.2. Step 2: Preparation of 2,6-bis(benzyloxy)-3-bromopyridine N-bromosuccinimide (41.7 g, 0.23 mol) was added to a solution of 2,6-bis(benzyloxy)pyridine (75.9 g, 0.26 mol) in acetonitrile (600 mL). The reaction mixture was stirred at 80 °C for 2 hours. After the reaction was complete, the reaction mixture was concentrated under reduced pressure. The concentrate was diluted with ethyl acetate (500 mL) and washed with water and saturated brine. The organic layer was collected, dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by silica gel column chromatography to give the target product, 2,6-bis(benzyloxy)-3-bromopyridine. 1H NMR (DMSO- d 6, 400 MHz): δ7.88 (d, J= 8.4 Hz, 1H), 7.45-7.37 (m, 10H), 6.44 (d, J= 8.4 Hz, 1H), 5.42 (s, 2H), 5.33 (s, 2H). LC-MS: (ESI, m / z): [M+H] +=372.1. Step 3: Preparation of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-4-fluorobenzoic acid To a mixture of 31 mL of dioxane (3.1 g, 8.37 mmol) of 2,6-bis(benzyloxy)-3-bromopyridine and 1.85 g, 10.05 mmol of 3-boronico-4-fluorobenzoic acid and water (7.5 mL), PdCl₂(dppf)-chloroform complex (612 mg, 0.84 mmol) and sodium carbonate (1.77 g, 16.74 mmol) were added. The reaction mixture was heated to 90 °C under nitrogen protection and maintained for 16 hours. After the reaction was complete, 20 mL of 15% hydrochloric acid solution was added, and the mixture was extracted with ethyl acetate (100 mL × 3), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to obtain the target product 3-(2,6-bis(benzyloxy)pyridine-3-yl)-4-fluorobenzoic acid. LC-MS: (ESI, m / z): [M+H] += 430.2 Step 4: Preparation of 3-(2,6-dioxopiperidin-3-yl)-4-fluorobenzoic acid Palladium / carbon (10%, 120 mg) was added to a solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-4-fluorobenzoic acid (1.50 g, 3.49 mmol) in methanol (10 mL). The reaction mixture was stirred at room temperature under a hydrogen atmosphere for 48 hours. After the reaction was complete, the reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The concentrate was purified by column chromatography to give the target product, 3-(2,6-dioxopiperidin-3-yl)-4-fluorobenzoic acid. LC-MS: (ESI, m / z): [M+H] += 252.1 1H NMR (400 MHz, DMSO- d 6) δ 13.04 (s, 1H), 10.92 (s, 1H), 7.91 –7.95 (m, 2H), 7.30-7.34 (m, 1H), 4.15-4.19 (m, 1H), 2.70-2.79 (m, 1H), 2.53-2.57 (m, 1H), 2.23-2.27 (m, 1H), 2.01-2.07 (m, 1H).
[0239] Intermediate 9: 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid pentafluorophenyl ester A mixture of 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid (2.0 g, 7.58 mmol), 2,3,4,5,6-pentafluorophenol (1.67 g, 9.09 mmol), and N,N'-dicyclohexylcarbamate (1.87 g, 9.09 mmol) in a solution of N,N-dimethylformamide (20 mL) was stirred at room temperature for 3 h. The reaction mixture was poured into water (200 mL) and stirred for 0.5 h. The solution was extracted with ethyl acetate (200 mL × 3). The organic phase was collected, washed with water (500 mL × 2) and saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by silica gel column chromatography to obtain the target product, 3-(2,4-dioxotetrahydropyrimidine-1(2H)-yl)-4-methoxybenzoic acid pentafluorophenyl ester. LC-MS: (ESI, m / z): [M+H] +=431.1 The following intermediates are prepared using the same method as intermediate 9: intermediate structure name LC-MS Intermediate 10 4-Chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (ESI, m / z): [M+H] +=435.0 Intermediate 11 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-ethoxybenzoic acid pentafluorophenyl ester (ESI, m / z): [M+H] +=445.1 Intermediate 12 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethoxy)benzoic acid pentafluorophenyl ester (ESI, m / z): [M+H] +=485.0 Intermediate 13 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-fluorobenzoic acid pentafluorophenyl ester (ESI, m / z): [M+H] +=419.0 Intermediate 14 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-(trifluoromethyl)benzoate pentafluorophenyl ester (ESI, m / z): [M+H] +=469.0 Intermediate 15 4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (ESI, m / z): [M+H] +=401.0 Intermediate 16 3-(2,6-dioxopiperidin-3-yl)-4-fluorobenzoic acid pentafluorophenyl ester (ESI, m / z):[M+H] +=418.0 Intermediate 36 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methylbenzoic acid pentafluorophenyl ester (ESI, m / z): [M+H] +=415.0
[0240] Intermediate 17: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazol[1,5-a]pyrimidine-3-carboxylic acid Step 1: Preparation of ethyl 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester (5.0 g, 22.1 mmol) and (1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride (3.0 g, 22.1 mmol) were dissolved in acetonitrile (60 mL), and N,N-diisopropylethylamine (11.4 g, 88.5 mmol) was added. The mixture was stirred at 60 °C for 2 hours, the solvent was removed under reduced pressure, and water (100 mL) was added. The mixture was extracted with ethyl acetate (100 mL x 3), the organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the target crude product 5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester. LC-MS: (ESI, m / z): [M+H] +=289.0. Step 2: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazol[1,5-a]pyrimidine-3-carboxylic acid Ethyl 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (5.5 g, 19.0 mmol) was added to ethanol (50 mL) and tetrahydrofuran (25 mL), followed by a saturated aqueous solution of lithium hydroxide (an aqueous solution prepared by adding 912 mg of lithium hydroxide to 0.75 mL of water). The reaction mixture was stirred overnight at room temperature, concentrated under reduced pressure, and the concentrate was directly purified by reverse phase (0.05% formic acid, 15% acetonitrile) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=261.0. 1H NMR (400 MHz, DMSO- d 6) δ 11.67 (s, 1H), 8.76 (dd, J= 7.6, 3.8 Hz, 1H), 8.22 (d, J= 3.8 Hz, 1H), 6.90-6.30 (m, 1H), 5.30-5.00 (m, 1H), 4.85-4.74 (m, 1H), 3.93-3.70 (m, 2H), 3.65-3.50 (m, 2H), 1.90 – 2.05 (m, 2H).
[0241] Intermediate 18: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of benzyl 4-(toluenesulfonyl)piperidine-1-carboxylate A mixture of 4-hydroxypiperidine-1-carboxylate (8.0 g, 34 mmol), p-toluenesulfonyl chloride (7.8 g, 40.1 mmol), triethylamine (10.3 g, 102 mmol), and 4-dimethylaminopyridine (0.41 g, 3.4 mmol) in dichloromethane (100 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (100 mL × 3). The organic layer was collected, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated by filtration. The concentrate was purified by column chromatography to give the target product, 4-(toluenesulfonoxy)piperidine-1-carboxylate. LC-MS: (ESI, m / z): [M+Na] +=412.1. Step 2: Preparation of benzyl 4-(3-carboxymethyl-1H-pyrrole-1-yl)piperidine-1-carboxylic acid ester A mixture of 1H-pyrazole-3-carboxaldehyde (2.5 g, 26 mmol), 4-(toluenesulfonyloxy)piperidine-1-carboxylate benzyl ester (12.5 g, 32.1 mmol), cesium carbonate (25.4 g, 78 mmol), and potassium iodide (5.33 g, 32.1 mmol) in N,N-dimethylformamide (50 mL) was stirred overnight at 50 °C. The reaction mixture was diluted with water (250 mL) and extracted with ethyl acetate (250 mL × 3). The organic layer was collected, washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by column chromatography to give the target product, 4-(3-carboxyl-1H-pyrrole-1-yl)piperidine-1-carboxylate benzyl ester. LC-MS: (ESI, m / z): [M+Na] +=336.3. Step 3: Preparation of benzyl 4-(3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate At 0 °C, diethylaminosulfur trifluoride (4.62 g, 28.7 mmol) was added to a mixture of 1.5 g (4.8 mmol) of 4-(3-carboxymethyl-1H-pyrrolo-1-yl)piperidine-1-carboxylate in a solution of dichloromethane (50 mL). The reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, and the concentrate was purified by column chromatography to give the target product, 4-(3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate. LC-MS: (ESI, m / z): [M+H] +=336.1. Step 4: Preparation of 4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)piperidine At 0 °C, nitric acid (1 mL) was added to a mixture of 1.0 g (3.0 mmol) of 4-(3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid benzyl ester in sulfuric acid (5 mL). The reaction mixture was stirred overnight at room temperature. The reaction mixture was poured into ice water (30 mL) and extracted with methanol / dichloromethane (10%, 50 mL × 3). The organic layer was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the target product 4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)piperidine. The crude product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=247.1. Step 5: Preparation of tert-butyl 4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylate A mixture of 4-(3-(difluoromethyl)-4-nitro-1H-pyrazole-1-yl)piperidine (650 mg, 2.6 mmol), di-tert-butyl dicarbonate (680 mg, 3.1 mmol), triethylamine (788 mg, 7.8 mmol), and 4-dimethylaminopyridine (32 mg, 0.26 mmol) in dichloromethane (10 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (20 mL) and extracted with dichloromethane (20 mL × 3). The organic layer was collected and washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by chromatographic chromatography to give the target product, 4-(3-(difluoromethyl)-4-nitro-1H-pyrazole-1-yl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M-57+2H] +=291.1. Step 6: Preparation of tert-butyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate To a solution of 4-(3-(difluoromethyl)-4-nitro-1H-pyrazole-1-yl)piperidine-1-carboxylic acid tert-butyl ester (710 mg, 2.052 mmol) in ethanol (20 mL), Raney-Ni (70 mg) and hydrazine hydrate (85%, 1.0 mL) were added. The reaction mixture was stirred at room temperature for 2 hours, filtered, and the filtrate was concentrated under reduced pressure to give the target product, 4-(4-amino-3-(difluoromethyl)-1H-pyrazole-1-yl)piperidine-1-carboxylic acid tert-butyl ester. The crude product was ready for use in the next step without further purification. LC-MS: (ESI, m / z): [M-57+2H] +=261.3. Step 7: Preparation of tert-butyl 4-(4-(5-((1R,4R)-2-oxa-5-aza[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid To a mixture of tert-butyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (560 mg, 1.77 mmol) in N,N-dimethylformamide (5 mL), 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (461 mg, 1.77 mmol), HATU (874 mg, 2.3 mmol), and N,N-diisopropylethylamine (685 mg, 5.1 mmol) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with water (100 mL). The resulting solution was extracted with ethyl acetate (50 mL × 3). The organic layer was collected and washed with saturated brine (150 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by chromatographic column chromatography to obtain the target product tert-butyl 4-(4-(5-((1R,4R)-2-oxa-5-aza[2.2.1]hept-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=559.2. Step 8: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine A solution of tert-butyl 4-(4-(5-((1R,4R)-2-oxa-5-aza[2.2.1]hept-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamidoyl)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (540 mg, 0.97 mmol) in trifluoroacetic acid / dichloromethane (8 mL, 1:3) was stirred at room temperature for 1 hour. The solution was concentrated under reduced pressure to obtain the crude product 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-N-(3-(difluoromethyl)-1-(piperidine-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methamidoylamine. The crude product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=459.2.
[0242] Intermediate 19: N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of 9-((4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a]]pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester To a methanol (10 mL) solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine (200 mg, crude, 0.334 mmol), N,N-diisopropylethylamine (0.5 mL) and tert-butyl 9-methoxy-3-azaspiro[5.5]undecane-3-carboxylate (94 mg, 0.334 mmol) were added. After stirring the mixture for 30 min, sodium cyanoborohydride (106 mg, 1.67 mmol) was added, and the reaction mixture was stirred at room temperature for 3 h. The resulting mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL × 3). The organic layer was collected and washed with saturated brine (50 mL), dried with anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by chromatographic column chromatography to obtain the target product 9-((4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a]]pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=724.4. Step 2: Preparation of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine The mixture of 9-((4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a] pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (130 mg, 0.18 mmol) in trifluoroacetic acid / dichloromethane (6 mL, 1:2) was stirred at room temperature for 1 hour. The crude product was obtained by vacuum concentration: N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. The crude product was used directly in the next step. LC-MS: (ESI, m / z): [M+H] +=624.4.
[0243] Intermediate 20: N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Step 1: Preparation of 9-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester The reaction mixture of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-methoxycyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methamide (150 mg, 0.31 mmol), 3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (86 mg, 0.34 mmol), and triacetoxyborohydride sodium (326 mg, 1.55 mmol) in tetrahydrofuran (15 mL) was stirred overnight at room temperature. The reaction mixture was quenched with water (50 mL). The resulting solution was extracted with dichloromethane (20 mL × 3). The organic layer was collected and washed with saturated brine (60 mL), dried with anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by column chromatography to give 9-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=724.3. Step 2: Preparation of N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Add 2 mL of trifluoroacetic acid to a stirred solution of 9-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (200 mg, 0.27 mmol) in dichloromethane (5 mL). Stir the reaction mixture at room temperature for 2 hours. The reaction mixture was concentrated to give the crude product N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. The crude product was used directly in the next step. LC-MS: (ESI, m / z): [M+H] +=624.3.
[0244] Intermediate 21. ((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol Step 1: Preparation of (1S,4S)-4-(p-toluenesulfonoxy)cyclohexane-1-carboxylic acid methyl ester (1S,4S)-4-hydroxycyclohexane-1-carboxylic acid methyl ester (5.0 g, 31.6 mmol) was dissolved in DCM (50 mL), and DMAP (1.9 g, 15.8 mmol), TEA (16.0 g, 158 mmol), and TsCl (9.1 g, 47.5 mmol) were added. The mixture was stirred overnight at room temperature, and water (100 mL) was added to the reaction solution. The mixture was extracted with DCM (100 mL x 3). The organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (EA / PE = 1:1) to obtain (1S,4S)-4-(p-toluenesulfonoxy)cyclohexane-1-carboxylic acid methyl ester. LC-MS: (ES, m / z): [M+NH 4 +] +=330.0. 1H NMR (400 MHz, DMSO- d 6) δ 7.83 – 7.76 (m, 2H), 7.47 (d, J= 7.9 Hz, 2H), 4.66 (s, 1H), 3.59 (s, 3H), 2.42 (s, 3H), 1.67 – 1.53 (m, 8H). Step 2: Preparation of (1R,4R)-4-(3-aldehyde-1H-pyrazole-1-yl)cyclohexane-1-carboxylic acid methyl ester 1H-pyrazole-3-carboxaldehyde (2.4 g, 25.0 mmol) was dissolved in DMF (50 mL), and methyl (1S,4S)-4-(p-toluenesulfonoxy)cyclohexane-1-carboxylate (9.4 g, 30.0 mmol), Cs₂CO₃ (24.5 g, 75 mmol) and KI (5.0 g, 30.0 mmol) were added. The mixture was stirred overnight at 50 °C, and water (500 mL) was added. After stirring for 5 min, the mixture was extracted with EA (500 mL x 3). The organic phase was washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (EA:PE = 7:13) to obtain methyl (1R,4R)-4-(3-aldehyde-1H-pyrazole-1-yl)cyclohexane-1-carboxylate. LC-MS: (ES, m / z): [M+H] +=237.1. 1H NMR (400 MHz, DMSO- d 6) δ 9.86 (s, 1H), 7.97 (d, J= 2.4Hz, 1H), 6.77 (d, J= 2.4 Hz, 1H), 4.39 – 4.29 (m, 1H), 3.62 (s, 3H), 2.47 – 2.38 (m, 1H), 2.14 – 2.01 (m, 4H), 1.91 – 1.77 (m, 2H), 1.62 – 1.48 (m, 2H). Step 3: Preparation of methyl (1R,4R)-4-(3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid (1R,4R)-4-(3-aldehyde-1H-pyrazole-1-yl)cyclohexane-1-carboxylic acid methyl ester (1.0 g, 4.2 mmol) was dissolved in anhydrous DCM (20 mL), and DAST (4.1 g, 25.4 mmol) was added at 0 °C. The mixture was then slowly heated to room temperature and stirred overnight. The reaction was quenched by adding saturated sodium bicarbonate solution dropwise under ice bath conditions. The mixture was separated into liquid and liquid phases, and the aqueous phase was extracted twice with dichloromethane. The solution was concentrated under reduced pressure, and the crude product was purified by column chromatography (EA:PE = 1:4) to obtain (1R,4R)-4-(3-(difluoromethyl)-1H-pyrazole-1-yl)cyclohexane-1-carboxylic acid methyl ester. LC-MS: (ES, m / z): [M+H] +=259.1. 1H NMR (400 MHz, DMSO- d 6) δ 7.88 (s, 1H), 7.08-6.85 (m, 1H), 6.49 (s, 1H), 4.28-4.17 (m, 1H), 3.62 (s, 3H), 2.47-2.36 (m, 1H), 2.15-1.95 (m, 4H), 1.86 – 1.73 (m, 2H), 1.61 – 1.48 (m, 2H). Step 4: Preparation of methyl (1R,4R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid (1R,4R)-4-(3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester (1.0 g, 3.9 mmol) was dissolved in concentrated H₂SO₄ (5 mL), and concentrated HNO₃ (1 mL) was added dropwise at 0 °C. The mixture was then slowly heated to room temperature and stirred overnight. The reaction solution was slowly poured into an ice-water mixture (20 mL), filtered, and the filter cake was washed three times with water. The product was then dried under vacuum to obtain (1R,4R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester. The obtained product was used directly in the next reaction step. 1H NMR (400 MHz, DMSO- d 6) δ 9.05 (s, 1H), 7.39-7.20 (m, 1H), 4.42-4.30 (m, 1H), 3.62 (s, 3H), 2.46 – 2.37 (m, 1H), 2.16 – 2.00 (m, 4H), 1.93-1.72 (m, 2H), 1.59-1.40 (m, 2H). Step 5: Preparation of methyl (1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid (1R,4R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazole-1-yl)cyclohexane-1-carboxylic acid methyl ester (880 mg, 2.9 mmol) was dissolved in THF (10 mL), Pd / C (440 mg, 50%) was added, the mixture was substituted with H₂ three times, and stirred at room temperature for 4 h in an H₂ atmosphere. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain (1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazole-1-yl)cyclohexane-1-carboxylic acid methyl ester. The crude product was used directly in the next reaction step. LC-MS: (ES, m / z): [M+H] +=274.1. Step 6: Preparation of ((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol Methyl (1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid (750 mg, 2.7 mmol) was dissolved in anhydrous THF (5 mL). BH3 / THF (27.5 mL, 1M / THF, 27.5 mmol) was added at 0 °C, and the mixture was slowly heated to room temperature and stirred overnight. MeOH was added dropwise to the reaction solution under ice bath until no obvious bubbles were produced. The solution was concentrated under reduced pressure, and the crude product was purified by column chromatography (MeOH:DCM = 1:9) to obtain ((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol. LC-MS: (ES, m / z): [M+H] +=246.1. 1H NMR (400 MHz, DMSO- d 6) δ 7.17 (d, J= 14.3 Hz, 1H), 7.06 – 6.68 (m, 1H), 4.46 (t, J= 5.3 Hz, 1H), 4.03 (s, 2H), 3.94 (td, J= 8.2, 4.0 Hz, 1H), 3.27 – 3.22 (m, 2H), 1.97 (d, J= 9.5 Hz, 2H), 1.83 (d, J= 11.4 Hz, 2H), 1.69-1.57 (m, 2H), 1.39 (d, J= 2.9 Hz, 1H), 1.12 – 0.97 (m, 2H).
[0245] Intermediate 22. 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Step 1: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine ((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol (360 mg, 1.5 mmol) was dissolved in DMF (10 mL), and 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (380 mg, 1.5 mmol), DIEA (566 mg, 4.4 mmol), and HATU (726 g, 1.9 mmol) were added. The mixture was stirred overnight at room temperature, and water (50 mL) was added. After stirring for 5 min, the mixture was extracted with EA (50 mL x 3). The organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the crude product was purified by column chromatography (MeOH:DCM=1:9) to obtain 5-((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol (360 mg, 1.5 mmol), DIEA (566 mg, 4.4 mmol), and HATU (726 g, 1.9 mmol). R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ES, m / z): [M+H] +=488.2. 1H NMR (400 MHz, DMSO- d 6) δ 9.49 (d, J= 5.4 Hz, 1H), 8.78 (d, J= 7.7 Hz, 1H), 8.39 (d, J= 4.2 Hz, 1H), 8.23 (d, J= 5.4 Hz, 1H), 7.30-6.94 (m, 1H), 6.90-6.34 (m, 1H), 5.33-5.03 (m, 1H), 4.77 (d, J= 16.7 Hz, 1H), 4.52-4.30 (m, 1H), 4.22 – 4.05 (m, 1H), 3.89 – 3.69 (m, 2H), 3.67 – 3.42 (m, 2H), 3.17-2.97 (m, 2H), 2.12 – 1.80 (m, 6H), 1.80 – 1.61 (m, 2H), 1.48-1.36 (m, 1H), 1.19-1.01 (m, 2H). Step 2: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Add IBX (460 mg, 1.64 mmol) to a solution of 5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1 R,4 R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methoxyamine (400 mg, 0.82 mmol) in ACN (20 mL), and then stir the reaction mixture at 85 °C for 1 h. After the reaction mixture was concentrated under reduced pressure, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (MeOH:DCM=1:9) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ES, m / z): [M+H] +=486.2. 1H NMR (400 MHz, DMSO- d 6) δ 9.62 (s, 1H), 9.51 (d, J= 5.7 Hz, 1H), 8.78 (d, J= 7.7 Hz, 1H), 8.44 – 8.35 (m, 1H), 8.26 (d, J= 5.2 Hz, 1H), 7.27-6.98 (m, 1H), 6.93-6.40 (m 1H), 5.30-5.05 (m, 1H), 4.77 (d, J= 16.6 Hz, 1H), 4.26-4.15 (m, 1H), 3.84 – 3.72 (m, 2H), 3.67 – 3.59 (m, 2H), 3.45 (d, J= 9.9 Hz, 1H), 2.45-2.35 (m, 1H), 2.18-1.74 (m, 8H), 1.45-1.28 (m, 2H).
[0246] Intermediate 23: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((methyl(2-(piperidin-4-yl)ethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of tert-butyl 4-(2-(phenyl(methyl)amino)ethyl)piperidine-1-carboxylic acid Under N₂ protection, N-methyl-1-phenylmethylamine (1.067 g, 8.82 mmol) and AcOH (0.79 g, 13.23 mmol) were added to a DCE (3 mL) solution of 4-(2-oxoethyl)piperidin-1-carboxylic acid tert-butyl ester (1 g, 4.41 mmol). The mixture was stirred at room temperature for 30 min, and then STAB (2.8 g, 13.23 mmol) was added. The reaction mixture was then stirred at room temperature for 2 h. The reaction mixture was diluted with water (20 mL), extracted with EA (30 mL × 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM = 0~1:20) to obtain 4-(2-(phenyl(methyl)amino)ethyl)piperidin-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 333.2. Step 2: Preparation of tert-butyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylic acid Pd(OH)₂ / C (250 mg) was added to a THF (3 mL) solution of 1 g (3.01 mmol) of 4-(2-(phenyl(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester. The reaction solution was then stirred at room temperature for 2 h under a H₂ atmosphere. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain 4-(2-(methylamino)ethyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 243.2. Step 3: Preparation of 4-(2-((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester To a solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (300 mg, 0.618 mmol) in THF (3 mL), 4-(2-(methylamino)ethyl)piperidine-1-carboxylic acid tert-butyl ester (329 mg, 0.928 mmol) and STAB (419 mg, 1.862 mmol) were added, and the reaction was stirred at room temperature under a nitrogen atmosphere for 2 h. The reaction was quenched with water (20 mL), extracted with DCM (20 mL × 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM=0~1:9) to obtain 4-(2-((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 712.4. Step 4: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((methyl(2-(piperidin-4-yl)ethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Add TFA (1 mL) to a DCM (3 mL) solution of 4-(2-((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.281 mmol), and then stir the reaction mixture at room temperature under N2 atmosphere for 2 h. The reaction solution was directly concentrated under reduced pressure to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((methyl(2-(piperidin-4-yl)ethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 612.4.
[0247] Preparation of Intermediate 24: N-(3-(difluoromethyl)-1-((1R,4R)-4-(aldehyde)cyclohexyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine Step 1: Preparation of ethyl 5-morphofolinpyrazolo[1,5-a]pyrimidine-3-carboxylate 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid tert-butyl ester (6 g, 27 mmol), mofolin (2.3 g, 27 mmol) and N,N-diisopropylethylamine (10.4 g, 81 mmol) were dissolved in acetonitrile (60 mL) and heated to 60 °C with stirring overnight. The reaction solution was directly concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate) to obtain 5-mofolinpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester. LC-MS: (ESI, m / z): [M+H] +=277.3. Step 2: Preparation of 5-Mofolinpyrazolo[1,5-a]pyrimidine-3-carboxylic acid Ethyl 5-morphofolinpyrazolo[1,5-a]pyrimidine-3-carboxylic acid was dissolved in a mixed solution (methanol / water = 5:1, 40 mL), lithium hydroxide (2.6 g, 64 mmol) was added, and the mixture was heated to 60 °C and stirred for 2 hours. The pH of the reaction solution was adjusted to 2 with dilute hydrochloric acid (2 mol / L), filtered, and the solid was dried under vacuum to obtain 5-morphofolinpyrazolo[1,5-a]pyrimidine-3-carboxylic acid. Step 3: Preparation of N-(3-(difluoromethyl)-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine 5-Modolinpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (248 mg, 1.0 mmol), ((1 R,4 R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol (245 mg, 1.0 mmol), and HATU (494 mg, 1.3 mmol) were dissolved in DMF (5 mL), and DIEA (387 mg, 3.0 mmol) was added. The reaction mixture was stirred at room temperature for 16 h. After the reaction was completed, the reaction mixture was diluted with water (50 mL), stirred, filtered, and the filter cake was washed with water (5 mL x 3) and dried under vacuum to obtain N-(3-(difluoromethyl)-1-((1 R,4 R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-Modolinpyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 476.1. Step 4: Preparation of N-(3-(difluoromethyl)-1-((1R,4R)-4-(aldehyde)cyclohexyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine N-(3-(difluoromethyl)-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine (80 mg, 0.17 mmol) was dissolved in DCM (4 mL), and then Dess-Martin reagent (144 mg, 0.34 mmol) was added. The reaction mixture was stirred overnight at room temperature. After filtration, the solid was washed with DCM (10 mL x 3), the organic phase was concentrated under reduced pressure, and the crude product was purified by normal column chromatography to obtain N-(3-(difluoromethyl)-1-((1R,4R)-4-(aldehyde)cyclohexyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 474.1.
[0248] Intermediate 25: N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of tert-butyl 4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid HATU (900 mg, 2.4 mmol) was added to a DMF (20 mL) solution of 5-morphofolinpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (470 mg, 1.9 mmol) and DIEA (1 mL, 4.7 mmol). The mixture was stirred at 25 °C for 2 h, and then tert-butyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid (0.5 g, 1.5 mmol) was added. The reaction mixture was then stirred at 25 °C overnight. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with EA (50 mL × 3). The organic phases were combined, washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column (EA) to obtain tert-butyl 4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid. LC-MS: (ESI, m / z): [M+H] += 547.4. Step 2: Preparation of N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine TFA (1 mL) was added to a 3 mL solution of 4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methoxylamine)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (0.2 g, 0.366 mmol) in DCM at 25 °C. The reaction solution was stirred at 25 °C for 1 h. The reaction solution was then directly concentrated under reduced pressure to give N-(3-(difluoromethyl)-1-(piperidine-4-yl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methoxylamine. LC-MS: (ESI, m / z): [M+H] += 447.2. Step 3: Preparation of 9-((4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester At 25 °C, tert-butyl 9-aldehyde-3-azaspiro[5.5]undecane-3-carboxylic acid (150 mg, 0.45 mmol) and NaBH3CN (100 mg, 2.25 mmol) were added to a MeOH (5 mL) solution of N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-carboxylic acid (200 mg, 0.45 mmol) and DIEA (0.5 mL, 1.35 mmol). The reaction mixture was stirred at 25 °C for 16 h. The crude product was filtered, concentrated under reduced pressure, and purified by flash column chromatography (MeOH:DCM=3:97) to obtain 9-((4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methoxyamine)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 712.4. Step 4: Preparation of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine TFA (1 mL) was added to a DCM (3 mL) solution of 0.14 g (0.2 mmol) of 9-((4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (DCM). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was then directly concentrated under reduced pressure to give N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine. The product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] += 612.5.
[0249] Intermediate 26: ((1R,4R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazole-1-yl)cyclohexyl)methanol A THF (50 mL) solution of (1 R,4 R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester (4.0 g, 13.2 mmol) was cooled to -20 °C, and LiAlH4 (1 M THF solution, 16 mL) was added dropwise. After stirring the reaction solution at room temperature for 0.5 hours, 15% sodium hydroxide solution (8 mL) was slowly added, followed by water (50 mL). The mixture was extracted with a MeOH / DCM mixture (V / V = 1:9, 50 mL x 3), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by column chromatography (MeOH:DCM = 1:9) to obtain ((1 R,4 R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)cyclohexyl)methanol. LC-MS: (ESI, m / z): [M-56] +=276.0.
[0250] Intermediate 27: N-(1-(1-(2-(3-azaspiro[5.5]undecane-9-yl)ethyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine Step 1: Preparation of tert-butyl 9-(2-oxoethyl)-3-azaspiro[5.5]undecane-3-carboxylic acid 9-(2-hydroxyethyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (250 mg, 0.842 mmol) and PCC (543.8 mg, 2.523 mmol) were added to DCM (5 mL), stirred at room temperature for 2 h, then filtered, water (20 mL) was added, extracted with ethyl acetate (25 mL x 4), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain crude 9-(2-oxoethyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M-56] += 240.1. Step 2: Preparation of 9-(2-(4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidin-1-yl)ethyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine (140 mg, 0.314 mmol) and 9-(2-oxoethyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (185 mg, 0.628 mmol) were added to THF, followed by the addition of sodium triacetoxyborohydride (133 mg, 0.628 mmol). The mixture was stirred at room temperature for 2 h, then water (20 mL) was added, and the mixture was extracted with ethyl acetate (25 mL x 4). The extract was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and subjected to normal phase column chromatography (MeOH:DCM = 10 ... 9-(2-(4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidin-1-yl)ethyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester was obtained by purification at 1:19. LC-MS: (ESI, m / z): [M+H] +=726.4. Step 3: Preparation of N-(1-(1-(2-(3-azaspiro[5.5]undecane-9-yl)ethyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine 9-(2-(4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidin-1-yl)ethyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (121 mg, 0.167 mmol) was added to TFA (0.5 mL) and DCM (2.5 mL), stirred at room temperature for 2 h, and the reaction solution was concentrated under reduced pressure to obtain crude N-(1-(1-(2-(3-azaspiro[5.5]undecane-9-yl)ethyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=626.4.
[0251] Intermediate 28: N-(3-(difluoromethyl)-1-((1R,4S)-4-carboxaldehydecyclohexyl)-1H-pyrazol-4-yl)-5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methamide Step 1: Preparation of ethyl (S)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (1.0 g, 4.4 mmol), (S)-piperidin-3-ol (445 mg, 4.4 mmol), and N,N-diisopropylethylamine (1.7 g, 13.3 mmol) were dissolved in acetonitrile (10 mL), and the reaction mixture was heated to 60 °C and stirred overnight. The reaction mixture was directly concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate:petroleum ether = 87:13) to obtain ethyl (S)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. LC-MS: (ESI, m / z): [M+H] +=291.1. [] Step 2: Preparation of (S)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Ethyl (S)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid was dissolved in a mixed solution (methanol / water = 5:1, 10 mL), and lithium hydroxide (643 mg, 16 mmol) was added. The mixture was heated to 60 °C and stirred for 2 hours. The pH of the reaction solution was adjusted to 2 with dilute hydrochloric acid (2 mol / L), filtered, and the filter cake was dried under vacuum to obtain (S)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=263.1. Step 3: Preparation of 5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (S)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (300 mg, 1.14 mmol) was dissolved in tetrahydrofuran (15 mL), and 3,4-dihydro-2H-pyran (962 mg, 11.4 mmol) and tetrabutylammonium tribromide (111 mg, 0.23 mmol) were added. The mixture was heated to 60 °C and stirred overnight. The reaction solution was concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate) to give 5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=347.2. Step 4: Preparation of N-(3-(difluoromethyl)-1-((1R,4S)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine 5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (180 mg, 0.52 mmol) and ((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol (137 mg, 0.52 mmol) were dissolved in DMF (10 mL), and N,N-diisopropylethylamine (201 mg, 1.56 mmol) and py-BOP (348 mg, 0.67 mmol) were added with stirring. The mixture was stirred overnight at 60 °C. The reaction solution was cooled to room temperature, water (100 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol:dichloromethane = 1:9) to obtain N-(3-(difluoromethyl)-1-((1R,4S)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=574.3. Step 5: Preparation of N-(3-(difluoromethyl)-1-((1R,4S)-4-carboxaldehydecyclohexyl)-1H-pyrazol-4-yl)-5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbamate N-(3-(difluoromethyl)-1-((1R,4S)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (200 mg, 0.35 mmol) was dissolved in acetonitrile (20 mL), and IBX (196 mg, 0.70 mmol) was added. The mixture was stirred at 80 °C for 2 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol:dichloromethane = 1:9) to obtain N-(3-(difluoromethyl)-1-((1R,4S)-4-carboxaldehydecyclohexyl)-1H-pyrazol-4-yl)-5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. LC-MS: (ESI, m / z): [M+H] +=572.3.
[0252] Intermediate 29: (S)-N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methamide Step 1: Preparation of tert-butyl 4-(3-(difluoromethyl)-4-(5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid [] 5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (210 mg, 0.61 mmol) and 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid tert-butyl ester (191 mg, 0.61 mmol) were dissolved in DMF (10 mL), and N,N-diisopropylethylamine (236 mg, 1.83 mmol) and Py-BOP (475 mg, 0.91 mmol) were added with stirring. The mixture was heated to 60 °C and stirred overnight. Water (100 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phase was washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol:dichloromethane = 1:9) to obtain 4-(3-(difluoromethyl)-4-(5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=645.3. Step 2: Preparation of (S)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-methamide [] 180 mg (0.28 mmol) of 4-(3-(difluoromethyl)-4-(5-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid tert-butyl ester was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (1 mL) was added and stirred at room temperature for 1 hour. The reaction solution was directly concentrated under reduced pressure to obtain (S)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methamide, which was used directly in the next reaction without purification. LC-MS: (ESI, m / z): [M+H] +=461.2. Step 3: Preparation of (S)-9-((4-(3-(difluoromethyl)-4-(5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester [] (S)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-methoxyamine (180 mg, crude, 0.28 mmol) and 9-methoxy-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (87 mg, 0.31 mmol) were dissolved in tetrahydrofuran (10 mL), and sodium triacetoxyborohydride (180 mg, 0.84 mmol) was added with stirring. The mixture was stirred overnight at room temperature. Water (50 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol:dichloromethane = 1:9) to obtain (S)-9-((4-(3-(difluoromethyl)-4-(5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=726.3. Step 4: Preparation of (S)-N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine [] (S)-9-((4-(3-(difluoromethyl)-4-(5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (160 mg, 0.22 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 2 hours. The reaction solution was directly concentrated under reduced pressure to obtain (S)-N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(3-hydroxypiperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine, which was used directly in the next reaction without purification. LC-MS: (ESI, m / z): [M+H] +=626.4.
[0253] Intermediate 30: N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)-5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Step 1: Preparation of ethyl 5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate [, , ] Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (1.0 g, 4.4 mmol), 2-oxo-6-azaspiro[3.3]heptane (439 mg, 4.4 mmol), and N,N-diisopropylethylamine (1.7 g, 13.3 mmol) were dissolved in acetonitrile (10 mL), and the reaction mixture was heated to 60 °C and stirred overnight. The reaction mixture was directly concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate) to obtain ethyl 5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. LC-MS: (ESI, m / z): [M+H] +=289.2. Step 2: Preparation of 5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Ethyl 5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (1.1 g, 3.8 mmol) was dissolved in 10 mL of a mixed solution (methanol / water = 5:1), lithium hydroxide (639 mg, 15 mmol) was added, and the mixture was heated to 60 °C and stirred for 2 hours. The pH of the reaction solution was adjusted to 2 with 2 mol / L dilute hydrochloric acid. The mixture was filtered, and the solid was dried under vacuum to obtain 5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=261.1. Step 3: Preparation of N-(3-(difluoromethyl)-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine 5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (110 mg, 0.41 mmol) and ((1 R,4 R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol (100 mg, 0.41 mmol) were dissolved in DMF (3 mL), and HATU (202 mg, 0.53 mmol) and DIEA (212 mg, 1.6 mmol) were added. The reaction mixture was heated to 90 °C and stirred overnight. The solution was diluted with water (80 mL), extracted with ethyl acetate (100 mL x 2), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by column chromatography (PE:EA = 1:9) to give compound N-(3-(difluoromethyl)-1-((1 R,4 R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methanol (100 mg, 0.41 mmol). R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-methamide. LC-MS: (ESI, m / z): [M+H] +=488.2. Step 4: Preparation of N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)-5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine The compound N-(3-(difluoromethyl)-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)-5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (120 mg, 0.246 mmol) was dissolved in DCM (3 mL), and then PCC (107 mg, 0.493 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction solution was diluted with water (20 mL), extracted with dichloromethane (25 mL x 4), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by column chromatography (DCM:MEOH=1:10) to obtain compound N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)-5-(2-oxo-6-azaspiro[3.3]heptane-6-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=486.3.
[0254] Intermediate 31: N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of ethyl 5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (1.0 g, 4.4 mmol), thiomorphofolin 1,1-dioxide (906 mg, 5.3 mmol), and N,N-diisopropylethylamine (2.3 g, 18 mmol) were dissolved in acetonitrile (10 mL) and heated to 60 °C with stirring overnight. The reaction solution was directly concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether = 9:1) to obtain ethyl 5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. LC-MS: (ESI, m / z): [M+H] +=325.0. Step 2: Preparation of 5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Ethyl 5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (900 mg, 2.8 mmol) was dissolved in a mixed solution (methanol / water = 5:1, 10 mL), lithium hydroxide (470 mg, 11.2 mmol) was added, and the mixture was heated to 60 °C and stirred for 2 hours. The pH of the reaction solution was adjusted to 3 with dilute hydrochloric acid (2 mol / L), filtered, and the filter cake was dried under vacuum to obtain 5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=297.0. Step 3: Preparation of tert-butyl 4-(3-(difluoromethyl)-4-(5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid 5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (150 mg, 0.51 mmol) and tert-butyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid (161 mg, 0.51 mmol) were dissolved in DMF (5 mL), and DIEA (271 mg, 2.1 mmol) and HATU (251 mg, 0.66 mmol) were added with stirring. The reaction mixture was stirred at room temperature for 12 hours. The reaction solution was finally diluted with water (60 mL), extracted with ethyl acetate (60 mL x 3), the organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether = 7:3) to obtain 4-(3-(difluoromethyl)-4-(5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+Na] +=617.1. Step 4: Preparation of N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidine-3-methylamine 4-(3-(difluoromethyl)-4-(5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (80 mg, 0.13 mmol) was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.4 mL) was added and stirred at room temperature for 2 hours. The reaction solution was directly concentrated under reduced pressure to obtain N-(3-(difluoromethyl)-1-(piperidine-4-yl)-1H-pyrazol-4-yl)-5-(1,1-dioxothiomorphofolinyl)pyrazolo[1,5-a]pyrimidin-3-methylamine, which was used directly in the next reaction without purification. LC-MS: (ESI, m / z): [][M+H] +=495.2.
[0255] Intermediate 32: 3-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methylbenzoyl)-3-azaspiro[5.5]undecane-9-carboxaldehyde Step 1: Preparation of 3-azaspiro[5.5]undecane-9-carboxaldehyde 200 mg (0.71 mmol) of 9-methoxy-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester was dissolved in DCM (2 mL), and TFA (0.4 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. The solution was then concentrated under reduced pressure to obtain 3-azaspiro[5.5]undecane-9-carboxaldehyde. LC-MS: (ESI, m / z): [M+H] +=182.2. [] Step 2: Preparation of 3-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methylbenzyl)-3-azaspiro[5.5]undecane-9-carboxaldehyde 3-azaspiro[5.5]undecane-9-carboxaldehyde (345 mg, 0.71 mmol) and 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methylbenzoic acid pentafluorophenyl ester (295 mg, 0.71 mmol) were dissolved in DMSO (5 mL) and stirred at room temperature for 1 hour. Water (50 mL) was added to the final reaction mixture, and the mixture was extracted with EA (30 mL x 3). The organic phases were combined and washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by normal-phase column chromatography to obtain 3-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methylbenzoyl)-3-azaspiro[5.5]undecane-9-carboxaldehyde. LC-MS: (ESI, m / z): [M+H] +=412.2.
[0256] Intermediate 33: 3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-carboxaldehyde The preparation method is the same as that for intermediate 32. LC-MS: (ESI, m / z): [M+H] +=432.1.
[0257] Intermediate 34: (S)-(1-(3-((3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)carbamoyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-3-yl)tert-butyl carbamate Step 1: Preparation of ethyl (S)-5-(3-((tert-Butoxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (2.0 g, 8.9 mmol), (S)-piperidin-3-ylcarboxylate tert-butyl ester (1.8 g, 8.9 mmol), and N,N-diisopropylethylamine (3.5 g, 27 mmol) were dissolved in acetonitrile (20 mL). The reaction mixture was heated to 60 °C and stirred overnight. The mixture was then concentrated under reduced pressure. The crude product was purified by column chromatography (ethyl acetate:petroleum ether = 9:1) to obtain ethyl (S)-5-(3-((tert-butyloxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. LC-MS: (ESI, m / z): [M+H] +=390.0. Step 2: Preparation of (S)-5-(3-((tert-Butoxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [] Ethyl (S)-5-(3-((tert-Butoxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (3.2 g, 8.2 mmol) was dissolved in a mixed solution (methanol / water = 5:1, 30 mL), lithium hydroxide (787 mg, 32.8 mmol) was added, and the mixture was heated to 60 °C and stirred for 2 hours. The pH of the reaction solution was adjusted to 2 with dilute hydrochloric acid (2 mol / L), filtered, and the filter cake was dried under vacuum to obtain (S)-5-(3-((tert-Butoxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=362.5. Step 3: Preparation of 4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)piperidine 4-(3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (1 g, 3 mmol) was dissolved in concentrated sulfuric acid (10 mL) and cooled to 0°C. Concentrated nitric acid (1 mL) was slowly added dropwise, and the reaction mixture was stirred overnight at room temperature. The reaction mixture was slowly poured into ice water (300 mL), and the pH of the aqueous phase was adjusted to 8 with sodium carbonate. The mixture was extracted with a methanol / dichloromethane mixture (10 / 1, 60 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)piperidine. LC-MS: (ESI, m / z): [M+H] +=247.0. Step 4: Preparation of benzyl 4-(3-(difluoromethyl)-4-nitro-1H-pyrazole-1-yl)piperidine-1-carboxylic acid ester 4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)piperidine (460 mg, 1.9 mmol) was dissolved in dichloromethane (6 mL), and DIEA (735 mg, 5.7 mmol) and CbzCl (391 mg, 2.3 mmol) were added and stirred at room temperature for 2 hours. Water (80 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (100 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (ethyl acetate: petroleum ether = 1:1) to give benzyl 4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)piperidine-1-carboxylic acid. LC-MS: (ESI, m / z): [M+H] +=381.2. [] Step 5: Preparation of benzyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 4-(3-(difluoromethyl)-4-nitro-1H-pyrazole-1-yl)piperidine-1-carboxylic acid benzyl ester (500 mg, 1.3 mmol), iron powder (294 mg, 5.2 mmol) and NH4Cl (418 mg, 7.9 mmol) were added to water (10 mL). The reaction mixture was heated to 90 °C and stirred for 2 hours. After filtration, the mixture was diluted with water (80 mL) and extracted with ethyl acetate (100 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 4-(4-amino-3-(difluoromethyl)-1H-pyrazole-1-yl)piperidine-1-carboxylic acid benzyl ester. [] LC-MS: (ESI, m / z): [M+H] += [351.2.] Step 6: Preparation of (S)-4-(4-(5-(3-((tert-butoxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid benzyl ester (S)-5-(3-((tert-butoxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (56 mg, 0.15 mmol), 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid benzyl ester (54 mg, 0.15 mmol) and Py-BOP (240 mg, 0.45 mmol) were dissolved in DMF (5 mL), and then DIEA (60 mg, 0.45 mmol) was added. The mixture was stirred at room temperature for 16 hours. Water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined and washed with saturated brine (50 mL). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by normal-phase column chromatography to obtain (S)-4-(4-(5-(3-((tert-butoxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] +=694.4. [] Step 7: Preparation of (S)-(1-(3-((3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)carbamoyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-3-yl)tert-butyl carbamate (S)-4-(4-(5-(3-((tert-butyloxycarbonyl)amino)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-carboxyamino)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-carboxylic acid benzyl ester (90 mg, 0.13 mmol) was dissolved in THF (3 mL), Pd / C (10%, 50 mg) was added, H2 was replaced three times, and the mixture was stirred at room temperature for 1 hour under hydrogen protection. The reaction solution was filtered through diatomaceous earth, and the filter cake was washed with THF (10 mL x 3). The filtrate was concentrated under reduced pressure to obtain crude (S)-(1-(3-((3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)aminomethyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-3-yl)carbamate tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 560.3.
[0258] Example 1: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine A solution of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide (150 mg, crude, 0.18 mmol), pentafluorophenyl 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate (78 mg, 0.18 mmol), and N,N-diisopropylethylamine (116 mg, 0.9 mmol) in dimethyl sulfoxide (5 mL) was stirred overnight at room temperature. The resulting mixture was poured into water (50 mL) and stirred for 10 minutes. The filter cake was filtered and purified by preparative HPLC to obtain the target product 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=874.5. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.50 (d, J= 5.9 Hz, 1H), 8.78 (d, J= 7.7 Hz, 1H), 8.39 (d, J= 4.0 Hz, 1H), 8.26 (d, J= 5.7 Hz, 1H), 7.63 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.9 Hz, 1H), 7.39 (dd, J= 8.3, 2.0 Hz, 1H), 7.27-6.96 (m, 1H), 6.90 – 6.41 (m, 1H), 5.30-5.05 (m, 1H), 4.77 (d, J= 17.4 Hz, 1H), 4.26-4.14 (m, 1H), 3.86 – 3.70 (m, 3H), 3.66 – 3.41 (m, 5H), 3.30-3.25 (m, 2H), 2.96-2.84 (m, 2H), 2.79 – 2.70 (m, 2H), 2.22-2.08 (m, 2H), 2.06 – 1.83 (m, 8H), 1.75-1.65 (m, 2H), 1.63 – 1.24 (m, 7H), 1.19 – 0.91 (m, 4H). []
[0259] Example 2: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1r,4R)-4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidine-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine The preparation method is the same as in Example 1. LC-MS: (ESI, m / z): [M+H] +=874.4 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.50 (d, J= 6.3 Hz, 1H), 8.78 (d, J= 7.7 Hz, 1H), 8.38 (d, J= 4.4 Hz, 1H), 8.25 (d, J= 5.7 Hz, 1H), 7.64 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.9 Hz, 1H), 7.39 (dd, J= 8.2, 1.9 Hz, 1H), 7.26-6.95 (m, 1H), 6.91-6.41 (m, 1H), 5.32-5.03 (m, 1H), 4.77 (d, J= 17.4 Hz, 1H), 4.17 (t, J= 12.9 Hz, 1H), 3.84 – 3.71 (m, 3H), 3.67-3.57 (m, 4H), 3.45 (d, J= 9.8 Hz, 1H), 3.30-3.25 (m, 2H), 2.79 – 2.71 (m, 2H), 2.38-2.24 (m, 4H), 2.13 – 1.77 (m, 8H), , 1.79-1.66 (m, 2H), 1.60-1.35 (m, 9H), 1.12-0.92 (m, 2H).
[0260] Example 3: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((4-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperazine-1-yl)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of 4-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)piperazine-1-carboxylic acid tert-butyl ester 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-methoxycyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (130 mg, 0.268 mmol) and piperidine-1-carboxylic acid tert-butyl ester (60 mg, 0.322 mmol) were dissolved in tetrahydrofuran (10 mL), stirred at room temperature, and then sodium triacetoxyborohydride (284 mg, 1.34 mmol) was added and stirred at room temperature for 2 hours. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3) and saturated brine (50 mL x 3). The organic phase was washed with mL of water, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol:dichloromethane = 1:9) to obtain 4-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)piperazine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=656.3. Step 2: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-(piperazo-1-ylmethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine 4-(((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)piperazine-1-carboxylic acid tert-butyl ester (120 mg, 0.183 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (1 mL) was added and stirred at room temperature for 2 hours. The reaction solution was directly concentrated under reduced pressure to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-(piperazo-1-ylmethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine, which could be used directly in the next step of the reaction without purification. LC-MS: (ESI, m / z): [M+H] +=556.3 Step 3: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((4-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperazine-1-yl)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-(piperazol-1-ylmethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine (120 mg, 0.185 mmol, trifluoroacetate) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (96 mg, 0.22 mmol) were dissolved in dimethyl sulfoxide (10 mL), stirred at room temperature, DIEA (0.5 mL) was added and stirred at room temperature for 2 hours, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3) and saturated brine (50 mL x 3). The organic phase was washed with mL, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by pre-HPLC to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((4-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperazine-1-yl)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=806.2. 1H NMR (400 MHz, DMSO- d 6) δ 10.50 (s, 1H), 9.49 (d, J= 6.0 Hz, 1H), 8.78 (d, J= 7.8 Hz, 1H), 8.38 (d, J= 4.3 Hz, 1H), 8.25 (d, J= 5.6 Hz, 1H), 7.65 (d, J= 8.2 Hz, 1H), 7.57 (d, J= 2.0 Hz, 1H), 7.41 (dd, J= 8.2, 2.0 Hz, 1H), 7.27-6.94 (m, 1H), 6.89-6.38 (m, 1H), 5.32-5.02 (m, 1H), 4.77 (d, J= 17.6 Hz, 1H), 4.25 – 4.15 (m, 1H), 3.86 – 3.71 (m, 3H), 3.68 – 3.57 (m, 4H), 3.45 (d, J= 10.3 Hz, 2H), 2.80-2.70 (m, 2H), 2.45 – 2.25 (m, 4H), 2.16 (d, J= 7.0 Hz, 2H), 2.11 – 1.83 (m, 7H), 1.1-1.67 (m, 2H), 1.68 – 1.50 (m, 1H), 1.16 – 0.98 (m, 2H).
[0261] Example 4: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)methyl)(methyl)amino)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of 4-(((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)methyl)piperidine-1-carboxylic acid tert-butyl ester 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-methoxycyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methamide (130 mg, 0.268 mmol) and 4-((methylamino)methyl)piperidine-1-carboxylic acid tert-butyl ester (73 mg, 0.320 mmol) were dissolved in tetrahydrofuran (10 mL), stirred at room temperature, and then added to triethoxyborohydride sodium (284 mg, 1.34 mmol) and stirred at room temperature for 2 hours. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3) and saturated brine (50 mL x 3). The organic phase was washed with mL, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (methanol:dichloromethane = 1:9) to obtain 4-(((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)methyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=698.4. Step 2: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((methyl(piperidin-4-ylmethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine 4-((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)methyl)piperidine-1-carboxylic acid tert-butyl ester (150 mg, 0.215 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (1 mL) was added and stirred at room temperature for 2 hours, and then directly concentrated under reduced pressure to obtain 5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1 R,4 R)-4-((methyl(piperidine-4-ylmethyl)amino)methyl)cyclohexyl)-1 H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide can be used directly in the next reaction without purification. LC-MS: (ESI, m / z): [M+H] +=598.3. Step 3: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)methyl)(methyl)amino)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((methyl(piperidin-4-ylmethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methamide (150 mg, 0.251 mmol, trifluoroacetate) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (134 mg, 0.309 mmol) were dissolved in dimethyl sulfoxide (10 mL), stirred at room temperature, DIEA (0.5 mL) was added and stirred at room temperature for 2 hours, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3) and saturated brine (50 mL x 3). The organic phase was washed with mL, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by pre-HPLC to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)methyl)(methyl)amino)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=848.3. 1H NMR (400 MHz, DMSO- d 6) δ 10.50 (s, 1H), 9.50 (d, J= 5.8 Hz, 1H), 8.78 (d, J= 7.7 Hz, 1H), 8.38 (d, J= 4.4 Hz, 1H), 8.25 (d, J= 5.5 Hz, 1H), 8.17 (s, 1H), 7.64 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.9 Hz, 1H), 7.38 (dd, J= 8.2, 2.0 Hz, 1H), 7.27-7.94 (m, 1H), 6.90-6.42 (m, 1H), 5.33-5.00 (m, 1H), 4.77 (d, J= 17.4 Hz, 1H), 4.52-4.33 (m, 1H), 4.17 (t, J= 10.6 Hz, 1H), 3.86-3.70 (m, 3H), 3.68-3.53 (m, 3H), 3.45 (d, J= 10.1 Hz, 1H), 3.14-2.96 (m, 1H), 2.90 – 2.68 (m, 3H), 2.25 – 1.46 (m, 19H), 1.18 – 0.88 (m, 4H).
[0262] Example 5: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1R,4R)-4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of (1R,4R)-4-(4-nitro-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester 4-Nitro-1H-pyrazole (1.8 g, 15.9 mmol) and (1S,4S)-4-(p-toluenesulfonyl)cyclohexane-1-carboxylic acid methyl ester (5.2 g, 16.7 mmol) were dissolved in DMF (50 mL), Cs₂CO₃ (15.6 g, 47.7 mmol) and KI (2.78 g, 16.7 mmol) were added, and the mixture was stirred overnight at 50 °C. Water (200 mL) was added and stirred for 10 min. The mixture was extracted with ethyl acetate (100 mL x 3), and the organic phase was washed with saturated brine (150 mL). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (EA:PE = 7:11) to obtain (1R,4R)-4-(4-nitro-1H-pyrazole-1-yl)cyclohexane-1-carboxylic acid methyl ester. LC-MS: (ESI, m / z): [M+H] +=254.1. 1H NMR (400 MHz, DMSO- d 6) δ 8.90 (s, 1H), 8.26 (s, 1H), 4.33-4.25 (m, 1H), 3.63 (s, 3H), 2.42 – 2.35 (m, 1H), 2.15 – 2.00 (m, 4H), 1.89 – 1.76 (m, 2H), 1.59 – 1.45 (m, 2H). Step 2: Preparation of (1R,4R)-4-(4-amino-3-chloro-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester Methyl (1 R,4 R)-4-(4-nitro-1H-pyrazole-1-yl)cyclohexane-1-carboxylate (1.4 g, 5.5 mmol) was dissolved in ethanol (45 mL), and HCl (4.6 mL, 55.3 mmol) and Pd (5%, alumina-supported, 140 mg) were added. Triethylsilane (3.85 g, 33.2 mmol) was added dropwise under N2 protection, and the mixture was stirred overnight at room temperature. The pH was adjusted to 8 with saturated NaHCO3 solution, and the mixture was extracted with ethyl acetate (150 mL × 3). The organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (MeOH:DCM = 1:19) to obtain methyl (1 R,4 R)-4-(4-amino-3-chloro-1H-pyrazole-1-yl)cyclohexane-1-carboxylate. LC-MS: (ESI, m / z): [M+H] +=258.1 and [M+14] +=272.1. Step 3: Preparation of ((1R,4R)-4-(4-amino-3-chloro-1H-pyrazol-1-yl)cyclohexyl)methanol Methyl (1 R,4 R)-4-(4-amino-3-chloro-1 H-pyrazol-1-yl)cyclohexane-1-carboxylate (1.0 g, 3.9 mmol) was dissolved in THF (20 mL), and BH3 / THF (1 M, 39 mL, 39 mmol) was added. The reaction was carried out overnight at room temperature. After quenching with MeOH (10 mL), the mixture was concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM = 1:19) to give ((1 R,4 R)-4-(4-amino-3-chloro-1 H-pyrazol-1-yl)cyclohexyl)methanol. LC-MS: (ESI, m / z): [M+H] +=230.2. Step 4: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Add ((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (260 mg, 1.0 mmol) to a DMF (10 mL) solution of 5-((1R,4R)-4-(4-amino-3-chloro-1H-pyrazol-1-yl)cyclohexyl)methanol (300 mg, 1.3 mmol), HATU (570 mg, 1.5 mmol) and DIEA (387 mg, 3.0 mmol) to the solution and stir overnight at room temperature. Add water (100 mL) and stir for 10 min. Extract with ethyl acetate (100 mL x 3). Wash the organic phase with saturated brine (150 mL). Dry with anhydrous sodium sulfate, filter, concentrate under reduced pressure, and purify the crude product by column chromatography (MeOH:DCM=1:9) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=472.0. Step 5: Preparation of 5-((1R,4R)-2-oxo-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1R,4R)-4-methoxycyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide IBX (297 mg, 1.06 mmol) was added to a solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine (250 mg, 0.53 mmol) in ACN (20 mL). The mixture was stirred at 85 °C for 1.5 h, concentrated under reduced pressure, and the crude product was purified by column chromatography (MeOH:DCM=1:9) to obtain 5-((1R,4R)-2-oxo-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1R,4R)-4-methoxycyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine (250 mg, 0.53 mmol). H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide. LC-MS: (ESI, m / z): [M+H] +=470.2. Step 6: Preparation of 9-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-chloro-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester STAB (285 mg, 1.34 mmol) was added to a THF (10 mL) solution of 5-((1 R,4 R)-2-oxo-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1 R,4 R)-4-methoxycyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (210 mg, 0.45 mmol) and 3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (114 mg, 0.45 mmol). The mixture was stirred overnight at room temperature, concentrated under reduced pressure, and extracted with water (30 mL). The extract was then extracted with ethyl acetate (30 mL x 3) and saturated brine (50 mL). The organic phase was washed with mL, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (MeOH:DCM=1:9) to obtain 9-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-chloro-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+Na] +=708.2. Step 7: Preparation of N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-chloro-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine TFA (1 mL) was added to a DCM (5 mL) solution of 9-(((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-chloro-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (190 mg, 0.27 mmol) and stirred at room temperature for 2 hours. The solution was then concentrated under reduced pressure to obtain N-(1-(((1 R,4 R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-chloro-1H-pyrazol-4-yl)-5- ...4-(5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-chloro-1H-pyrazol-4-yl)-5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazol[1,5-a]pyrimidin-3-methoxyamine)-3-chloro-1H-pyrazol-1-methyl)-3-chloro-1H-pyrazol-1-methyl)-3-((1 R,4 R)-2-oxa-5-azabicyclo[ R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methamide. LC-MS: (ESI, m / z): [M+H] +=608.3. Step 8: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1R,4R)-4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-chloro-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide (190 mg, 0.31 mmol) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (136 mg, 0.31 mmol) were dissolved in DMSO (5 mL), and then DIEA (202 mg, 1.6 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. Add water (50 mL) to the reaction solution, stir for 10 minutes, filter, and purify the solid by reverse phase preparation to obtain 5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-chloro-1-((1 R,4 R)-4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2 H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-1 H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=858.2. 1H NMR (400 MHz, DMSO- d 6) δ 10.50 (s, 1H), 9.44 (d, J= 8.7 Hz, 1H), 8.80 (d, J= 7.7 Hz, 1H), 8.24 (d, J= 3.5 Hz, 1H), 8.06 (s, 1H), 7.63 (d, J= 8.2 Hz, 1H), 7.55 (s, 1H), 7.39 (d, J= 8.3 Hz, 1H), 6.95-6.39 (m, 1H), 5.30-5.00 (m, 1H), 4.79 (s, 1H), 4.25 – 4.15 (m, 1H), 3.92 – 3.38 (m, 9H), 2.80 – 2.68 (m, 2H), 2.40 – 2.20 (m, 4H), 2.11 (d, J= 6.5 Hz, 2H), 2.06 – 1.95 (m, 2H), 1.94 – 1.76 (m, 6H), 1.70 – 1.30 (m, 9H), 1.10 – 0.95 (m, 2H).
[0263] Example 6: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)piperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of (1-(3-chloro-4-nitrophenyl)piperidin-4-yl)methanol K₂CO₃ (1.57 g, 11.4 mmol) and 2-(piperidin-4-yl)ethane-1-ol (0.78 g, 6.8 mmol) were added to DMF (20 mL) containing 2-chloro-4-fluoro-1-nitrobenzene (1.0 g, 5.7 mmol). The mixture was stirred at 100 °C for 1 h, then water (200 mL) was added and stirred for 10 min. The mixture was extracted with ethyl acetate (100 mL x 3), and the organic phase was washed with saturated brine (150 mL). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (EA:PE = 1:1) to obtain (1-(3-chloro-4-nitrophenyl)piperidin-4-yl)methanol. LC-MS: (ESI, m / z): [M+H] +=271.0. Step 2: Preparation of (1-(4-amino-3-chlorophenyl)piperidin-4-yl)methanol (1-(3-chloro-4-nitrophenyl)piperidin-4-yl)methanol (1.3 g, 4.8 mmol) was dissolved in ethanol (30 mL), Raney-Ni (1 mL) and N2H4-H2O (1 mL) were added, the mixture was stirred at room temperature for 1 h, filtered, concentrated and dried to obtain (1-(4-amino-3-chlorophenyl)piperidin-4-yl)methanol. LC-MS: (ESI, m / z): [M+H] +=241.1. Step 3: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-methylamine To a DMF (20 mL) solution of (1-(4-amino-3-chlorophenyl)piperidin-4-yl)methanol (1.0 g, 4.2 mmol), 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (0.6 g, 2.3 mmol), HATU (1.33 g, 3.5 mmol), and DIEA (0.89 g, 6.9 mmol) were added. The mixture was stirred overnight at room temperature, followed by the addition of water (200 mL) and stirring for 10 min. The mixture was extracted with ethyl acetate (100 mL x 3), washed with saturated brine (150 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (MeOH:DCM = 1:9) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (0.6 g, 2.3 mmol), HATU (1.33 g, 3.5 mmol), and DIEA (0.89 g, 6.9 mmol). R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-methamide. LC-MS: (ESI, m / z): [M+H] +=483.1. Step 4: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-aldehydepiperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-methylamine IBX (560 mg, 2.0 mmol) was added to a CAN (20 mL) solution of 5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-methamide (500 mg, 1.0 mmol). The mixture was stirred at 100 °C for 1.5 h. The reaction solution was directly concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM=1:9) to obtain 5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-aldehydepiperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidine-3-methamide. LC-MS: (ESI, m / z): [M+H] +=481.1. Step 5: Preparation of 9-((1-(4-(5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-chlorophenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester A solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-aldehydepiperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine (400 mg, 0.83 mmol) and tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylic acid (232 mg, 0.91 mmol) in THF (10 mL) was mixed with STAB (528 mg, 2.49 mmol) and stirred overnight at room temperature. The mixture was concentrated under reduced pressure, and water (20 mL) was added. The mixture was extracted with ethyl acetate (20 mL x 3), and the organic phase was washed with saturated brine (50 mL). The mixture was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (MeOH:DCM=1:9) to obtain 9-((1-(4-(5-((1 R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-chlorophenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+Na] +=719.3. Step 6: Preparation of N-(4-(4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)piperidin-1-yl)-2-chlorophenyl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]undecane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine TFA (1 mL) was added to a DCM (5 mL) solution of 9-((1-(4-(5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-chlorophenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (150 mg, 0.21 mmol). The mixture was stirred at room temperature for 2 hours and concentrated under reduced pressure to obtain N-(4-(4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)piperidin-1-yl)-2-chlorophenyl)-5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-chlorophenyl)piperidin-1-yl)-2-chlorophenyl)-5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-chlorophenyl)piperidin-4-yl)methyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl ... R)-2-oxa-5-azabicyclo[2.2.1]undecane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methamide. LC-MS: (ESI, m / z): [M+H] +=619.2. Step 7: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)piperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-methylamine N-(4-(4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)piperidin-1-yl)-2-chlorophenyl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]undecane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine (150 mg, 0.24 mmol) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (105 mg, 0.24 mmol) were dissolved in DMSO (5 mL), and DIEA (155 mg, 1.2 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. Water (50 mL) was added to the reaction mixture, and the mixture was stirred for 2 minutes. The mixture was filtered, and the solid was purified by reverse-phase reaction to obtain 5-((1R,4R)-2-chlorophenyl)-2-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]undecane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine (150 mg, 0.24 mmol) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (105 mg, 0.24 mmol) R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(2-chloro-4-(4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)piperidin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=869.3. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.60 (d, J= 11.9 Hz, 1H), 8.80 (d, J= 7.7 Hz, 1H), 8.26 (d, J= 3.3 Hz, 1H), 8.08 (dd, J= 15.0, 9.1 Hz, 1H), 7.64 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 2.0 Hz, 1H), 7.39 (dd, J= 8.2, 2.0 Hz, 1H), 7.00 (d, J= 2.4 Hz, 1H), 6.99-6.92 (m, 1H), 6.90-6.44 (m, 1H), 5.34-5.04 (m, 1H), 4.77 (d, J= 12.1 Hz, 1H), 3.84 – 3.70 (m, 3H), 3.68-3.43 (m, 7H), 3.30 – 3.20 (m, 2H), 2.78 – 2.70 (m, 2H), 2.64 (t, J= 11.6 Hz, 2H), 2.39 – 2.21 (m, 4H), 2.14 (d, J= 6.9 Hz, 2H), 2.07 – 1.92 (m, 2H), 1.82 – 1.30 (m, 11H), 1.23 – 1.08 (m, 2H).
[0264] Example 7: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of (1R,4R)-4-(3-methyl-4-nitro-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester A solution of (1S,4S)-4-(p-toluenesulfonyl)cyclohexane-1-carboxylic acid methyl ester (2.0 g, 15.7 mmol), 3-methyl-4-nitro-1H-pyrazole (5.9 g, 18.8 mmol), Cs₂CO₃ (15.4 g, 47.1 mmol), and KI (3.1 g, 18.8 mmol) in DMF (30.0 mL) was stirred at 120 °C for 2 h. Water (200 mL) was added to the reaction mixture, followed by extraction with EA (200 mL x 2). The organic phases were combined, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (EA:PE = 0~1:5) to give (1R,4R)-4-(3-methyl-4-nitro-1H-pyrazole-1-yl)cyclohexane-1-carboxylic acid methyl ester. LC-MS: (ESI, m / z): [M+H] += 268.0. 1H NMR (400 MHz, DMSO- d 6) δ 8.79 (s, 1H), 4.24-4.14 (m, 1H), 3.61 (s, 3H), 2.42 (s, 3H), 2.44-2.34 (m, 1H), 2.14-1.96 (m, 4H), 1.87 – 1.71 (m, 2H), 1.62 – 1.41 (m, 2H). Step 2: Preparation of (1R,4R)-4-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester A solution of (1R,4R)-4-(3-methyl-4-nitro-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester (2.0 g, 7.4 mmol), Fe (2.5 g, 37.0 mmol), and NH₄Cl (4.8 g, 74.0 mmol) in MeOH (50.0 mL) was stirred at 80 °C for 3 h. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC (acetonitrile / 0.05% NH₄OH aqueous solution, 5%–95%) to obtain (1R,4R)-4-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester. LC-MS: (ESI, m / z): [M+H] += 238.3. Step 3: Preparation of ((1R,4R)-4-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclohexyl)methanol A solution of (1R,4R)-4-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid methyl ester (300.0 mg, 1.3 mmol) and LiBH4 (111.0 mg, 4.0 mmol) in THF / MeOH (10.0 mL / 2.0 mL) was stirred at 60 °C for 1 h. The reaction was quenched with water (20.0 mL) and then extracted with DCM (50 mL x 2). The organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM = 0~1:9) to give ((1R,4R)-4-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclohexyl)methanol. LC-MS: (ESI, m / z): [M+H] += 210.1. Step 4: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine To a solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (260.0 mg, 1.0 mmol), HATU (418.0 mg, 1.1 mmol), and DIEA (387.0 mg, 3.0 mmol) in DMF (500.0 mL), ((1R,4R)-4-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclohexyl)methanol (230.0 mg, 1.1 mmol) was added. The reaction mixture was stirred at room temperature for 1.0 h. Cold water (250.0 mL) was then added to the reaction mixture. The resulting suspension was filtered, and the filter cake was washed with water and vacuum dried to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. The crude product obtained did not require purification and was used directly in the next reaction. LC-MS: (ESI, m / z): [M+H] += 452.1. Step 5: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-aldehydecyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine A mixture of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-(hydroxymethyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (320.0 mg, 0.7 mmol) and IBX (392 mg, 1.4 mmol) in ACN (10 mL) was stirred at 60 °C for 1 h. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM=0~1:9) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-aldehydecyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 450.1. Step 6: Preparation of 9-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-methyl-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester STAB (381.6 mg, 1.8 mmol) was added to a THF (10 mL) solution of 5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1 R,4 R)-4-aldehydecyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (250.0 mg, 0.6 mmol) and 3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (203.0 mg, 0.8 mmol). The reaction mixture was then stirred at 25 °C for 1.0 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM=0~1:9) to obtain 9-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-methyl-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 688.3. Step 7: Preparation of N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine A TFA / DCM solution of 9-(((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-methyl-1H-pyrazol-1-yl)cyclohexyl)methyl)-3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (300.0 mg, 0.4 mmol) was stirred at room temperature for 1.0 h in 1.0 h. The reaction solution was directly concentrated under vacuum to obtain N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. The crude product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] += 588.6. Step 8: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine To a solution of N-(1-((1R,4R)-4-((3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine (200.0 mg, 0.3 mmol) in DMSO (5.0 mL), DIEA (54.20 mg, 0.42 mmol) and pentafluorophenyl 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate (143.2 mg, 0.33 mmol) were added, and the reaction mixture was stirred at room temperature for 2 h. Water (15.0 mL) was added to the reaction solution, and then extracted with DCM (30.0 mL x 2). The organic phases were combined, washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Prep-HPLC (acetonitrile / 0.05% NH₄HCO₃ aqueous solution, 5%~95%) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((9-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3,9-diazaspiro[5.5]undecane-3-yl)methyl)cyclohexyl)-3-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 838.4. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.21 (d, J= 7.6 Hz, 1H), 8.80 (d, J= 7.8 Hz, 1H), 8.22 (s, 1H), 8.04 (s, 1H), 7.64 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.9 Hz, 1H), 7.39 (dd, J= 8.2, 1.9 Hz, 1H), 6.92-6.43 (m, 1H), 5.25-5.05 (m, 1H), 4.78 (s, 1H), 4.05-3.88 (m, 1H), 3.88 – 3.57 (m, 7H), 3.45 (d, J= 10.1 Hz, 1H), 3.30 – 3.26 (m, 2H), 2.78 – 2.68 (m, 2H), 2.41-1.93 (m, 12H), 1.86 (d, J= 11.5 Hz, 2H), 1.77-1.62 (m, 2H), 1.60-1.31 (m, 10H), 1.11-0.95 (m, 2H).
[0265] Example 8: N-(2-((1S,4S)-4-(((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidine-1(2H)-yl)benzoyl)piperidin-4-yl)methoxy)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine Step 1: Preparation of (1-oxaspiro[2,5]octane-6-yl)tert-butyl carbamate At 0 °C, NaH (1.17 g, 29.3 mmol) was added to a DMSO (50 mL) solution of Me 3OS + I - (6.2 g, 28.2 mmol) with stirring. The reaction mixture was stirred at room temperature for 1 h, and then a DMSO (20 mL) solution of (4-oxocyclohexyl)carbamate (5.0 g, 23.5 mmol) was added dropwise. After the addition was complete, the reaction mixture was stirred at room temperature for another 1 h. Water (700 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (100 mL × 3). The organic phase was washed with saturated brine (300 mL), dried over anhydrous Na 2SO 4, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (EA:PE = 0~1:1) to obtain (1-oxaspiro[2.5]octane-6-yl)carbamate. 1H NMR (400 MHz, DMSO- d 6) δ 6.79 (d, J= 7.2 Hz, 1H), 3.37 (m, 1H), 2.57 (s, 2H), 1.83 (td, J= 13.3, 4.1 Hz, 2H), 1.77 – 1.64 (m, 2H), 1.48 – 1.40 (m, 2H), 1.38 (s, 9H), 1.20 (d, J= 13.1 Hz, 2H). Step 2: Preparation of tert-butyl (4-hydroxy-4-(hydroxymethyl)cyclohexyl)carbamate 4.7 g of (1-oxaspiro[2.5]octane-6-yl)carbamate tert-butyl ester was added to a 2N NaOH solution (50 mL) containing 20.7 mmol of NMP, and the reaction mixture was stirred at 100 °C for 2 h. Water (500 mL) was added to the reaction mixture, and the mixture was extracted with EA (100 mL × 3). The organic phase was washed with saturated brine (300 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (MeOH:DCM = 0~1:9) to obtain (4-hydroxy-4-(hydroxymethyl)cyclohexyl)carbamate tert-butyl ester. 1H NMR (400 MHz, DMSO- d 6) δ 6.67 (d, J= 7.9 Hz, 1H), 4.46 (t, J= 5.8 Hz, 1H), 3.81 (s, 1H), 3.11 (t, J= 6.8 Hz, 3H), 1.56 – 1.45 (m, 4H), 1.44 – 1.34 (m, 13H). Step 3: Preparation of tert-butyl (4-hydroxy-4-((pyridin-4-ylmethoxy)methyl)cyclohexyl)carbamate NaH (292 mg, 7.3 mmol) was added to a THF (20 mL) solution of (600 mg, 2.4 mmol) of tert-butyl (4-hydroxy-4-(hydroxymethyl)cyclohexyl)carbamate at 0 °C. The reaction mixture was stirred at 0 °C for 20 min, and then stirred for another 30 min at room temperature before adding 4-(bromomethyl)pyridine hydrogen bromide (617 mg, 2.4 mmol). The reaction mixture was stirred overnight at room temperature. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with EA (20 mL × 3). The organic phase was washed with saturated brine (60 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (EA:PE = 0~4:1) to obtain tert-butyl (4-hydroxy-4-((pyridin-4-ylmethoxy)methyl)cyclohexyl)carbamate. LC-MS: (ESI, m / z): [M+H] +=337.1. 1H NMR (400 MHz, DMSO- d 6) δ 8.53 (d, J= 5.8 Hz, 2H), 7.34 (d, J= 5.6 Hz, 2H), 6.69 (d, J= 7.6 Hz, 1H), 4.55 (s, 2H), 4.19 (s, 1H), 3.23 (s, 2H), 3.18 – 3.07 (m, 1H), 1.60-1.48 (m, 6H), 1.42-1.35 (m, J= 9.2 Hz, 11H). Step 4: Preparation of tert-butyl (4-hydroxy-4-((piperidin-4-ylmethoxy)methyl)cyclohexyl)carbamate A mixture of tert-butyl (4-hydroxy-4-((pyridin-4-ylmethoxy)methyl)cyclohexyl)carbamate (700 mg, 2.07 mmol) and Pd / C (400 mg) in i-PrOH / H₂O (18 mL / 21 mL) was stirred overnight at 75 °C under a H₂ atmosphere. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain tert-butyl (4-hydroxy-4-((piperidin-4-ylmethoxy)methyl)cyclohexyl)carbamate. The crude product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=343.2. Step 5: Preparation of 4-(((4-((tert-Butoxycarbonyl)amino)-1-hydroxycyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester A solution of tert-butyl (4-hydroxy-4-((piperidin-4-ylmethoxy)methyl)cyclohexyl)carbamate (630 mg, 1.83 mmol), CbzCl (376 mg, 2.20 mmol) in ACN (10 mL) and saturated NaHCO3 aqueous solution (10 mL) was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure and then extracted with DCM (50 mL × 3). The organic phase was washed with saturated brine (150 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (EA:PE = 0~7:3) to obtain benzyl 4-(((4-((tert-butyloxycarbonyl)amino)-1-hydroxycyclohexyl)methoxy)methyl)piperidin-1-carboxylic acid. LC-MS: (ESI, m / z): [M+Na] +=499.3. Step 6: Preparation of 4-(((4-amino-1-hydroxycyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester At -10 to 0 °C, TFA (3 mL) was added to a DCM (12 mL) solution of 4-(((4-((tert-Butoxycarbonyl)amino)-1-hydroxycyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester (300 mg, 0.63 mmol) while stirring. The reaction mixture was then stirred at room temperature for 2 h. The pH of the reaction mixture was adjusted to 9.0 with DIEA, and then concentrated directly under reduced pressure to obtain 4-(((4-amino-1-hydroxycyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester. The crude product obtained did not require purification and was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=377.2. Step 7: Preparation of 4-((((1S,4S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indol-2-yl)cyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester 2-Azide-4-methoxy-5-nitrobenzaldehyde (170 mg, 0.76 mmol) was added to a toluene (10 mL) solution of 4-(((4-amino-1-hydroxycyclohexyl)methoxy)methyl)piperidin-1-carboxylic acid benzyl ester (237 mg, 0.63 mmol) with stirring. The reaction solution was stirred at 100 °C for 3 h. The reaction solution was then concentrated directly under reduced pressure. The crude product was first purified by flash column (EA:PE = 0~4:1) and then purified by Prep-HPLC (CH3CN / 0.08% NH4HCO3 aqueous solution, 5%~95%) to obtain 4-((((1S,4S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indol-2-yl)cyclohexyl)methoxy)methyl)piperidin-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] +=553.2. 1H NMR (400 MHz, DMSO- d 6) δ 8.58 (s, 1H), 8.37 (s, 1H), 7.40 – 7.29 (m, 5H), 7.26 (s, 1H), 5.07 (s, 2H), 4.45 (t, J= 12.0 Hz, 1H), 4.36 (s, 1H), 4.06 – 3.99 (m, 2H), 3.90 (s, 3H), 3.29 (d, J= 6.2 Hz, 2H), 3.20 (s, 2H), 2.85-2.75 (m, 2H), 2.35 – 2.20 (m, 2H), 1.89 (d, J= 11.8 Hz, 2H), 1.76-1.61 (m, 7H), 1.15-1.02 (m, 2H). Step 8: Preparation of 4-((((1S,4S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid tert-butyl ester To a solution of 200 mg (0.36 mmol) of 4-((((1 S,4 S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indol-2-yl)cyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester (200 mg, 0.36 mmol) in EtOH (20 mL), Raney-Ni (0.3 mL) and N₂H₄H₂O (0.3 mL) were added. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was directly concentrated under reduced pressure to obtain 4-((((1 S,4 S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid tert-butyl ester. The crude product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=523.2. Step 9: Preparation of 4-((((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2H-indol-2-yl)cyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester Under stirring, 6-(trifluoromethyl)pyridinecarboxylic acid (90 mg, 0.47 mmol), HATU (178 mg, 0.47 mmol), and DIEA (140 mg, 1.08 mmol) were added to a DMF (5 mL) solution of 4-((((1 S,4 S)-4-(5-amino-6-methoxy-2 H-indol-2-yl)-1-hydroxycyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid tert-butyl ester (190 mg, 0.36 mmol) and DIEA (140 mg, 1.08 mmol). The reaction mixture was then stirred at room temperature for 2 h. Water (30 mL) was added to the reaction mixture, followed by EA (20 mL × 3). The organic phase was washed with saturated brine (60 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column (EA:PE=0~4:1) to obtain 4-((((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2H-indol-2-yl)cyclohexyl)methoxy)methyl)piperidine-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] +=696.3. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 8.69 (s, 1H), 8.47 (d, J= 7.7 Hz, 1H), 8.41 (t, J= 7.8 Hz, 1H), 8.32 (s, 1H), 8.22 (d, J= 7.7 Hz, 1H), 7.41 – 7.29 (m, 5H), 7.16 (s, 1H), 5.08 (s, 2H), 4.40 – 4.29 (m, 2H), 4.15-3.95 (m 5H), 3.29 (d, J= 6.2 Hz, 2H), 3.21 (s, 2H), 2.91-2.70 (m, 2H), 2.35-2.15 (m, 2H), 1.90 (d, J= 9.5 Hz, 2H), 1.85-1.60 (m, 7H), 1.12-.1.02 (m, 2H). Step 10: Preparation of N-(2-((1S,4S)-4-hydroxy-4-((piperidin-4-ylmethoxy)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine Pd(OH)₂ / C (80 mg) was added to a 20 mL solution of 4-((((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinecarboxymethylamine)-2H-indol-2-yl)cyclohexyl)methoxy)methyl)piperidin-1-carboxylic acid benzyl ester (170 mg, 0.24 mmol). The reaction mixture was then stirred overnight at 70 °C under a H₂ atmosphere. The reaction mixture was filtered through diatomaceous earth, and the filtrate was directly concentrated under reduced pressure to obtain N-(2-(((1S,4S)-4-hydroxy-4-((piperidin-4-ylmethoxy)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinecarboxymethylamine). LC-MS: (ESI, m / z): [M+H] +=562.3. Step 11: Preparation of N-(2-((1S,4S)-4-(((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)methoxy)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine A mixture of N-(2-((1S,4S)-4-hydroxy-4-((piperidin-4-ylmethoxy)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine (130 mg, 0.23 mmol), pentafluorophenyl 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate (121 mg, 0.28 mmol) and DIEA (89 mg, 0.69 mmol) in DMSO (6 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (50 mL) and then with DCM (20 mL × 3). The organic phase was washed with saturated brine (60 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Prep-HPLC (CH3CN / 0.08% NH4HCO3 aqueous solution, 5%~95%) to obtain N-(2-((1S,4S)-4-(((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)methoxy)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine. LC-MS: (ESI, m / z): [M+H] +=812.1. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (d, J= 7.5 Hz, 2H), 8.69 (s, 1H), 8.46 (d, J= 7.7 Hz, 1H), 8.40 (t, J= 7.8 Hz, 1H), 8.32 (s, 1H), 8.21 (d, J= 7.6 Hz, 1H), 7.65 (d, J= 8.2 Hz, 1H), 7.57 (d, J= 1.4 Hz, 1H), 7.40 (dd, J= 8.2, 1.5 Hz, 1H), 7.16 (s, 1H), 4.58 – 4.29 (m, 3H), 3.99 (s, 3H), 3.84 – 3.55 (m, 3H), 3.33 – 3.28 (m, 2H), 3.22 (s, 2H), 3.13-3.03 (m, 1H), 2.88 – 2.70 (m, 3H), 2.35-2.20 (m, 2H), 1.94 – 1.59 (m, 9H), 1.21-1.15 (m, 2H).
[0266] Example 9: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)ethoxy)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of tert-butyl 4-(2-(((1R,4R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid NaH (60%, 580 mg, 14.5 mmol) was added to an anhydrous THF (30 mL) solution of ((1R,4R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)cyclohexyl)methanol (1.0 g, 3.64 mmol). After stirring at room temperature for 1 h, tert-butyl 4-(2-(p-toluenesulfonyl)ethyl)piperidine-1-carboxylic acid (2.79 g, 7.28 mmol) and KI (1.21 g, 7.28 mmol) were added, and the reaction mixture was stirred overnight at 70 °C. Water (50 mL) was slowly added to the reaction mixture, and the mixture was extracted with EtOAc (100 mL × 3). The combined organic phases were washed with saturated brine (50 mL) and concentrated under reduced pressure. The crude product was purified by flash column (EA:PE=0~7:13) to obtain tert-butyl 4-(2-(((1 R,4 R)-4-(3-(difluoromethyl)-4-nitro-1 H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid. LC-MS: (ESI, m / z): [M+Na] +=509.2. Step 2: Preparation of tert-butyl 4-(2-(((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid To a 10 mL ethanol solution of 4-(2-(((1R,4R)-4-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid tert-butyl ester (185 mg, 0.38 mmol), Raney-Ni (0.4 mL) and hydrazine hydrate (85%, 0.4 mL) were added, and the reaction mixture was stirred at room temperature for 1 h. The mixture was filtered, and the filtrate was directly concentrated under reduced pressure to obtain 4-(2-(((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=457.2. Step 3: Preparation of 4-(2-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid tert-butyl ester To a DMF (5 mL) solution of 4-(2-(((1R,4R)-4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid tert-butyl ester (150 mg, 0.33 mmol), 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (86 mg, 0.33 mmol), HATU (188 mg, 0.50 mmol), and DIEA (128 mg, 0.99 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water (50 mL) and then extracted with EA (50 mL × 3). The organic phase was washed with saturated brine (150 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by reverse-phase (CH3CN / H2O (0.5% FA), 5%~95%) to obtain 4-(2-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yll)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+Na] +=721.2. Step 4: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((2-(piperidin-4-yl)ethoxy)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine The reaction mixture of 4-(2-(((1R,4R)-4-(4-(5-(((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid tert-butyl ester (80 mg, 0.11 mmol) in TFA / DCM (3 mL, 1 / 5) was stirred at room temperature for 1 h. The reaction solution was directly concentrated under reduced pressure to give 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((2-(piperidin-4-yl)ethoxy)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. The obtained product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=599.3 Step 5: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperidin-4-yl)ethoxy)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine A solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((2-(piperidin-4-yl)ethoxy)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methoxymethylamine (80 mg, 0.13 mmol), 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid pentafluorophenyl ester (58 mg, 0.13 mmol), and DIEA (86 mg, 0.66 mmol) in DMSO (5 mL) was stirred overnight at room temperature. The reaction mixture was then poured into water (50 mL) and stirred for 10 min. The filter cake was filtered and purified by flash column (MeOH:DCM=0~1:9) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)ethoxy)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=849.1. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.50 (d, J= 5.7 Hz, 1H), 8.78 (d, J= 7.7 Hz, 1H), 8.39 (d, J= 4.3 Hz, 1H), 8.25 (d, J= 5.6 Hz, 1H), 7.64 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.9 Hz, 1H), 7.38 (dd, J= 8.2, 1.9 Hz, 1H), 7.29 – 6.93 (m, 1H), 6.90-6.40 (m, 1H), 5.30-5.03 (m, 1H), 4.77 (d, J= 17.2 Hz, 1H), 4.50-4.35 (m, 1H), 4.24-4.11 (m, 1H), 3.86 – 3.70 (m, 3H), 3.66 – 3.52 (m, 3H), 3.50-3.40 (m, 3H), 3.22 (d, J= 6.4 Hz, 2H), 3.12-2.95 (m, 1H), 2.83-2.70 (m, 3H), 2.08 – 1.91 (m, 4H), 1.88 – 1.54 (m, 8H), 1.55 – 1.44 (m, 2H), 1.19-1.04 (m, 4H).
[0267] Example 10: N-(2-((1S,4S)-4-((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidine-1(2H)-yl)benzoyl)piperidin-4-yl)ethoxy)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine Step 1: Preparation of 4-(2-((4-((tert-butoxycarbonyl)amino)-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester NaH (376 mg, 9.4 mmol) was added to a THF (20 mL) solution of (4-hydroxy-4-(hydroxymethyl)cyclohexyl)carbamate (770 mg, 3.13 mmol) at 0 °C, and the mixture was stirred at 0 °C for 2 h. Then, benzyl 4-(2-(p-toluenesulfonyl)ethyl)piperidine-1-carboxylate (2.62 g, 6.26 mmol) and KI (1.04 g, 6.26 mmol) were added. The reaction mixture was stirred overnight at 70 °C. The reaction mixture was diluted with water (50 mL) and extracted with EA (30 mL × 3). The organic phase was washed with saturated brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was subjected to flash column chromatography (EA:PE = 0~3:2) to obtain 4-(2-((4-((tert-butoxycarbonyl)amino)-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+Na] +=513.1. 1H NMR (400 MHz, DMSO- d 6) δ 7.41 – 7.29 (m, 5H), 6.67 (d, J= 7.5 Hz, 1H), 5.06 (s, 2H), 4.05-3.90 (m, 3H), 3.42 (t, J= 6.4 Hz, 2H), 3.10 (s, 3H), 2.88-2.68 (m, 2H), 1.65 (d, J= 12.6 Hz, 2H), 1.55-1.32 (m, 20H), 1.13-0.92 (m, 2H). Step 2: Preparation of benzyl 4-(2-((4-amino-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid ester At -10 to 0 °C, TFA (1.2 mL) was added to a DCM (3 mL) solution of 4-(2-((4-((tert-butoxycarbonyl)amino)-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester (270 mg, 0.55 mmol) with stirring. The reaction solution was then stirred at room temperature for 2 h. DIEA was added to adjust the pH to 9.0, and the solution was concentrated under reduced pressure to obtain 4-(2-((4-amino-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] +=391.2. Step 3: Preparation of 4-(2-(((1S,4S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indol-2-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester 2-Azide-4-methoxy-5-nitrobenzaldehyde (150 mg, 0.66 mmol) was added to a toluene (15 mL) solution of 4-(2-((4-amino-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester (400 mg, 0.55 mmol) with stirring. The reaction mixture was stirred at 100 °C for 3 h. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by flash column chromatography (EA:PE = 0~9:1) to obtain 4-(2-(((1 S,4 S)-1-hydroxy-4-(6-methoxy-5-nitro-2 H-indol-2-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] +=567.3. 1H NMR (400 MHz, DMSO- d 6) δ 8.59 (s, 1H), 8.38 (s, 1H), 7.41 – 7.29 (m, 5H), 7.27 (s, 1H), 5.07 (s, 2H), 4.50-4.40 (m, 1H), 4.34 (s, 1H), 4.05-3.95 (m, 2H), 3.91 (s, 3H), 3.47 (t, J= 6.4 Hz, 2H), 3.21 (s, 2H), 2.90-2.70 (m, 2H), 2.35 – 2.19 (m, 2H), 1.90 (d, J= 9.7 Hz, 2H), 1.75-1.50 (m, 7H), 1.50-1.40 (m, 2H), 1.11 – 0.98 (m, 2H). Step 4: Preparation of 4-(2-(((1S,4S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester To a solution of 250 mg (0.44 mmol) of 4-(2-(((1 S,4 S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indol-2-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester (20 mL) in EtOH, Raney-Ni (0.5 mL) and N₂H₄·H₂O (0.5 mL) were added. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain 4-(2-(((1 S,4 S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester. The obtained product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=537.3 Step 5: Preparation of 4-(2-(((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2H-indol-2-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester While stirring, 6-(trifluoromethyl)pyridinecarboxylic acid (101 mg, 0.53 mmol), HATU (217 mg, 0.57 mmol), and DIEA (170 mg, 1.32 mmol) were added to a DMF (5 mL) solution of 4-(2-(((1 S,4 S)-4-(5-amino-6-methoxy-2 H-indol-2-yl)-1-hydroxycyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid (236 mg, 0.44 mmol) in 1 mL. The reaction mixture was then stirred at room temperature for 2 h. The reaction mixture was diluted with water (50 mL) and extracted with EA (20 mL × 3). The organic phase was washed with saturated brine (60 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column (EA:PE=0~4:1) to obtain 4-(2-(((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2H-indol-2-yl)cyclohexyl)methoxy)ethyl)piperidine-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] +=710.2. 1H NMR (400 MHz, DMSO- d 6) δ 10.50 (s, 1H), 8.69 (s, 1H), 8.46 (d, J= 7.7 Hz, 1H), 8.40 (t, J= 7.8 Hz, 1H), 8.32 (s, 1H), 8.21 (d, J= 7.7 Hz, 1H), 7.41 – 7.28 (m, 5H), 7.16 (s, 1H), 5.06 (s, 2H), 4.40-4.20 (m, 2H), 4.10-3.90 (m, 5H), 3.47 (t, J= 6.4 Hz, 2H), 3.21 (s, 2H), 2.90-2.70 (m, 2H), 2.32 – 2.18 (m, 2H), 1.90 (d, J= 10.4 Hz, 2H), 1.72-1.53 (m, 7H), 1.52-1.40 (m, 2H), 1.15-1.00 (m, 2H). Step 6: Preparation of N-(2-((1S,4S)-4-hydroxy-4-((2-(piperidin-4-yl)ethoxy)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine Pd(OH)₂ / C (100 mg) was added to a 20 mL solution of 4-(2-(((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2H-indol-2-yl)cyclohexyl)methoxy)ethyl)piperidin-1-carboxylic acid benzyl ester (200 mg, 0.28 mmol). The reaction mixture was then stirred overnight at 70 °C under a H₂ atmosphere. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain N-(2-(((1S,4S)-4-hydroxy-4-((2-(piperidin-4-yl)ethoxy)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine, which was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=576.2. Step 7: Preparation of N-(2-((1S,4S)-4-((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)ethoxy)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine A solution of N-(2-((1S,4S)-4-hydroxy-4-((2-(piperidin-4-yl)ethoxy)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine (130 mg, 0.22 mmol), pentafluorophenyl 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate (118 mg, 0.27 mmol), and DIEA (87 mg, 0.68 mmol) in DMSO (3 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (30 mL) and extracted with DCM (10 mL × 3). The organic phase was washed with saturated brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (MeOH:DCM = 0~1:9) to obtain N-(2-((1S,4S)-pyridinemethylamine (1S,4S)-4-hydroxy-4-((2-(piperidin-4-yl)ethoxy)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine (130 mg, 0.22 mmol), pentafluorophenyl 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate (118 mg, 0.27 mmol), and DIEA (87 mg, 0.68 mmol) in DMSO (3 mL). S,4S)-4-((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperidin-4-yl)ethoxy)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine. LC-MS: (ESI, m / z): [M+H] +=826.1. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (d, J= 5.7 Hz, 2H), 8.69 (s, 1H), 8.46 (d, J= 7.8 Hz, 1H), 8.41 (t, J= 7.8 Hz, 1H), 8.33 (s, 1H), 8.22 (d, J= 7.7 Hz, 1H), 7.64 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.8 Hz, 1H), 7.39 (dd, J= 8.2, 1.8 Hz, 1H), 7.16 (s, 1H), 4.50-4.26 (m, 3H), 3.98 (s, 3H), 3.83 – 3.53 (m, 3H), 3.48 (t, J= 6.3 Hz, 2H), 3.21 (s, 2H), 3.13-2.97 (m, 1H), 2.86 – 2.71 (m, 3H), 2.32 – 2.18 (m, 2H), 1.90 (d, J= 9.8 Hz, 2H), 1.85-1.45 (m, 9H), 1.15-1.05 (m, 2H).
[0268] Example 11: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-(((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)ethyl)(methyl)amino)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of tert-butyl 4-(2-(phenyl(methyl)amino)ethyl)piperidine-1-carboxylic acid Under N₂ protection, N-methyl-1-phenylmethylamine (1.067 g, 8.82 mmol) and AcOH (0.79 g, 13.23 mmol) were added to a DCE (3 mL) solution of 4-(2-oxoethyl)piperidin-1-carboxylic acid tert-butyl ester (1 g, 4.41 mmol). The mixture was stirred at room temperature for 30 min, and then STAB (2.8 g, 13.23 mmol) was added. The reaction mixture was then stirred at room temperature for 2 h. The reaction mixture was diluted with water (20 mL), extracted with EA (30 mL × 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM = 0~1:20) to obtain 4-(2-(phenyl(methyl)amino)ethyl)piperidin-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 333.2. Step 2: Preparation of tert-butyl 4-(2-(methylamino)ethyl)piperidine-1-carboxylic acid Pd(OH)₂ / C (250 mg) was added to a THF (3 mL) solution of 1 g (3.01 mmol) of 4-(2-(phenyl(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester. The reaction solution was then stirred at room temperature for 2 h under a H₂ atmosphere. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain 4-(2-(methylamino)ethyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 243.2. Step 3: Preparation of 4-(2-((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester To a solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-aldehydecyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methamide (300 mg, 0.618 mmol) in THF (3 mL), 4-(2-(methylamino)ethyl)piperidine-1-carboxylic acid tert-butyl ester (329 mg, 0.928 mmol) and STAB (419 mg, 1.862 mmol) were added, and the reaction was stirred at room temperature under a nitrogen atmosphere for 2 h. The reaction was quenched with water (20 mL), extracted with DCM (20 mL × 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM=0~1:9) to obtain 4-(2-((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 712.4. Step 4: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((methyl(2-(piperidin-4-yl)ethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Add TFA (1 mL) to a DCM (3 mL) solution of 4-(2-((((1 R,4 R)-4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)cyclohexyl)methyl)(methyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.281 mmol), and then stir the reaction mixture at room temperature under N2 atmosphere for 2 h. The reaction solution was directly concentrated under reduced pressure to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1R,4R)-4-((methyl(2-(piperidin-4-yl)ethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 612.4. Step 5: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-(((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)ethyl)(methyl)amino)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Add DIEA (109 mg, 1.564 mmol) and pentafluorophenyl 4-chloro-3-(2,4-dioxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-((1 R,4 R)-4-((methyl(2-(piperidin-4-yl)ethyl)amino)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methoxyamine (175 mg, 0.521 mmol) to a DMSO (3 mL) solution, and then stir the reaction mixture at room temperature for 3 h. Water (15 mL) was added to the reaction solution, and the mixture was extracted with DCM (30 mL × 2). The solution was dried over anhydrous Na₂SO₄, and the organic phase was concentrated under reduced pressure. The crude product was purified by Prep-HPLC (acetonitrile / 0.05% NH₄HCO₃ aqueous solution, 5%~95%) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-((1R,4R)-4-(((2-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)ethyl)(methyl)amino)methyl)cyclohexyl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 862.1. 1H NMR (400 MHz, DMSO- d 6) δ 10.50 (s, 1H), 9.50 (d, J= 6.0 Hz, 1H), 8.78 (d, J= 7.7 Hz, 1H), 8.38 (d, J= 4.4 Hz, 1H), 8.25 (d, J= 5.6 Hz, 1H), 7.62 (t, J= 7.7 Hz, 1H), 7.54 (d, J= 1.9 Hz, 1H), 7.38 (dd, J= 8.2, 2.0 Hz, 1H), 7.26-6.95 (m, 1H), 6.90-6.42 (m, 1H), 5.31-5.05 (m, 1H), 4.77 (d, J= 17.3 Hz, 1H), 4.52-4.34 (m, 1H), 4.24-4.12 (m, 1H), 3.86-3.70 (m, 3H), 3.65 – 3.53 (m, 3H), 3.45 (d, J= 10.0 Hz, 1H), 3.11-2.94 (m, 1H), 2.77 – 2.65 (m, 3H), 2.29 (t, J= 7.0 Hz, 2H), 2.15 – 2.07 (m, 5H), 2.05 – 1.82 (m, 6H), 1.80 – 1.68 (m, 3H), 1.66-1.46 (m, 3H), 1.41-1.32 (m, 2H), 1.18 – 0.95 (m, 4H).
[0269] Example 12: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(3-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)prop-2-ynyl-1-yl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of 4-(3-(4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)prop-1-ynyl-1-yl)piperidin-1-carboxylic acid tert-butyl ester A mixture of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine (150 mg, TFA salt, 0.33 mmol), 4-(3-bromopropyl-1-ynyl-1-yl)piperidin-1-carboxylic acid tert-butyl ester (99 mg, 0.33 mmol) and K₂CO₃ (227 mg, 1.65 mmol) in THF (20 mL) was stirred overnight at 70 °C. The reaction solution was diluted with water (20 mL), extracted with DCM (20 mL × 3), dried over anhydrous Na₂SO₄, concentrated under reduced pressure, and the crude product was purified by flash column (EA:PE=0~1) to obtain 4-(3-(4-(4-(5-((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)prop-1-ynyl-1-yl)piperidin-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=680.3. Step 2: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(3-(piperidin-4-yl)prop-2-ynyl-1-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine The TFA / DCM mixture of 4-(3-(4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)prop-1-ynyl-1-yl)piperidin-1-carboxylic acid tert-butyl ester (70 mg, 0.10 mmol) was stirred at room temperature for 1 h. The reaction solution was directly concentrated under reduced pressure to give 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(3-(piperidin-4-yl)prop-2-ynyl-1-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. The product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=580.2. Step 3: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(3-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperidin-4-yl)prop-2-ynyl-1-yl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine A mixture of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(3-(piperidin-4-yl)prop-2-ynyl-1-yl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methamide (70 mg, crude, 0.12 mmol), pentafluorophenyl 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate (52 mg, 0.12 mmol) and DIEA (774 mg, 0.60 mmol) in DMSO (5 mL) was stirred overnight at room temperature. The reaction mixture was then poured into water (50 mL) and stirred for 10 min. The filter cake was filtered and purified by flash column (MeOH:DCM=0~1:9) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(3-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperidin-4-yl)prop-2-ynyl-1-yl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=830.3. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.51 (d, J= 5.8 Hz, 1H), 8.79 (d, J= 7.7 Hz, 1H), 8.42 (s, 1H), 8.26 (d, J= 5.6 Hz, 1H),7.64 (d, J= 8.2 Hz, 1H), 7.58 (d, J= 1.9 Hz, 1H), 7.41 (dd, J= 8.2, 2.0 Hz, 1H), 7.28-6.97 (m, 1H), 6.90-6.43 (m, 1H), 5.30-5.02 (m, 1H), 4.77 (d, J= 18.9 Hz, 1H), 4.30 – 4.20 (m, 1H), 4.18 – 3.90 (m, 1H), 3.88-3.70 (m, 3H), 3.68 – 3.56 (m, 3H), 3.54 – 3.36 (m, 3H), 3.30 – 3.21 (m, 2H), 3.00 – 2.64 (m, 5H), 2.40 -2.20 (m, 2H), 2.12 – 1.73 (m, 8H), 1.62 – 1.42 (m, 2H).
[0270] Example 13: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-((3-(3-(2,4-dioxotetrahydropyrimidine-1(2H)-yl)-4-methoxybenzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine A mixture of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxymethylamine (160 mg, 0.26 mmol), 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid pentafluorophenyl ester (110 mg, 0.26 mmol) and DIEA (168 mg, 1.3 mmol) in DMSO (5 mL) was stirred overnight at room temperature. The reaction mixture was then poured into water (50 mL) and stirred for 10 min. The filter cake was filtered and purified by Prep-HPLC to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-((3-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=870.3. 1H NMR (400 MHz, DMSO- d 6) δ 10.33 (s, 1H), 9.50 (d, J= 5.7 Hz, 1H), 8.79 (d, J= 7.7 Hz, 1H), 8.39 (d, J= 4.0 Hz, 1H), 8.26 (d, J= 5.6 Hz, 1H), 7.41 – 7.29 (m, 2H), 7.27 – 6.95 (m, 2H), 6.91-6.40 (m, 1H), 5.31-5.00 (m, 1H), 4.77 (d, J= 17.5 Hz, 1H), 4.27-4.15 (m, 1H), 3.86 – 3.71 (m, 5H), 3.65 – 3.39 (m, 8H), 2.89 (d, J= 10.4 Hz, 2H), 2.68 (t, J= 6.5 Hz, 2H), 2.15 (d, J= 6.1 Hz, 2H), 2.08 – 1.87 (m, 8H), 1.76-1.65 (m, 2H), 1.63-1.38 (m, 5H), 1.36-1.21 (m, 2H), 1.19-0.95 (m, 4H).
[0271] Example 14: 5-((1R,4R)-2-oxa--5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(3-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)propyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of tert-butyl 4-(3-oxopropyl)piperidine-1-carboxylic acid IBX (2.88 g, 10.285 mmol) was added to a solution of 4-(3-hydroxypropyl)piperidine-1-carboxylic acid tert-butyl ester (1.0 g, 4.115 mmol) in ACN (30 mL). The mixture was stirred at 80 °C for 2 h. After the reaction was complete, the mixture was extracted with ethyl acetate (50 mL × 3), washed with saturated brine (150 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (PE:EA = 1:1) to obtain 4-(3-oxopropyl)piperidine-1-carboxylic acid tert-butyl ester. 1H NMR (400 MHz, DMSO- d 6) δ 9.68 (t, J= 1.5 Hz, 1H), 3.96-3.86 (m, 2H), 2.70-2.60 (m, 2H), 2.46 (td, J= 7.5, 1.4 Hz, 2H), 1.66-1.56 (m, 3H), 1.56-1.36 (m, 4H), 1.39 (s, 9H). Step 2: Preparation of 4-(3-(4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide 3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)propyl)piperidin-1-carboxylic acid tert-butyl ester 4-(3-oxopropyl)piperidin-1-carboxylic acid tert-butyl ester (95 mg, 0.394 mmol) and STAB (208 mg, 0.981 mmol) were added to a THF (30 mL) solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methoxyamine (150 mg, 0.327 mmol). The mixture was stirred at room temperature for 2 h, extracted with ethyl acetate (40 mL × 3), washed with saturated brine (150 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was purified by column chromatography (PE:EA = 3:7) to obtain 4-(3-(4-(4-(5-((1 R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide 3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)propyl)piperidin-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=684.2. Step 3: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(3-(piperidin-4-yl)propyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine TFA (5 mL) was added to a DCM (20 mL) solution of 4-(3-(4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine 3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)propyl)piperidin-1-carboxylic acid tert-butyl ester (200 mg, 0.293 mmol). The mixture was stirred at room temperature for 2 h, adjusted to alkalinity with saturated NaHCO3 solution, extracted with ethyl acetate (60 mL × 3), washed with saturated brine (150 mL), and concentrated under reduced pressure to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)- N-(3-(difluoromethyl)-1-(1-(3-(piperidin-4-yl)propyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=584.2. Step 4: Preparation of 5-((1R,4R)-2-oxa--5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(3-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperidin-4-yl)propyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(3-(piperidin-4-yl)propyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine (150 mg, 0.257 mmol) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (134 mg, 0.308 mmol) were dissolved in DMSO (5 mL), and DIEA (100 mg, 0.775 mmol) was added. The mixture was stirred at room temperature for 2 hours. Water (50 mL) was added to the reaction mixture, and the mixture was stirred for 2 minutes. The mixture was filtered, and the filter cake was purified by reverse-phase chromatography to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(3-(piperidin-4-yl)propyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine (150 mg, 0.257 mmol) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (134 mg, 0.308 mmol) in DMSO (5 mL). R)-2oxa--5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(3-(1-(4-chloro-3-(2,4-dioxotetrahydropyrimidine-1(2H)-yl)benzoyl)piperidin-4-yl)propyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] +=834.0. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.50 (d, J= 5.8 Hz, 1H), 8.79 (d, J= 7.7 Hz, 1H), 8.40 (d, J= 3.7 Hz, 1H), 8.26 (d, J= 5.6 Hz, 1H), 7.64 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.8 Hz, 1H), 7.39 (dd, J= 8.2, 1.9 Hz, 1H), 7.27 – 6.96 (m, 1H), 6.90-6.40 (m, 1H), 5.30-5.05 (m, 1H), 4.77 (d, J= 17.5 Hz, 1H), 4.52-4.33 (m, 1H), 4.26-4.14 (m, 1H), 3.85 – 3.72 (m, 3H), 3.66 – 3.57 (m, 3H), 3.45 (d, J= 10.2 Hz, 1H), 3.11-2.89 (m, 3H), 2.79 – 2.66 (m, 3H), 2.30 (t, J= 6.9 Hz, 2H), 2.09-1.84 (m, 9H), 1.82-1.69 (m, 1H), 1.68-1.58 (m, 1H), 1.56-1.40 (m, 3H), 1.30-1.20 (m, 2H), 1.16-1.02 (m, 2H).
[0272] Example 15: N-(1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-methylfolinpyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of 4-(3-(difluoromethyl)-4-(5-m-folinpyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester HATU (900 mg, 2.4 mmol) was added to a DMF (20 mL) solution of 5-morphofolinpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (470 mg, 1.9 mmol) and DIEA (1 mL, 4.7 mmol). The mixture was stirred at 25 °C for 2 h, and then tert-butyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid (0.5 g, 1.5 mmol) was added. The reaction mixture was then stirred at 25 °C overnight. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with EA (50 mL × 3). The organic phases were combined, washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column (EA) to obtain tert-butyl 4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid. LC-MS: (ESI, m / z): [M+H] += 547.4. Step 2: Preparation of N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine TFA (1 mL) was added to a 3 mL solution of 4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methoxylamine)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (0.2 g, 0.366 mmol) in DCM at 25 °C. The reaction solution was stirred at 25 °C for 1 h. The reaction solution was then directly concentrated under reduced pressure to give N-(3-(difluoromethyl)-1-(piperidine-4-yl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methoxylamine. LC-MS: (ESI, m / z): [M+H] += 447.2. Step 3: Preparation of 9-((4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methamide)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester At 25 °C, tert-butyl 9-aldehyde-3-azaspiro[5.5]undecane-3-carboxylic acid (150 mg, 0.45 mmol) and NaBH3CN (100 mg, 2.25 mmol) were added to a MeOH (5 mL) solution of N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-carboxylic acid (200 mg, 0.45 mmol) and DIEA (0.5 mL, 1.35 mmol). The reaction mixture was stirred at 25 °C for 16 h. The crude product was filtered, concentrated under reduced pressure, and purified by flash column chromatography (MeOH:DCM=3:97) to obtain 9-((4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methoxyamine)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 712.4. Step 4: Preparation of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidine-3-methylamine TFA (1 mL) was added to a DCM (3 mL) solution of 0.14 g (0.2 mmol) of 9-((4-(3-(difluoromethyl)-4-(5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (DCM). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was then directly concentrated under reduced pressure to give N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine. The product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] += 612.5. Step 5: Preparation of N-(1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine DIEA (0.1 mL, 0.54 mmol) was added to a DMSO (2 mL) solution of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-morphofolinpyrazolo[1,5-a]pyrimidin-3-methylamine (110 mg, 0.18 mmol) and 1-(2-chloro-5-pentafluorobenzoyl)phenyl)dihydropyrimidin-2,4(1H,3H)-dione (90 mg, 0.19 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 16 h. The reaction mixture was then poured into water (10 mL), filtered, and the filter cake was purified by Prep-HPLC. LC-MS: (ESI, m / z): [M+H] += 862.4. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 1H), 9.40 (s, 1H), 8.83 (d, J= 7.9 Hz, 1H), 8.39 (s, 1H), 8.29 (s, 1H), 7.63 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.9 Hz, 1H), 7.39 (dd, J= 8.2, 1.8 Hz, 1H), 7.25-6.95 (m, 1H), 6.91 (d, J= 8.0 Hz, 1H), 4.26-4.14 (m, 1H), 3.87 – 3.68 (m, 9H), 3.66 – 3.50 (m, 3H), 3.31 – 3.20 (m, 2H), 2.95-2.83 (m, 2H), 2.80 – 2.68 (m, 2H), 2.21-2.08 (m, 2H), 2.07 – 1.87 (m, 6H), 1.70 (d, J= 8.7 Hz, 2H), 1.63 – 1.41 (m, 5H), 1.38 – 1.25 (m, 2H), 1.16 – 1.02 (m, 4H).
[0273] Example 16: 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-N-(3-(difluoromethyl)-1-(1-((3-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of ethyl 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate To a solution of ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (2.0 g, 8.9 mmol) in ACN (20 mL), 1.3 g (8.9 mmol) of 8-oxa-3-azabicyclo[3.2.1]octane and DIEA (3.4 g, 26 mmol) were added, and the reaction mixture was heated to 60 °C for 2 h. The reaction was quenched with water (200 mL), extracted with EA (200 mL × 2), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by chromatography (PE:EA = 1~5:1) to obtain ethyl 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. LC-MS: (ESI, m / z): [M+H] += 303.2. Step 2: Preparation of 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid LiOH (1.4 g, 34 mmol) was added to a mixture of ethyl 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (2.6 g, 8.6 mmol) in H₂O / MeOH (3 ml / 26 mL), and the reaction mixture was heated to 60 °C for 12 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by Prep-HPLC (acetonitrile / 0.05% NH₄OH aqueous solution, 5%~95%) to obtain 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] += 275.3. Step 3: Preparation of 4-(4-(5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester To a DMF (5 mL) solution of 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (274 mg, 1 mmol), tert-butyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid (316 mg, 1 mmol), HATU (456 mg, 1.2 mmol), and DIEA (387 mg, 3 mmol) were added, and the reaction mixture was reacted at 25 °C for 12 h. The reaction mixture was poured into water and extracted with EA (50 mL × 2). The organic phase was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by chromatography (MeOH:DCM=0~1:9) to obtain 4-(4-(5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 573.4. Step 4: Preparation of 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine A solution of 240 mg (0.42 mmol) of 4-(4-(5-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester (HCl / 1,4-dioxane (5 mL)) was stirred at room temperature for 1 h. The reaction solution was then directly concentrated under reduced pressure to give 5-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(3-(difluoromethyl)-1-(piperidine-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine. LC-MS: (ESI, m / z): [M+H] += 473.4. Step 5: Preparation of 9-((4-(4-(5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester To a THF (10 mL) solution of 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (130 mg, 0.27 mmol), tert-butyl 9-aldehyde-3-azaspiro[5.5]undecane-3-carboxylic acid (77 mg, 0.27 mmol) and STAB (175 mg, 0.8 mmol) were added. The reaction mixture was then stirred at 25 °C for 12 minutes. h. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM=0~1:9) to obtain 9-((4-(4-(5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 738.3. Step 6: Preparation of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine A solution of 9-((4-(4-(5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidin-3-methoxy)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (100 mg, 0.14 mmol) in HCl / 1,4-dioxane (4 mL) was stirred at 25 °C for 1 h. The reaction solution was then concentrated under reduced pressure to obtain N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 638.3. Step 7: Preparation of 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-N-(3-(difluoromethyl)-1-(1-((3-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine To a DMSO (2 mL) solution of N-(1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidin-3-methoxymethylamine (150.0 mg, 0.24 mmol) 3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoic acid pentafluorophenyl ester (123 mg, 0.28 mmol) and DIEA (93 mg, 0.72 mmol), the reaction mixture was stirred at room temperature for 12 h. The reaction solution was poured into water (20 mL), extracted with EA (30 mL × 2), and the organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by Prep-HPLC (acetonitrile / 0.05% NH₄HCO₃ aqueous solution, 5% ~ 95%) to obtain 5-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-N-(3-(difluoromethyl)-1-(1-((3-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-4-methoxybenzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 884.5. 1H NMR (400 MHz, DMSO- d 6) δ 10.33 (s, 1H), 9.41 (s, 1H), 8.81 (d, J= 7.8 Hz, 1H), 8.39 (s, 1H), 8.28 (d, J= 1.3 Hz, 1H), 7.37 (d, J= 8.4 Hz, 1H), 7.32 (s, 1H), 7.27 – 6.95 (m, 2H), 6.82 (d, J= 7.9 Hz, 1H), 4.50-4.37 (m, 2H), 4.30-4.00 (m, 2H), 3.84 (s, 3H), 3.68-3.34 (m, 6H), 3.28-3.11 (m, 2H), 2.98-2.78 (m, 2H), 2.73-2.60 (m, 2H), 2.22 – 1.63 (m, 14H), 1.61 – 1.17 (m, 8H), 1.18-0.93 (m, 4H).
[0274] Example 17: N-(2-((1S,4S)-4-((((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)(methyl)amino)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine Step 1: Preparation of tert-butyl (4-hydroxy-4-(methylamino)methyl)cyclohexyl)carbamate Methylamine (40 mL, 25%–30% aqueous solution) was added to an EtOH / H₂O (90 mL / 15 mL) mixture of (1-oxaspiro[2.5]octane-6-yl)carbamate (4.2 g, 18.42 mmol). The reaction mixture was then stirred overnight at 25 °C. The reaction mixture was directly concentrated under reduced pressure, and the crude product was purified by flash (MeOH:DCM = 0–1:1) to obtain (4-hydroxy-4-(methylamino)methyl)cyclohexyl)carbamate tert-butyl. LC-MS: (ESI, m / z): [M+H] +=259.2. Step 2: Preparation of ((4-((tert-Butoxycarbonyl)amino)-1-hydroxycyclohexyl)methyl)(methyl)carbamate benzyl ester A mixture of tert-butyl (4-hydroxy-4-(methylamino)methyl)cyclohexyl)carbamate (1.2 g, 4.61 mmol) and benzyl chloroformate (941 mg, 5.53 mmol) in ACN / sat.NaHCO3 (20 mL / 20 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (50 mL) and then extracted with EA (50 mL × 3). The organic phase was washed with saturated brine (150 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was flash purified (EA:PE = 0~7:3) to give ((4-((tert-butyloxycarbonyl)amino)-1-hydroxycyclohexyl)methyl)(methyl)carbamate. LC-MS: (ESI, m / z): [M+Na] +=415.2. Step 3: Preparation of ((4-amino-1-hydroxycyclohexyl)methyl)(methyl)carbamate benzyl ester At 0 °C, TFA (5 mL) was added to a DCM (15 mL) solution of ((4-((tert-butoxycarbonyl)amino)-1-hydroxycyclohexyl)methyl)(methyl)carbamate (1.5 g, 3.81 mmol) while stirring. The reaction solution was then stirred at 0 °C for 2 h. The pH of the reaction solution was adjusted to 9.0 with DIEA, and then the solution was directly concentrated under reduced pressure to obtain ((4-amino-1-hydroxycyclohexyl)methyl)(methyl)carbamate. The crude product was used directly in the next step of the reaction. LC-MS: (ESI, m / z): [M+H] +=293.1. Step 4: Preparation of (((1S,4S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indole-2-yl)cyclohexyl)methyl)(methyl)carbamate benzyl ester 2-Azide-4-methoxy-5-nitrobenzaldehyde (1.2 g, 5.7 mmol) was added to a toluene (40 mL) solution of ((4-amino-1-hydroxycyclohexyl)methyl)(methyl)carbamate (1.5 g, 3.8 mmol) with stirring. The reaction mixture was stirred at 100 °C for 3 h. The reaction mixture was then concentrated under reduced pressure. The crude product was purified by flash column chromatography (EA:PE = 0~1) to obtain (((1S,4S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indol-2-yl)cyclohexyl)methyl)(methyl)carbamate. LC-MS: (ESI, m / z): [M+H] +=469.2 1H NMR (400 MHz, DMSO- d 6) δ 8.58 (s, 1H), 8.38 (s, 1H), 7.45 – 7.23 (m, 6H), 5.09 (s, 2H), 4.66-4.36 (m, 2H), 3.91 (s, 3H), 3.28 (s, 2H), 3.10-2.95 (m, 3H), 2.30-2.20 (m, 2H), 1.95-1.60 (m, 2H), 1.78-1.63 (m, 2H), 1.59 – 1.41 (m, 2H). Step 5: Preparation of (((1S,4S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexylmethyl)(methyl)carbamate benzyl ester To a solution of (((1S,4S)-1-hydroxy-4-(6-methoxy-5-nitro-2H-indol-2-yl)cyclohexyl)methyl)(methyl)carbamate (1.1 g, 2.34 mmol) in EtOH (20 mL), add N₂H₄H₂O (1.2 mL) and Raney-Ni (0.5 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain (((1S,4S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexylmethyl)(methyl)carbamate. The crude product was used directly in the next reaction step. LC-MS: (ESI, m / z): [M+H] +=439.2 Step 6: Preparation of (((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinecarboxylic acid)-2H-indol-2-yl)cyclohexyl)methyl)(methyl)carbamate benzyl ester Under stirring, 6-(trifluoromethyl)pyridinecarboxylic acid (538 mg, 2.78 mmol), HATU (1.06 g, 2.78 mmol), and DIEA (828 mg, 6.42 mmol) were added to a DMF (10 mL) solution of (((1 S,4 S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexylmethyl)(methyl)carbamate (940 mg, 2.14 mmol) and stirred overnight at room temperature. The reaction mixture was diluted with water (100 mL) and extracted with EA (30 mL × 3). The organic phase was washed with saturated brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (EA:PE = 0~9:1) to obtain (((1 S,4 S)-4-(5-amino-6-methoxy-2H-indol-2-yl)-1-hydroxycyclohexylmethyl)(methyl)carbamate (940 mg, 2.14 mmol). S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinecarboxylic acid)-2H-indol-2-yl)cyclohexyl)methyl)(methyl)carbamate benzyl ester. LC-MS: (ESI, m / z): [M+H] +=612.2. 1H NMR (400 MHz, DMSO- d 6) δ 10.50 (s, 1H), 8.69 (s, 1H), 8.46 (d, J= 7.5 Hz, 1H), 8.40 (t, J= 7.8 Hz, 1H), 8.31 (s, 1H), 8.21 (dd, J= 7.7, 1.0 Hz, 1H), 7.42 – 7.28 (m, 5H), 7.16 (s, 1H), 5.09 (s, 2H), 4.60-4.31 (m, 2H), 3.98 (s, 3H), 3.28 (s, 2H), 3.10-2.95 (m, 3H), 2.30-2.15 (m, 2H), 1.95-1.60 (m, 2H), 1.67 (t, J= 14.9 Hz, 2H), 1.57 – 1.40 (m, 2H). Step 7: Preparation of N-(2-((1S,4S)-4-hydroxy-4-((methylamino)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine Pd(OH)₂ / C (200 mg) was added to a solution of (((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinecarboxylic acid)-2H-indol-2-yl)cyclohexyl)methyl)(methyl)carbamate (500 mg, 0.81 mmol) in EA (20 mL). The reaction mixture was then stirred overnight at 70 °C under a H₂ atmosphere. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain N-(2-((1S,4S)-4-hydroxy-4-((methylamino)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinecarboxylic acid. The crude product was used directly in the next step of the reaction. LC-MS: (ESI, m / z): [M+H] +=478.1. Step 8: Preparation of 9-(((((1S,4S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2H-indol-2-yl)cyclohexyl)methyl)(methyl)amino)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester A mixture of N-(2-((1S,4S)-4-hydroxy-4-((methylamino)methyl)cyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine (200 mg, 0.41 mmol), 9-aldehyde-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (141 mg, 0.50 mmol) and STAB (434 mg, 2.05 mmol) in THF (10 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (30 mL) and then extracted with DCM (10 mL × 3). The organic phase was washed with saturated brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column (MeOH:DCM=0~1:9) to obtain 9-(((((1 S,4 S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2 H-indol-2-yl)cyclohexyl)methyl)(methyl)amino)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] +=743.3. Step 9: Preparation of N-(2-((1S,4S)-4-((((3-azaspiro[5.5]undecane-9-yl)methyl)(methyl)amino)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine TFA (2 mL) was added to a DCM (5 mL) solution of 9-(((((1 S,4 S)-1-hydroxy-4-(6-methoxy-5-(6-(trifluoromethyl)pyridinemethylamine)-2 H-indol-2-yl)cyclohexyl)methyl)(methyl)amino)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (200 mg, 0.27 mmol) at 0 °C. The reaction solution was then stirred at room temperature for 2 h. The pH of the reaction solution was adjusted to 9.0 using DIE. The organic phase was washed with water (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain N-(2-((1S,4S)-4-((((3-azaspiro[5.5]undecane-9-yl)methyl)(methyl)amino)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine. The crude product was used directly in the next step of the reaction. LC-MS: (ESI, m / z): [M+H] +=643.3. Step 10: Preparation of N-(2-((1S,4S)-4-((((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)(methyl)amino)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine A mixture of N-(2-((1S,4S)-4-((((3-azaspiro[5.5]undecane-9-yl)methyl)(methyl)amino)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine (130 mg, 0.20 mmol), pentafluorophenyl 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate (105 mg, 0.24 mmol) and DIEA (77 mg, 0.60 mmol) in DMSO (5 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (50 mL), extracted with DCM (20 mL × 3), washed with saturated brine (60 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Prep-HPLC (CH3CN / 0.08% NH4HCO3 aqueous solution, 5%~95%) to obtain N-(2-((1S,4S)-4-((((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)(methyl)amino)methyl)-4-hydroxycyclohexyl)-6-methoxy-2H-indol-5-yl)-6-(trifluoromethyl)pyridinemethylamine. LC-MS: (ESI, m / z): [M+H] +=893.1. 1H NMR (400 MHz, DMSO- d 6) δ 10.51 (s, 2H), 8.69 (s, 1H), 8.47 (d, J= 7.8 Hz, 1H), 8.41 (t, J= 7.8 Hz, 1H), 8.32 (s, 1H), 8.22 (d, J= 7.8 Hz, 1H), 7.63 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 1.7 Hz, 1H), 7.39 (d, J= 8.3 Hz, 1H), 7.15 (s, 1H), 4.37-4.27 (m, 1H), 4.10-3.90 (m, 4H), 3.82 – 3.49 (m, 4H), 3.35-3.25 (m, 1H), 2.80-2.70 (m, 2H), 2.36-2.15 (m, 9H), 1.95-1.85 (m, 2H), 1.78 – 1.22 (m, 14H), 1.18-0.98 (m, 4H).
[0275] Example 18: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(2-((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)methoxy)ethyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of tert-butyl 4-((2-hydroxyethoxy)methyl)piperidine-1-carboxylic acid Under N₂ protection at 0 °C, LiAlH₄ (1.0 mol / L, 5.8 mL) was added dropwise to an anhydrous THF (30 mL) solution of methyl 4-((2-methoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate (1.1 g, 3.83 mmol), and the reaction mixture was stirred at room temperature for 3 h. While stirring, 15% NaOH solution was slowly added dropwise to the reaction mixture. The mixture was filtered, and the filtrate was washed with EA (30 mL × 2). The organic phase was washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM = 0~3:97) to obtain tert-butyl 4-((2-hydroxyethoxy)methyl)piperidine-1-carboxylate. LC-MS: (ESI, m / z): [M+H] += 260.1. Step 2: Preparation of tert-butyl 4-((2-oxoethoxy)methyl)piperidine-1-carboxylic acid A mixture of 4-((2-hydroxyethoxy)methyl)piperidine-1-carboxylic acid tert-butyl ester (700 mg, 2.7 mmol) and IBX (1.5 g, 5.4 mmol) in acetonitrile (15 mL) was stirred at 80 °C for 2 h. The mixture was filtered, diluted with water (30 mL), extracted with EA (30 mL × 2), washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (EA:PE = 0~2:3) to obtain 4-((2-oxoethoxy)methyl)piperidine-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [Mt-Bu] += 202.1. Step 3: Preparation of 4-((2-(4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)ethoxy)methyl)piperidin-1-carboxylic acid tert-butyl ester STAB (277.8 mg, 1.44 mmol) was added to a THF (5 mL) solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine (220.0 mg, 0.48 mmol) and 4-((2-oxoethoxy)methyl)piperidin-1-carboxylic acid tert-butyl ester (185.2 mg, 0.72 mmol). The reaction mixture was then stirred at room temperature for 4 h. The reaction was quenched with water (20 mL), and the mixture was extracted with DCM (20 mL × 2). The organic phase was washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (MeOH:DCM=0~1:9) to obtain 4-((2-(4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)ethoxy)methyl)piperidin-1-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 700.2. Step 4: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(2-(piperidin-4-ylmethoxy)ethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine Add TFA (1.0 mL) to a DCM (3.0 mL) solution of 4-((2-(4-(4-(5-(((1 R,4 R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)ethoxy)methyl)piperidin-1-carboxylic acid tert-butyl ester (150.0 mg, 0.214 mmol), and stir the reaction solution at room temperature for 2 h. The reaction solution was directly concentrated under reduced pressure to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(2-(piperidin-4-ylmethoxy)ethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 600.4. Step 5: Preparation of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(2-((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperidin-4-yl)methoxy)ethyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Add DIEA (77.5 mg, 0.6 mmol) and pentafluorophenyl 4-chloro-3-(2,4-dioxa-tetrahydropyrimidin-1(2H)-yl)benzoate (95.6 mg, 0.22 mmol) to a DMSO (5.0 mL) solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(1-(2-(piperidin-4-ylmethoxy)ethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine (120.0 mg, 0.2 mmol) and pyrimidin-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate, and then stir the reaction mixture at room temperature for 2 h. The reaction was quenched with water (15 mL), then extracted with DCM (30 mL × 2), the organic phase was washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by Prep-HPLC (acetonitrile / 0.05% NH₄HCO₃ aqueous solution, 5%~95%) to obtain 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(2-((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzyl)piperidin-4-yl)methoxy)ethyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 850.3. 1H NMR (400 MHz, DMSO- d 6) δ 10.50 (s, 1H), 9.50 (d, J= 5.6 Hz, 1H), 8.79 (d, J= 7.7 Hz, 1H), 8.39 (d, J= 3.8 Hz, 1H), 8.26 (d, J= 5.6 Hz, 1H), 7.63 (d, J= 8.2 Hz, 1H), 7.55 (d, J= 2.0 Hz, 1H), 7.38 (dd, J= 8.2, 2.0 Hz, 1H), 7.25-6.95 (m, 1H), 6.91-6.40 (m, 1H), 5.30-5.05 (m, 1H), 4.77 (d, J = 17.6 Hz, 1H), 4.55-4.35 (m, 1H), 4.28-4.10 (m, 1H), 3.83-3.75 (m, 3H), 3.66-3.57 (m, 3H), 3.53-3.42 (m, 3H), 3.30-3.26 (m, 2H), 3.06-2.96 (m, 3H), 2.77-2.66 (m, 3H), 2.34-2.20 (m, 3H), 2.06-1.85 (m, 10H), 1.14-1.08(m, 2H).
[0276] Example 19: N-(1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of ethyl 5-(4-((benzyloxy)carbonyl)piperazolo[1,5-a]pyrimidine-3-carboxylate Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (3.0 g, 13.3 mmol) and benzyl piperato-1-carboxylate (2.9 g, 13.3 mmol) were dissolved in ACN (30 mL) solution, and then DIEA (5.2 g, 40 mmol) was added. The reaction solution was heated to 60 °C and stirred for 2 hours. The solution was concentrated under reduced pressure. The crude product was dissolved in ethyl acetate (100 mL), washed with saturated brine, concentrated under reduced pressure, and purified by column chromatography (PE:EA = 2:1) to obtain ethyl 5-(4-((benzyloxy)carbonyl)piperazolo-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate. LC-MS: (ESI, m / z): [M+H] +=410.2. 1H NMR (400 MHz, DMSO- d 6) δ 8.76 (d, J = 7.9 Hz, 1H), 8.22 (s, 1H), 7.41 – 7.33 (m, 5H), 6.86 (d, J = 7.9 Hz, 1H), 5.13 (s, 2H), 4.19 (q, J = 7.1 Hz, 2H), 3.88-3.74 (m, 4H), 3.62-3.49 (m, 4H), 1.28 (t, J = 7.1 Hz, 3H). Step 2: Preparation of 5-(4-((benzyloxy)carbonyl)piperazolo-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Ethyl 5-(4-((benzyloxy)carbonyl)piperazolo[1,5-a]pyrimidine-3-carboxylic acid (2.6 g, 6.3 mmol) was dissolved in methanol (26 mL), and lithium hydroxide (1.0 g, 25.2 mmol) was added. The reaction solution was stirred at 60 °C for 2 hours. After the reaction was completed, dilute hydrochloric acid (2 mol / L) was added to adjust the pH of the reaction solution to 2. The solution was then filtered, and the resulting filter cake was washed with water and dried under vacuum to obtain 5-(4-((benzyloxy)carbonyl)piperazolo[1,5-a]pyrimidine-3-carboxylic acid. LC-MS: (ESI, m / z): [M+H] + [=]382.2. Step 3: Preparation of 4-(3-((1-(1-(tert-butyloxycarbonyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)carbamoyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester HATU (380 mg, 0.50 mmol) was added to a DMF (5 ml) solution of 5-(4-((benzyloxy)carbonyl)piperazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (270 mg, 0.4 mmol) and DIEA (0.5 ml, 1.0 mmol). The mixture was stirred at room temperature for 2 h, followed by the addition of tert-butyl 4-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylic acid (0.21 g, 0.3 mmol). The reaction mixture was stirred overnight at 25 °C. The reaction was quenched with water (30 mL), extracted with EA (50 mL × 3), and the organic phase was washed with saturated brine and anhydrous Na₂SO₄. 4. After drying, filtering, and concentration under reduced pressure, the crude product was purified by chromatography (MeOH:DCM=0~3:97) to obtain 4-(3-((1-(1-(tert-butyloxycarbonyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)aminomethoxy)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] += 680.4. Step 4: Preparation of 4-(3-((3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester TFA (1 mL) was added to a 5 mL solution of 4-(3-((1-(1-(tert-butyloxycarbonyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)aminomethyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester (0.29 g, 0.42 mmol) in DCM, and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then directly concentrated under reduced pressure to give 4-(3-((3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)carbonyl)pyrazololo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] += 580.5. Step 5: Preparation of 9-((4-(4-(5-(4-((benzyloxy)carbonyl)piperazolo-1-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester To a solution of 4-(3-((3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester (230 mg, 0.4 mmol) and DIEA (0.35 mL, 2.0 mmol) in MeOH (10 mL), 9-aldehyde-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (144 mg, 0.45 mmol) and NaBH3CN (138 mg, 1.2 mmol) were added. The reaction mixture was stirred overnight at 25 °C. The reaction was quenched with water (30 mL), then extracted with EA (50 mL × 3), the organic phase was washed with saturated brine, dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure, and the crude product was purified by flash column (MeOH:DCM=0~3:97) to obtain 9-((4-(4-(5-(4-((benzyloxy)carbonyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester. LC-MS: (ESI, m / z): [M+H] += 845.5. Step 6: Preparation of 4-(3-((1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester Add TFA (1 mL) to a DCM (3 mL) solution of 9-((4-(4-(5-(4-((benzyloxy)carbonyl)piperazolo[1,5-a]pyrimidin-3-methoxyamine)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)methyl)-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester (0.29 g, 0.34 mmol) and stir for 1 h at 25 °C. The reaction solution was directly concentrated under reduced pressure to obtain 4-(3-((1-(1-((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] += 745.4. Step 7: Preparation of 4-(3-((1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester DIEA (0.1 mL, 0.6 mmol) was added to a DMSO (5 mL) solution of 4-(3-((1-(1-(((3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester (240 mg, 0.32 mmol) and 4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoate pentafluorophenyl ester (144 mg, 0.33 mmol). The reaction mixture was then stirred at 25 °C for 16 h. Water (30 mL) was added to the reaction solution, and the mixture was extracted with EA (50 mL × 3). The organic phase was washed with saturated brine, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (MeOH:DCM=0~3:97) to obtain 4-(3-((1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester. LC-MS: (ESI, m / z): [M+H] += 995.0. Step 8: Preparation of N-(1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine At 0 °C, trimethylsilane (0.85 mL, 0.6 mmol) was added to a DCM (15 mL) solution of 4-(3-((1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)carbonyl)pyrazolo[1,5-a]pyrimidin-5-yl)piperidin-1-carboxylic acid benzyl ester (290 mg, 0.29 mmol), and the reaction mixture was stirred at 25 °C for 16 h. The reaction solution was poured into water, extracted with DCM (20 mL × 3), dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure, and the crude product was purified by Prep-HPLC to obtain N-(1-(1-((3-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)-3-azaspiro[5.5]undecane-9-yl)methyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-5-(piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine. LC-MS: (ESI, m / z): [M+H] += 861.1. 1H NMR (400 MHz, MeOD) δ 8.62 (d, J = 7.9 Hz, 1H), 8.43 (brs, 2.67H, FA), 8.35 (s, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.43 (d, J = 8.2 Hz, 1H), 7.08 – 6.77 (m, 2H), 4.57-4.43 (m, 1H), 4.15-4.03 (m, 4H), 3.79 (t, J = 6.4 Hz, 2H), 3.75-3.65 (m, 2H), 3.63-3.48 (m, 2H), 3.47-3.37 (m, 2H), 3.37-3.30 (m, 2H), 3.05-2.95 (m, 2H), 2.95-2.77 (m, 4H), 2.43-2.27 (m, 4H), 1.92-1.75 (m, 3H), 1.74-1.65 (m, 3H), 1.65-1.45 (m, 2H), 1.39-1.12 (m, 5H).
[0277] Example 20: 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(1-(1-(2-(((1-(4-chloro-3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)benzoyl)piperidin-4-yl)methyl)(methyl)amino)ethyl)piperidin-4-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methylamine Step 1: Preparation of (2-(4-(4-(5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)pyrazolo[1,5-a]pyrimidin-3-methamide)-3-(difluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)ethyl)(methyl)carbamate (9H-fluorene-9-yl)methyl ester To a THF (10 mL) solution of 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)-N-(3-(difluoromethyl)-1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-methamide (120 mg, 0.26 mmol), methyl(2-oxoethyl)carboxylic acid (9H-fluorene-9-yl)methyl (91 mg, 0...
Claims
1. A compound of formula I, its stereoisomers, enantiomers, diastereomers, deuterated derivatives, hydrates, or pharmaceutically acceptable salts thereof: PTM-L-ULM Ⅰ wherein: The PTM has the following structure, wherein in the PTM-3: n is 0 or 1; ring A is phenyl or contains one, two, or three 5-6-membered heteroaryl groups selected from N and O heteroatoms; each R1 is independently selected from: C1-C4 alkyl, C3-C8 cycloalkyl, 3-8-membered heterocyclic alkyl, CN, or halogen, wherein the alkyl, cycloalkyl, or heterocyclic alkyl is optionally substituted with a group selected from halogen, cyano, -OH, C1-C4 alkyl, and -O (C1-C4 alkyl); R2 and R3 are independently selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, or 3-8-membered heterocyclic alkyl, wherein the alkyl, cycloalkyl, or heterocyclic alkyl is each independently optionally substituted with one or more substituents selected from halogen, OH, N(Rb)2, and mofoolinyl, or R2 and R3 together with the atoms to which they are attached form a 3-8-membered heterocyclic alkyl, wherein the heterocyclic alkyl is optionally substituted with one or more substituents selected from Ra; Ra is independently selected from C1-C4 alkyl, C3-C6 cycloalkyl, CF3, CHF2, OH, halogen or NH2, wherein the alkyl group is optionally substituted with C3-C6 cycloalkyl or CF3; and Rb is independently selected from H or C1-C4 alkyl; L is a linking chain that covalently links PTM and ULM; L is -(CH2)j-, wherein one or more methylene groups in -(CH2)j- are optionally replaced by groups selected from -NR3'-, -O-, -C(O)-, -C(O)NR3'-, -NR3'C(O)-, vinylene, ethynylene, C3-C12 cycloalkylene, or 3-12 heterocyclic alkylene containing one or more heteroatoms selected from N, O, or S. The vinylene, cycloalkylene, and heterocyclic alkylene are each independently and optionally replaced by one or more substituents selected from halogens, -OR3', or C1-C6 alkyl groups. The alkyl group is optionally replaced by one or more substituents selected from halogens or -OH. R3' is independently hydrogen or a C1-C6 alkyl group. j is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The ULM has the following structure: ULM-1, wherein in ULM-1: X'' is C or N; Y'' is N. Q1, Q2, Q3, Q4, and Q5 are each independently CR3''; R3'' are each independently hydrogen, deuterium, halogen, C1-C6 alkyl, or -O (C1-C6 alkyl); the alkyl group is optionally substituted with 1-3 groups independently selected from hydroxyl or halogen; m'' is 2; R1'' is hydrogen; R2'' is hydrogen or C1-C6 alkyl, the C1-C6 alkyl and C3-C6 cycloalkyl groups are optionally substituted with 1-3 groups independently selected from halogen and -OC(O) (C1-C6 alkyl).
2. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that the ULM has the following structure; R3'' is a halogen, C1-C6 alkyl or -O (C1-C6 alkyl); and / or the pharmaceutically acceptable salt is a formate.
3. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that ring A is phenyl, pyridinyl, pyrroloyl, pyrazolyl, imidazolyl, pyrimidinyl, triazolyl, tetrazolyl, thienyl, thiazolyl, furanyl, acezolyl, isoacezolyl, isothiazolyl; and / or, R1 is independently selected from: C1-C4 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclic alkyl containing one or two N heteroatoms, CN or halogen, wherein the alkyl, cycloalkyl and heterocyclic alkyl are optionally substituted with halogen, OH, CH3 or OCH3; And / or, R2 and R3 together with the nitrogen atom to which they are attached form a 3-8 member heterocyclic alkyl group containing one N or O heterooxy atom in addition to the attached N atom, wherein the heterocyclic alkyl group is optionally substituted by one or more substituents selected from Ra; wherein Ra is independently selected from C1-C4 alkyl, CF3, CHF2, OH, halogen or NH2.
4. A compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that ring A is pyrazolyl or thiophene; and / or, R1 is CHF2, CF3, cyclohexyl, piperidinyl, methyl, cyano or piperidine; and / or, R2 and R3 together with the nitrogen atom to which they are attached form , , , , , , or .
5. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that the PTM has the following structure: where, R1, R2, and R3 are as defined and described in PTM-3 of request item 1.
6. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that the PTM has the following structure: .
7. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that R2'' in ULM-1 is hydrogen or a C1-C6 alkyl group, wherein the alkyl group is optionally substituted with 1-3 halogens; preferably R2'' is hydrogen.
8. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that each of the R3'' in the ULM-1 is independently hydrogen, deuterium, halogen, -O (C1-C6 alkyl), or C1-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 halogens.
9. The compound of formula I, its stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates or pharmaceutically acceptable salts thereof, characterized in that each of R3'' is independently hydrogen, deuterium, F, Cl, methyl, methoxy, ethoxy, trifluoromethoxy, 2-hydroxypropyl-2-yl or trifluoromethyl.
10. A compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that the ULM is selected from or; and / or, the L is a bond.
11. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates and / or pharmaceutically acceptable salts thereof, characterized in that L is -(CH2)j-, wherein one, two or three methylene groups in -(CH2)j- are optionally replaced by groups selected from -O-, -NH-, -NCH3-, -NCH2CH3-, -C(O)-, -C(O)NH-, -NHC(O)-, -NCH3C(O)-, -C(O)NCH3-, etc., and j is 2, 3, 4, 5, 6, 7 or 8.
12. A compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates and / or pharmaceutically acceptable salts thereof, characterized in that L is -(CH2)j-1-C(O)-, wherein the methylene group in -(CH2)j-1-C(O)- is as defined in claim 1, optionally replaced by one or more groups, and j is as defined in claim 1.
13. A compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that the L is LA, wherein the LA contains: ring D is absent, a C3-C12 cycloalkyl group or a 3-12 membered heteroalkyl group containing 1-2 heteroatoms selected from N, O or S, wherein the cycloalkyl group and heteroalkyl group are optionally substituted with a substituent selected from halogen, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl or -O-(C1-C6 alkyl); Ring B is absent or is a C3-C12 cyclohexane or contains 1-2 3-12 membered heterocyclic alkyl groups selected from N, O, or S heteroatoms, wherein the cyclohexane and heterocyclic alkyl groups are optionally substituted with a substituent selected from halogens, hydroxyl groups, C1-C6 alkyl groups, C1-C6 haloalkyl groups, C1-C6 hydroxyalkyl groups, or -O-(C1-C6 alkyl groups); Ring C is absent, is a C3-C12 cyclohexane or contains 1-2 3-12 membered heterocyclic alkyl groups selected from N, O, or S heteroatoms, wherein the cyclohexane and heterocyclic alkyl groups are optionally substituted with a substituent selected from halogens, hydroxyl groups, C1-C6 alkyl groups, C1-C6 haloalkyl groups, C1-C6 hydroxyalkyl groups, or -O-(C1-C6 alkyl groups); X'''' is a bond, -NH-, -NCH3-, -O-, -C(CH3)2-, -C=C-, -C≡C-, -C(O)-, -C(O)NH-, -C(O)NCH3-, -NHC(O)-, -(CH2)t- or -NCH3C(O)-; one or more methylene groups in -(CH2)t- are optionally replaced by a group selected from -O-, -NH-, -C≡C-, -N(C1-C6 alkyl)-, -C(O)-, and t is 0, 1, 2, 3, 4, 5, 6 or 7; L3 is -(CH2)k-, wherein one or more methylene groups in L3 are optionally replaced by a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -N(C1-C6 hydroxyalkyl)-, -C≡C- or -C(O)-, and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
14. The compound of formula I as claimed in claim 13, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that L is LA, wherein ring D and ring B are absent in LA, ring C is a 7-11 member spirocycloalkylene containing one or two nitrogen atoms; X'''' is -C(O)-; L3 is -(CH2)k-; k is 1, 2, 3, 4 or 5.
15. The compound of formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that the L is selected from [the group consisting of compounds from which the L is derived].
16. The compound of formula I as claimed in claim 13, its stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates or pharmaceutically acceptable salts thereof, characterized in that L is LA, wherein ring D and ring B are absent in LA, ring C is a 4-7 membered heterocyclic alkyl group containing one or two nitrogen atoms; X'''' is -C(O)-, bond or -CH2-; L3 is -(CH2)k-; k is 1, 2, 3, 4 or 5.
17. A compound of Formula I as claimed in claim 1, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that, L is LA, wherein LA is Scheme 1, Scheme 2, Scheme 3 or Scheme 4. Scheme 1: Ring D is a C3-C12 cycloalkylene ring or a 3-12-membered heteroalkylene ring containing 1-2 N heteroatoms, wherein the cycloalkylene ring and heteroalkylene ring are optionally substituted with a substituent selected from halogens, hydroxyl groups or -O-(C1-C6 alkyl); Ring B is a C3-C12 cycloalkylene ring or a 3-12-membered heteroalkylene ring containing 1-2 N, O or S heteroatoms, wherein the cycloalkylene ring and heteroalkylene ring are optionally substituted with a substituent selected from halogens, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl or -O-(C1-C6 alkyl); Cycle C is absent; X'''' is -C(O)-; L3 is -(CH2)k-, wherein one or both methylene groups in L3 are replaced by -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -C(O)-, -N(C1-C6 hydroxyalkyl)- or -N(C3-C8 cycloalkyl)-, and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Scheme 2: Cycle D is a C3-C12 cycloalkylene group or a 3-12 membered heteroalkylene group containing 1-2 N heteroatoms, wherein the cycloalkylene group and heteroalkylene group are optionally replaced by halogen, hydroxyl or methoxy groups; Cycle B is a 7-11 membered spirocycloalkylene group or fused heteroalkylene group containing 1 or 2 nitrogen heteroatoms; Cycle C is absent; X'''' is -C(O)-; L3 is -(CH2)k-, where k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; Scheme 3: Ring D is a C3-C12 cyclohexane or a 3-12 membered heterocyclic alkyl group containing 1-2 N heteroatoms, wherein the cyclohexane and heterocyclic alkyl group are optionally substituted with halogens, hydroxyl groups, or methoxy groups; Ring B is a 3-12 membered heterocyclic alkyl group containing 1-2 N, O, or S heteroatoms; Ring C is absent; X'''' is -C(O)-; L3 is -(CH2)k-, where k is 1, 2, 3, or 4; Scheme 4: Ring D is a cyclohexylene or a 6 membered heterocyclic alkyl group containing 1-2 N heteroatoms, wherein the cyclohexylene and 6 membered heterocyclic alkyl group are optionally substituted with halogens, hydroxyl groups, or methoxy groups; Ring B is , or ; Ring C is absent; X'''' is -C(O)-; L3 is -(CH2)k-, wherein one or both methylene groups in L3 are replaced by a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -C(O)-, -N(C1-C6 hydroxyalkyl)- or -N(C3-C8 cycloalkyl)-, and k is 1, 2, 3 or 4.
18. A compound of formula I, its stereoisomers, enantiomers, diastereomers, deuterated derivatives, hydrates, or pharmaceutically acceptable salts thereof: PTM-L-ULM Ⅰ Wherein: The PTM has the following structure, wherein in PTM-3': m is 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, or 4; ring A'' is a 9-10 membered bicyclic heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, or S; each R1 is independently selected from: C1-C4 alkyl, C3-C8 cycloalkyl, 3-8 membered heterocyclic alkyl, CN, or halogen, wherein the alkyl, cycloalkyl, or heterocyclic alkyl group is optionally substituted with a group selected from halogen, cyano, -OH, C1-C4 alkyl, and -O (C1-C4 alkyl); each R4 is independently hydrogen, C1-C4 alkyl, -O (C1-C4 alkyl), C3-C8 cycloalkyl, 3-8 membered heterocyclic alkyl, or halogen, wherein the alkyl, cycloalkyl, or heterocyclic alkyl group is optionally substituted with a group selected from halogen and -OH; L is a linking chain that covalently connects the PTM and ULM; wherein L is LA, LA Ring D is a C3-C12 cyclohexane or a 3-12 membered heterocyclic alkyl group containing 1-2 heteroatoms selected from N, O, or S, wherein the cyclohexane and heterocyclic alkyl group are independently substituted by 1, 2, or 3 hydroxyl groups or by 1, 2, or 3 -O-(C1-C6 alkyl) groups; Ring B is a C3-C12 cyclohexane or a 3-12 membered heterocyclic alkyl group containing 1-2 heteroatoms selected from N, O, or S, wherein the cyclohexane and heterocyclic alkyl group are optionally substituted by substituents selected from halogen, oxo, cyano, amino, hydroxyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or -O-(C1-C6 alkyl); Ring C is absent; X'''' is -C(O)-; L3 is -(CH2)k-, wherein one or both methylene groups in L3 are replaced by a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -C(O)-, -N(C1-C6 hydroxyalkyl)-, or -N(C3-C8 cycloalkyl)-, and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; the ULM has the following structure ULM-1, wherein in ULM-1: X'' is C or N; Y'' is N; Q1, Q2, Q3, Q4, and Q5 are each independently CR3''; R3'' are each independently hydrogen, deuterium, halogen, C1-C6 alkyl, or -O(C1-C6 alkyl); the alkyl group is optionally replaced by 1-3 groups independently selected from hydroxyl or halogen; m'' is 2; R1'' is hydrogen; R2'' is hydrogen or a C1-C6 alkyl group, wherein the C1-C6 alkyl group and the C3-C6 cycloalkyl group are optionally substituted by 1 to 3 groups independently selected from halogens and -OC(O)(C1-C6 alkyl).
19. A compound of formula I as claimed in claim 18, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, characterized in that: ring D is a cyclohexene or a 6-membered heterocyclic alkylene containing 1-2 N heteroatoms, said cyclohexene and 6-membered heterocyclic alkylene being substituted with hydroxyl or methoxy; ring B is , or ; ring C is absent; X'''' is -C(O)-; L3 is -(CH2)k-, wherein one or both methylene groups of said L3 are substituted with a group selected from -O-, -NH-, -N(C1-C6 alkyl)-, -N(C1-C6 haloalkyl)-, -C(O)-, -N(C1-C6 hydroxyalkyl)- or -N(C3-C8 cycloalkyl)-, and k is 1, 2, 3 or 4.
20. A compound of formula I, its stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates or pharmaceutically acceptable salts thereof, characterized in that the compound of formula I is, , or .
21. A pharmaceutical composition comprising a compound of Formula I as claimed in any one of claims 1-20, or a stereoisomer, enantiomer, diastereomer, deuterated compound, hydrate, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
22. The use of a compound of Formula I according to any one of claims 1-20, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment and / or prevention of IRAK4-mediated diseases or conditions, or in medicaments for diseases or conditions mediated by TLRs (other than TLR3R), IL-1α or IL-1β receptor families.
23. The use of a compound of Formula I according to any one of claims 1-20, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment and / or prevention of autoimmune diseases and inflammatory diseases.
24. The use of a compound of Formula I according to any one of claims 1-20, its stereoisomers, enantiomers, diastereomers, deuterated compounds, hydrates or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment and / or prevention of autoimmune blood disorders, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis, autoimmune inflammatory bowel disease, multiple sclerosis, systemic juvenile idiopathic arthritis, acute respiratory distress syndrome, allergies, enteritis, dermatitis, hidradenitis suppurativa, psoriasis, pericarditis, pneumonia, uveitis, acute and chronic gout, juvenile rheumatoid arthritis or osteoarthritis.
25. The use of a compound of Formula I as claimed in any one of claims 1-20, its stereoisomers, enantiomers, diastereomers, deuterates, hydrates or pharmaceutically acceptable salts thereof, or a pharmaceutical composition as claimed in claim 21 in the preparation of an IRAK4 protein degrader.
26. A compound of formula VII or VIII, its stereoisomers, enantiomers, diastereomers, deuterates, or salts thereof: Z is ____, ____, ____, ____, ____, ____, ____, ____, ____, ____, or ____; Z' is ____, ____, or ____; wherein, m, n, A, A', R1, R2, R3, and R4 as claimed in any one of claims 1-20; and / or, the compound of formula VIII is any one of the following compounds: , , or.
27. A compound of formula VII or VIII as claimed in claim 26, its stereoisomers, enantiomers, diastereomers, deuterates or salts thereof: The compound of formula VII is any one of the following compounds: , ...
Citation Information
Patent Citations
Compound for targeting and degrading protein, and preparation method therefor and use thereof
WO2022028547A1
